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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
Chapter 1 
Type 2 diabetes mellitus 
Type 2 diabetes mellitus is a metabolic disease with elevated blood 
glucose levels as the primary characteristic. By definition, the diagnosis is based 
on a fasting plasma glucose measurement and a post-load plasma glucose 
measurement, 2-hour after ingestion of a 75-gram glucose suspension (oral 
glucose tolerance test). Diabetes is defined as fasting plasma glucose ≥7.0 
mmol/l and/or post-load plasma glucose concentrations ≥11.1 mmol/l (1). 
Normal glucose metabolism is defined as fasting plasma glucose <6.1 mmol/l 
and post-load plasma glucose concentrations <7.8 mmol/l. Individuals with 
levels of plasma glucose between the normal and the diabetic range are 
categorized as impaired glucose metabolism.  
 
The prevalence of type 2 diabetes is rapidly increasing in Western and, 
even more, in developing countries due to population growth, aging, increased 
prevalence of obesity and decreased physical activity (2). The term ‘adult-
onset diabetes’ was previously used for type 2 diabetes, to differentiate 
between type 2 and type 1 diabetes. Type 1 diabetes is an autoimmune 
disease, characterized by an absolute lack of insulin secretion. This disease 
usually starts at early age. In contrast to type 1, type 2 diabetes gradually 
develops during lifetime, and often manifests at older age. However, with the 
increased prevalence of morbid obesity in children, today’s burden of type 2 
diabetes also includes younger people (3). 
Hyperglycaemia in type 2 diabetes is a result of an inappropriate insulin 
secretion and a concomitant presence of resistance to insulin. As long as the 
insulin secreting beta-cell can compensate for insulin resistance by enhancing 
insulin secretion, diabetes will not develop (4). Failure to do so will ultimately 
lead to occurrence of hyperglycaemia (5). 
Increased morbidity and mortality rates in type 2 diabetes are mainly 
caused by macrovascular complications. Also microvascular complications 
can occur, i.e. retinopathy, nephropathy and neuropathy. The present thesis 
focuses on the possible mechanisms underlying the increased cardiovascular 
risk in type 2 diabetes. 
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Cardiovascular risk in type 2 diabetes mellitus 
Type 2 diabetes confers a two- to three-fold enhanced risk in men and a 
three- to four-fold increased risk of cardiovascular morbidity and mortality in 
women (6). It has been demonstrated that patients with type 2 diabetes have a 
similar cardiovascular risk as patients who previously had a cardiovascular 
event (7). Classical risk factors for cardiovascular disease are high blood 
pressure, high levels of low-density lipoprotein (LDL) cholesterol and low levels of 
high-density lipoprotein (HDL) cholesterol (8), which are common in type 2 
diabetes. However, only part of the increased cardiovascular risk in type 2 
diabetes is explained by these so-called classical risk factors.  
 
Postprandial metabolism and cardiovascular risk in type 2 
diabetes 
In Western society, we are largely in the postprandial state, eating three 
meals per day, and in addition, coffee-, tee-breaks and several snacks. 
Probably, it is of critical value that the body metabolises all these nutrients. 
Metabolic risk factors for cardiovascular disease are usually measured in the 
fasting state, which only represents a small part of the actual metabolic state. In 
the postprandial phase, adipose tissue fatty acid release is suppressed and 
triglyceride clearance is enhanced (9). In addition, hepatic glucose production 
is lowered and insulin-mediated glucose uptake in skeletal muscle is stimulated. 
Measurement of postprandial metabolism provides important information with 
regard to daytime glucose, insulin and triglyceride exposure. Disturbances in 
postprandial metabolic control may substantially contribute to development of 
cardiovascular disease (10,11). 
Glucose metabolism 
Type 2 diabetes is, by definition, a deviation of fasting and/or post-load 
glucose levels (1). Maintenance of normal fasting and post-load glucose levels 
depends mainly on beta-cell function, the ability to create an adequate insulin 
response to a meal challenge. Abnormal glucose concentration in the fasting 
state is due to a relative lack of basal insulin secretion and an increased 
hepatic glucose output, whereas abnormal post-load glucose levels mainly 
result from peripheral insulin resistance (12). Suboptimal glycaemic control in 
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individuals with type 2 diabetes is associated with an increased risk of 
microvascular and macrovascular complications. With regard to cardiovascular 
risk, the post-load glucose levels, measured after an oral glucose tolerance test, 
were found to be a better predictor for cardiovascular risk than fasting glucose 
levels (13,14). In the present thesis, we will evaluate which factors contribute to 
meal-induced glucose elevations. Furthermore, we will assess whether meal-
induced glucose elevations are associated with cardiovascular risk in normal 
glucose metabolism and in diabetes. 
Insulin secretion 
In people with normal glucose tolerance, insulin secretion and insulin 
sensitivity are closely related, such that lower insulin sensitivity is compensated 
by an increase in insulin secretion in order to maintain normal glucose levels 
(14). Therefore, hyperinsulinaemia can be used as a marker of insulin resistance. 
High levels of insulin were found to be associated with cardiovascular disease 
and mortality in several prospective studies but results from a meta-analysis 
showed that the association was not very strong (15). In this analysis, it was 
found that proinsulin levels were more strongly associated with coronary heart 
disease than insulin levels (16,17).  Proinsulin is the precursor molecule of insulin, 
before it is split into C-peptide and insulin. It is not clear whether deteriorated 
glucose tolerance status or increased insulin resistance can explain the 
previously described associations of insulin and proinsulin with cardiovascular 
disease. 
Long before the onset of type 2 diabetes, the acute insulin response to a 
glucose challenge is already impaired (18,19). The early insulin response to 
glucose ingestion is an important determinant of the postprandial glucose 
excursion, probably because of the inhibitory effect on endogenous glucose 
production (20). Since in daily life different nutrients are consumed together, the 
early insulin response to a mixed meal might be relevant with regard to daytime 
glucose excursions.  
Lipid metabolism 
Diabetic dyslipidaemia is an important cardiovascular risk factor (21). This 
dyslipidaemia is mainly characterized by a low HDL-cholesterol level and an 
elevated triglyceride level. Insulin resistance and central obesity are important 
contributors to abnormalities in fasting and postprandial lipid metabolism. 
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Fasting and postprandial triglyceride concentrations have been found to be 
associated with atherosclerosis (22,23).  
 
Cholesteryl ester transfer protein (CETP) plays a key role in lipid 
metabolism and in reversed cholesterol transport (24). CETP transfers cholesterol 
from HDL to triglyceride-rich particles (chylomicrons and VLDL) in exchange for 
triglycerides (Figure 1). This way, CETP contributes to reversed cholesterol 
transport. However, when the amount of triglyceride-rich particles is increased, 
which is the case in the postprandial state and in type 2 diabetes, the transfer of 
cholesterol to these particles is increased resulting in an enhanced transfer of 
triglycerides to HDL- and LDL-particles (Figure 1B). This increase of triglyceride-
enriched HDL and LDL-particles results in a decrease of the HDL-cholesterol 
concentration and generation of atherogenic small, dense HDL and LDL (24). 
The latter is thought to be due to the effect of hepatic lipase on the triglyceride-
enriched LDL and HDL-particles. 
Because of these effects, CETP-inhibitors have been developed for 
therapeutical use. These inhibitors were indeed found to increase HDL-
cholesterol, to decrease LDL-cholesterol levels and to reduce the amount of 
atherogenic small LDL and HDL particles (25). A few prospective studies have 
been performed to investigate the association between CETP concentrations 
and cardiovascular outcome (26-28). These studies reported a positive 
association between CETP and cardiovascular disease in patients with 
hypercholesterolaemia (26), high levels of triglycerides (28) and in patients with 
coronary artery disease (27). However, until now, very little is known about non-
pharmacological factors (dietary or metabolic) that affect CETP 
concentrations.   
 
The Hoorn Study and the Hoorn prandial study  
The Hoorn prandial study was designed to elucidate the relative 
contribution of postprandial hyperglycaemia and hypertriglyceridaemia to 
cardiovascular disease risk.  
In postmenopausal women, diabetes confers a higher risk for 
cardiovascular disease than in men (29). Therefore, we consider these women 
as a high-risk population for development of cardiovascular disease. 
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Therefore, normoglycaemic women and women with type 2 diabetes 
were invited to participate in a cross-sectional study. Normoglycaemic women 
were randomly invited from the municipal registry of the region of Hoorn and 
women with diabetes were invited from the Diabetes Care System in Hoorn. All 
women were postmenopausal and aged 50-65 years. After a screening visit, 
women participated in two test-meal visits within one month. On one day, they 
received a fat-rich breakfast and lunch and on the other day, they received a 
carbohydrate-rich breakfast and lunch. Results of the studies assessing the 
postprandial responses to these meals are described in Chapter 2, 3, 4 and 9. 
The Hoorn Study is a population-based cohort study consisting of 2484 
participants of which baseline measurements started in 1989. In 2000-2001, at 
the age of 60-85 years, all participants with type 2 diabetes and impaired 
glucose metabolism and a stratified subsample of the participants with normal 
glucose metabolism were re-invited for follow-up examination. Follow-up data 
on morbidity and mortality are available. The Hoorn Study data were used for 
the analyses presented in Chapter 5, 6, 7, and 8. 
 
Outline of the thesis 
The main aim of the studies presented in this thesis was to investigate the 
associations of postprandial metabolism with cardiovascular disease. This 
question was addressed in the Hoorn prandial study and in the Hoorn Study.  
The present thesis deals with some of the possible determinants of 
elevated fasting and postprandial levels of insulin, glucose, triglycerides and 
CETP. Furthermore, the contribution of fasting and post-load glucose, 
triglyceride and (pro)insulin levels and of fasting CETP concentration to 
cardiovascular disease risk is investigated. Most of these questions were 
addressed in a high-risk population for development of cardiovascular disease; 
postmenopausal women with diabetes.  
In Chapter 2, we describe the course of glucose and triglyceride 
excursions after ingestion of two consecutive meals that were either fat-rich or 
carbohydrate-rich. Furthermore, potential determinants of fasting and 
postprandial glucose and triglyceride excursions were assessed. Thereafter, in 
Chapter 3, we investigated the relative contribution of these postprandial 
glucose and triglyceride excursions to carotid intima media thickness, as a 
marker for atherosclerosis. An index for early insulin secretion was used in 
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Chapter 4 to describe insulin secretion induced by meals of different 
composition. The relationship of fasting and post-load levels of insulin and 
proinsulin with 11-year risk on cardiovascular disease mortality and all-cause 
mortality was studied in Chapter 5.  
In Chapter 6 and 7, we assessed metabolic and dietary factors that were 
associated with fasting CETP. Whether elevated fasting CETP levels were 
associated with prevalent cardiovascular disease and intima media thickness 
was assessed in Chapter 8. Finally, we studied the effect of ingestion of two 
consecutive fat-rich meals as compared to carbohydrate-rich meals on CETP 
concentrations (Chapter 9). 
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Chapter 2 
Abstract 
 
Background: Both postprandial hyperglycaemia and 
hypertriglyceridaemia have been identified as risk markers for 
cardiovascular disease. However, the determinants of the 
magnitude of postprandial triglyceride and glucose responses are 
largely unknown. The objective was to assess potential 
determinants of postprandial glucose and triglyceride responses 
following two consecutive meals in women with normal glucose 
metabolism (NGM) and with type 2 diabetes (DM2). 
Methods: Post-menopausal women, 76 with NGM and 41 with DM2, 
received two consecutive fat-rich meals and carbohydrate-rich 
meals on separate occasions. Blood samples were taken before 
and at t=1, 2, 4, 6 and 8 hours following breakfast; lunch was given 
at t=4h.  
Results: In NGM women, fasting triglycerides, HbA1c, total 
cholesterol, and, inversely, HDL-cholesterol were independently 
associated with TG-iAUC, and age and fasting triglycerides were 
independently associated with glucose-iAUC (GL-iAUC). In women 
with DM2, fasting triglycerides were independently associated with 
TG-iAUC while HbA1c and fasting glucose were stronger than 
fasting triglycerides associated with GL-iAUC. GL-iAUC and TG-iAUC 
were associated with each other in women with DM2, but not in 
NGM. 
Conclusions: In conclusion, GL-iAUC and TG-iAUC were correlated 
with each other in women with DM2 and fasting triglycerides were 
associated with both GL-iAUC and TG-iAUC. These findings suggest 
a common underlying mechanism for postprandial increments in 
glucose and triglycerides. In women with NGM, elevated TG-iAUC 
may be part of a dyslipidemic lipid profile whereas fasting 
triglycerides were related to GL-iAUC, suggestive for an association 
with insulin resistance.  
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Introduction  
Already in 1979, Zilversmit postulated that atherogenesis might be a 
postprandial phenomenon (1). Since then, both postprandial hyperglycaemia 
and hypertriglyceridaemia have been identified as risk markers for 
cardiovascular disease (CVD) (2,3). Glucose values two hours following an oral 
glucose tolerance test (OGTT) have been shown to be better indicators of CVD 
risk than fasting glucose concentration in the general population (4). We 
recently demonstrated that postprandial glucose levels were stronger than the 
fasting levels, associated with carotid intima-media thickness in women with 
normal glucose metabolism (NGM) (5). Others have shown that postprandial 
hypertriglyceridaemia is more strongly related to carotid intima-media thickness 
than the fasting triglyceride levels (6,7).  
The determinants of these postprandial glucose and triglyceride 
responses are not well known but might, at least in part, overlap. However, the 
possible determinants of postprandial triglyceride and glucose concentrations, 
have not been described in a single study population before. To date, most 
studies used a single, often artificially composed liquid fat and/or carbohydrate 
load to assess postprandial responses. Since a first meal can affect the glucose 
and triglyceride response to a second meal, we chose to apply two 
consecutive meals (8,9). Postmenopausal women were invited for the present 
study because in these women, postprandial triglyceride responses have been 
shown to be elevated (10), and type 2 diabetes (DM2) was shown to confer a 
higher relative risk for CVD as compared to men (11).  
In light of the above considerations, we assessed associations of clinical 
and biochemical variables with postprandial triglyceride and glucose day 
profiles in postmenopausal women with NGM and DM2, in order to investigate 
whether postprandial hypertriglyceridaemia and hyperglycaemia are the result 
of a similar underlying mechanism.  
 
Subjects and methods 
Study population  
The study population has been described in detail previously (5). In brief, 
women with DM2 were randomly selected from the registry of the Diabetes 
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Care System in the city of Hoorn, the Netherlands. Women with NGM were 
randomly selected from the municipal registry of the city of Hoorn. All women 
were between 50 and 65 years of age, were post-menopausal, non-smokers, 
had no untreated endocrine disorder other than DM2, did not use HMG-CoA 
reductase inhibitors, short acting insulin analogues, peroxisome proliferator-
activated receptor-α and/or γ agonists, oral corticosteroids, or hormone 
replacement therapy. Women without known DM2 underwent an OGTT and 
were selected on NGM status (fasting glucose <6.1, 2-hour post-load glucose 
<7.8 mmol/L (12)). Women with DM2 were excluded if they had HbA1c >9.0%. 
Of the 1,063 women who were invited, a total of 431 of the women were total 
non-responders and 258 women were unwilling to participate. A total of 257 
women did not meet the inclusion criteria.  
Finally, 76 women with NGM and 41 women with DM2 completed the 
study protocol. All women gave written informed consent. The study was 
approved by the ethics committee of the VU University Medical Center, 
Amsterdam, the Netherlands. 
Measurements 
The study consisted of a screening visit and two separate visits for the test-
meals with a minimum interval of one week and a maximum interval of one 
month between visits. On the screening visit, blood samples were drawn after a 
12-h overnight fast to determine levels of HbA1c, plasma glucose, total 
cholesterol, triglycerides, alanine aminotransferase (ALT) and creatinine. 
Women who were selected from the municipal registry underwent an OGTT.  
Blood pressure was measured at the left upper arm three times with 5 
minutes intervals using an oscillometric blood pressure measuring device (Collin 
Press-mate BP-8800, Colin, Komaki-City, Japan) after a 15-minute supine rest. 
Weight and height were measured twice in barefooted participants wearing 
light clothes only. BMI was calculated as weight (in kg) divided by the square of 
height (in m). Waist circumference was measured twice at the level midway 
between the lowest rib margin and the iliac crest, and hip circumference was 
measured at the widest level over the greater trochanters. Medical history, 
medication, (former) smoking and alcohol use were assessed by a 
questionnaire (13). Finally, habitual physical activity was assessed by the Short 
Questionnaire to Assess Health-enhancing physical activity of which 
reproducibility and relative validity were described previously (14).  
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On the second and the third visit, women arrived at the test facility in the 
morning after an overnight fast. They had abstained from exercise 24 hours 
before the study visit. Blood samples were taken before (twice) and at t=1, t=2, 
t=4, t=6 and t=8 hours after ingestion of the first test meal. The second test meal 
was given at t=4 hour, immediately after the blood sample was taken. 
Test meal composition 
Postprandial meal responses were examined following the consumption 
of two standardized test meals (breakfast and lunch) on two separate 
occasions, either with a high fat content or a high carbohydrate content. The 
fat-rich and the carbohydrate-rich occasions were performed in random order. 
Each portion of the ingredients was weighed before the meal was prepared. 
The nutrient composition of the meals was calculated from the Dutch Food 
Composition Tables (15). The fat-rich meals (both breakfast and lunch) 
consisted of 2 croissants, 10 g of butter, 40 g of fat-rich cheese and 300 ml of 
fat-rich milk (3349 kJ; 50 g fat; 56 g carbohydrates and 28 g proteins). The 
carbohydrate-rich meals (both breakfast and lunch) consisted of 2 slices of 
bread, 25 g of marmalade, 30 g of cooked chicken breast, 50 g of ginger 
bread and 300 ml of drinkable yogurt enriched with 45 g of soluble sugars (3261 
kJ; 4 g fat, 162 g carbohydrates and 22 g of proteins). Both meals were eaten 
within 10 minutes. Apart from the test meals and water (ad libitum), participants 
refrained from food and drinks. In addition, physical activity was limited during 
the day.  
Laboratory analysis 
All laboratory analyses were performed at the VU University Medical 
Center (department of Clinical Chemistry) in Amsterdam, the Netherlands. 
Serum total cholesterol, HDL-cholesterol and triglycerides were measured by 
enzymatic colorimetric assays (Roche, Mannheim, Germany). LDL-cholesterol 
was calculated according to the Friedewald-formula (16). ALT was determined 
by an enzymatic assay (Roche, Mannheim, Germany) according to the 
methods proposed by the International Federation of Clinical Chemistry and 
Laboratory Medicine (17). Plasma glucose concentration was determined with 
a glucose oxidase method (Granutest, Merck, Darmstadt, Germany) and 
HbA1c was measured with cation-exchange chromatography (Menarini 
Diagnostics, Florance, Italy). The inter-assay coefficients of variation for the 
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triglyceride and glucose measurements were <1.8% and <2.2%, respectively. 
Immunospecific insulin was measured in serum by an immunometric assay in 
which proinsulin does not cross-react (ACS Centaur, Bayer Diagnostics, 
Mijdrecht The Netherlands). The inter- and intra-assay coefficients of variation 
for insulin were 6% and 3%, respectively. 
Statistical analyses 
Analyses were performed by SPSS for Windows 10 (SPSS Inc. Chicago, IL). 
Data are presented as mean values (standard deviation), percentage or, in 
case of skewed distribution, as median values (interquartile range) unless 
otherwise indicated. Differences in characteristics between NGM and DM2 
were tested with t-test for continuous variables and with χ2-test for dichotomous 
variables. Postprandial responses were calculated as incremental area under 
the curve (iAUC) with the trapezoid method. Missing values for a given time-
point (0.5% of all the glucose and triglyceride values) were imputed by 
interpolation.  
Insulin resistance was estimated by homeostasis model assessment 
(HOMA-IR), calculated as (mean fasting insulin(µU/mL)*mean fasting 
glucose(mmol/L))/22.5 (18). Mean glucose and insulin concentrations were 
derived from fasting measurements on two separate study days. 
To study the associations of possible determinants of postprandial 
triglyceride and glucose responses, linear regression analysis was performed 
with adjustment for age. As dependent variables, postprandial triglycerides 
(iAUC) after the fat-rich meals and postprandial glucose concentrations (iAUC) 
after the carbohydrate-rich meals were used. The associations were expressed 
as standardized regression coefficients (95% CI) by dividing the dependent and 
independent variables by the SD derived from the entire study population. A 
regression coefficient of 0.5 means that if the independent variable increases 
by 1.0 SD, the dependent variable increases by 0.5 SD. Multivariate models 
included age and all variables that were associated with the outcome 
variables at level P<0.10. For all other analysis, we considered a two-sided P 
value <0.05 to indicate statistical significance. 
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Results 
Characteristics of the study population 
Clinical and biochemical characteristics of the participants are listed in 
Table 1. Figure 1 shows the 8h-time courses of triglyceride and glucose 
concentrations following two consecutive fat-rich and two consecutive 
carbohydrate-rich meals. Triglyceride-iAUC (TG-iAUC) after the fat-rich meals 
was similar in the two groups (P=0.33) (Table2). Following the carbohydrate-rich 
meals, TG-iAUC was most marked in women with DM2 compared to NGM 
women (P=0.01). As expected, glucose-iAUC (GL-iAUC) and insulin-iAUC after 
the fat-rich and the carbohydrate-rich meals was most marked in the women 
with DM2 (All P<0.01). 
Associations with postprandial triglycerides 
Results of linear regression analyses are presented in Table 3. In the NGM 
group, fasting triglycerides were associated with TG-iAUC; also, HbA1c, fasting 
insulin, HOMA-IR, total cholesterol were positively associated, whereas HDL-
cholesterol and hip circumference were negatively associated with TG-iAUC. To 
study whether potential determinants of TG-iAUC were independent of fasting 
triglyceride levels, we made a multivariate model. For women with NGM, we 
included fasting triglycerides, hip circumference, HbA1c, fasting insulin, total 
cholesterol and HDL-cholesterol and adjusted for age and BMI (R2=0.52), and all 
these variables, except fasting insulin (P=0.08) and hip circumference (P=0.07), 
remained statistically significantly associated with TG-iAUC.  
In the DM2 group, fasting triglyceride, HbA1c and age were the strongest 
predictors of TG-iAUC. In a multivariate model with fasting triglycerides, HbA1c 
and age (R2=0.29), fasting triglyceride concentration was the only independent 
determinant of TG-iAUC. 
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Table 1. Clinical and biochemical characteristics of the 117 participants a 
 NGM DM2 
N 76 41 
Age (years) 60.1 (4.0) 58.9 (3.7) 
Duration of DM2 (years) NA 5 (3-9) 
Anthropometry    
     BMI (kg/m2)  26.3 (3.6) 32.7 (6.0) b
     Waist (m)   0.88 (0.10) 1.04 (0.14) b
     Hip (m) 1.04 (0.08) 1.12 (0.12) b
Glucose metabolism    
     HbA1c (%) 5.6 (0.3) 6.6 (0.6) b
     Fasting insulin (pmol/L) c 33.2 (25.5-47.5) 82.7 (38.8-122.5) b
     HOMA-IR c 1.29 (0.94-1.95) 4.05 (1.92-7.07) b
Lipids (mmol/L)   
     Total cholesterol 6.0 (0.9) 5.6 (1.0) 
     HDL-cholesterol 1.80 (0.49) 1.51 (0.34) b
     LDL-cholesterol 3.7 (0.9) 3.2 (1.0) b
Blood pressure (mmHg)   
     Systolic 131 (15) 143 (16) b
     Diastolic 72 (8) 79 (7) b
Liver enzyme (U/L)   
     Alanine aminotransferase 20 (16-26) 27 (20-40) b
Medication (%)   
    Antihypertensive  16 66 b
    Blood glucose lowering  NA 71 
    Use of insulin  NA 17 
Lifestyle    
     Former smoking (%) 49 39 
     Habitual hysical activity (h/week) 35 (23-46) 35 (22-46) 
     Alcohol > 0 gram/day (%) 78 37 b
NGM: Normal Glucose Metabolism, DM2: Diabetes Mellitus, HOMA-IR: Insulin resistance estimated by 
Homeostasis Model Assessment. Differences between groups tested with t-test for continuous variables and 
with χ2-test for dichotomous variables. a Data presented as mean values (SD) or percentages. In case of 
skewed distribution, data presented as median (interquartile range) and Ln-transformed values were tested. 
b P<0.05. c Subjects using insulin were excluded for these variables and insulin was calculated as mean of two 
measurements. 
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Figure 1. Figure 1. Triglyceride, glucose and insulin concentrations (mean±SEM) after ingestion of two 
consecutive meals. For insulin figures, patients who use insulin (n=7) were excluded. B: breakfast, L: lunch. 
NGM: normal glucose metabolism (○), DM2: type 2 diabetes mellitus (●). 
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Associations with postprandial glucose  
Results of the linear regression analyses for fasting and postprandial 
glucose after the carbohydrate-rich meals are presented in Table 3. In the NGM 
group, age, waist circumference and fasting triglycerides were positively, and 
HDL-cholesterol was inversely associated with GL-iAUC. In a multivariate model 
containing age, waist circumference, BMI, HDL-cholesterol and fasting 
triglycerides (R2=0.24), fasting triglycerides were still associated with GL-iAUC 
and age became significantly associated with GL-iAUC (beta=0.07 [0.01;0.14]).  
In women with DM2, HbA1c, fasting insulin, HOMA-IR and fasting 
triglycerides were positively associated with GL-iAUC. For this reason, fasting 
insulin was part of the multivariate model, and we excluded women with DM2 
who used insulin (n=7). In this model, only HbA1c remained associated with GL-
iAUC when adjusted for age, fasting glucose, fasting insulin, total cholesterol, 
triglycerides and habitual physical activity in a multivariate model (R2=0.68). 
Because HbA1c is not considered as a determinant but rather a consequence 
of GL-iAUC, we also made a multivariate model including the above 
mentioned variables except HbA1c. In this model (R2=0.51), fasting glucose was 
the strongest determinant of GL-iAUC (beta=0.49 [0.19;0.82]).  
 
Table 2. Fasting and postprandial glucose and triglyceride levels after fat-rich 
meals and after carbohydrate-rich meals a
 NGM DM2 
Fat-rich meals   
     Fasting triglycerides (mmol/L) 1.2 (0.6) 1.7 (0.7) b
     Triglycerides-iAUC (mmol/L) 0.9 (0.5) 1.0 (0.5) 
     Fasting glucose (mmol/L) 5.3 (0.4) 7.2 (1.5) b
     Glucose-iAUC (mmol/L) 0.1 (0.5) 0.7 (1.5) b
Carbohydrate-rich meals   
     Fasting triglycerides (mmol/L) 1.2 (0.6) 1.7 (0.6) b
     Triglycerides-iAUC (mmol/L) 0.2 (0.3) 0.3 (0.3) b
     Fasting glucose (mmol/L) 5.2 (0.4) 7.1 (1.3) b
     Glucose-iAUC (mmol/L) 0.4 (0.8) 3.6 (2.9) b
TG-iAUC and GL-iAUC were presented as mean incremental area under the curve (iAUC) during the day. 
Differences between groups tested with t-test. a Data presented as mean values (SD). b P<0.05. 
 
 
 
28 
Postprandial triglyceride and glucose responses 
G
L-
iA
UC
 
-0
.0
4 
(-
0.
46
;0
.3
9)
 
0.
18
 (-
0.
22
;0
.5
8)
 
0.
27
 (-
0.
09
;0
.6
2)
 
0.
22
 (-
0.
90
;1
.3
4)
 
0.
06
 (-
0.
82
;0
.9
4)
 
0.
30
 (-
0.
05
;0
.6
5)
 b
0.
86
 (0
.5
4;
1.
18
) b
,c
0.
47
 (0
.0
01
;0
.9
3)
 b
0.
42
 (0
.0
9;
0.
74
) b
0.
33
 (-
0.
03
;0
.6
8)
 b
-0
.1
6 
(-
0.
74
;0
.4
2)
 
0.
48
 (0
.0
8;
0.
88
) b
0.
31
 (-
0.
07
;0
.7
0)
 
0.
07
 (-
0.
37
;0
.5
1)
 
-0
.4
7 
(-
1.
06
;0
.1
2)
 
-0
.4
2 
(-
0.
90
;0
.0
6)
 b
D
M
2 
(n
=4
1)
 
TG
-iA
UC
 
0.
40
 (0
.0
4;
0.
75
) b
0.
02
 (-
0.
32
;0
.3
5)
 
0.
07
 (-
0.
24
;0
.3
7)
 
0.
34
 (-
0.
62
;1
.2
9)
 
0.
43
 (-
0.
32
;1
.1
8)
 
0.
11
 (-
0.
20
;0
.4
1)
 
0.
33
 (-
0.
01
;0
.6
7)
 b
0.
23
 (-
0.
23
;0
.6
8)
 
0.
18
 (-
0.
16
;0
.5
1)
 
0.
24
 (-
0.
06
;0
.5
4)
 
0.
01
 (-
0.
47
;0
.5
0)
 
0.
40
 (0
.0
6;
0.
73
) b
,c
0.
03
 (-
0.
30
;0
.3
6)
 
0.
17
 (-
0.
18
;0
.5
2)
 
0.
11
 (-
0.
40
;0
.6
2)
 
-0
.3
3 
(-
0.
72
;0
.0
7)
 
G
L-
iA
UC
 
0.
07
 (-
0.
00
3;
0.
14
) b
,c
- 
0.
04
 (-
0.
07
;0
.1
6)
 
0.
20
 (0
.0
1;
0.
38
) b
-0
.1
3 
(-
0.
29
;0
.0
3)
 
-0
.0
8 
(-
0.
32
;0
.1
6)
 
0.
13
 (-
0.
03
;0
.2
9)
 
0 
(-
0.
12
;0
.1
2)
 
0 
(-
0.
09
;0
.1
0)
 
-0
.0
1 
(-
0.
09
;0
.0
7)
 
-0
.1
0 
(-
0.
17
;-0
.0
4)
 b
0.
13
 (0
.0
5;
0.
21
) b
,c
0.
01
 (-
0.
08
;0
.0
9)
 
0.
04
 (-
0.
05
;0
.1
3)
 
0.
02
 (-
0.
05
;0
.0
9)
 
-0
.0
5 
(-
0.
12
;0
.0
3)
 
N
G
M
 (n
=7
6)
 
TG
-iA
UC
 
0.
04
 (-
0.
18
;0
.2
5)
 
- 
0.
05
 (-
0.
29
;0
.3
9)
 
0.
40
 (-
0.
15
;0
.9
7)
 
-0
.7
5 
(-
1.
21
;-0
.2
9)
 b
0.
50
 (-
0.
21
;1
.2
1)
 
0.
77
 (0
.3
1;
1.
22
) b
,c
0.
39
 (0
.0
5;
0.
74
) b
0.
32
 (0
.0
5;
0.
59
) b
0.
32
 (0
.0
9;
0.
55
) b
,c
-0
.3
1 
(-
0.
51
;-0
.1
2)
 b
,c
0.
60
 (0
.3
9;
0.
81
) b
,c
0.
09
 (-
0.
16
;0
.3
3)
 
0.
14
 (-
0.
13
;0
.4
1)
 
0.
06
 (-
0.
15
;0
.2
7)
 
0 
(-
0.
23
;0
.2
3)
 
Ta
bl
e 
3.
 L
in
ea
r r
eg
re
ss
io
n 
an
al
ys
is 
w
ith
 p
os
tp
ra
nd
ia
l t
rig
ly
ce
rid
e 
an
d 
gl
uc
os
e 
co
nc
en
tra
tio
ns
  
 V
a
ria
bl
es
 (S
D
) a
A
ge
 (3
.9
 y
ea
rs
) 
D
M
2 
d
ur
at
io
n 
(4
.3
 y
ea
rs
) 
BM
I (
5.
4 
kg
 m
-2
) 
W
a
ist
 (0
.1
4 
m
) c
H
ip
 (0
.1
0 
m
) c
Fa
st
in
g 
gl
uc
os
e 
(1
.2
 m
m
ol
/L
) 
Hb
A
1c
 (0
.7
%
) 
Fa
st
in
g 
in
su
lin
 (l
n)
 (0
.6
7)
 d
H
O
M
A
-IR
 (l
n)
 (0
.7
9)
 d
To
ta
l c
ho
le
st
er
ol
 (1
.0
 m
m
ol
/L
) 
HD
L-
c 
(0
.4
7 
m
m
ol
/L
) 
Tr
ig
ly
ce
rid
es
 (0
.6
 m
m
ol
/L
) 
A
LT
 (l
n)
 (0
.4
5)
 
Sy
st
ol
ic
 B
P 
(1
6 
m
m
H
g)
 e
A
lc
oh
ol
 (6
5 
g/
w
ee
k)
 
H
a
bi
tu
a
l p
hy
sic
a
l a
ct
iv
ity
 (1
8 
h/
w
ee
k)
 
a  
St
an
da
rd
ize
d 
re
gr
es
sio
n 
co
ef
fic
ie
nt
s (
95
%
 C
I) 
ad
ju
st
ed
 fo
r a
ge
 in
 S
D
 p
er
 1
 S
D
 in
cr
ea
se
 in
 in
de
p
en
de
nt
 v
ar
ia
b
le
. S
D
 fo
r T
G
-iA
UC
 0
.5
 m
m
ol
/L
 a
nd
 fo
r G
L-
iA
UC
 2
.3
 m
m
ol
/L
. b
 P
<0
.1
0,
 v
ar
ia
b
le
 in
cl
ud
ed
 in
 th
e 
m
ul
tiv
ar
ia
te
 m
od
el
; i
ns
ul
in
 a
nd
 n
ot
 H
O
M
A
-IR
 w
as
 in
cl
ud
ed
 w
he
n 
b
ot
h 
w
er
e 
sig
ni
fic
a
nt
. c
 v
ar
ia
bl
e 
sig
ni
fic
a
nt
 a
t l
ev
el
 P
<0
.0
5 
in
 m
ul
tiv
ar
ia
te
 m
od
el
. d
 A
dd
iti
on
al
ly
 a
dj
us
te
d 
fo
r B
M
I. 
e  
Su
b
je
ct
s u
sin
g 
in
su
lin
 (n
=7
) w
er
e 
ex
cl
ud
ed
. f
 A
dd
iti
on
al
ly
 a
dj
us
te
d 
fo
r 
us
e 
of
 a
nt
ih
yp
er
te
ns
iv
e 
m
ed
ic
at
io
n.
 
29 
Chapter 2 
Association between postprandial triglyceride and glucose responses 
We additionally assessed the age-adjusted association of GL-iAUC with 
TG-iAUC. In NGM women, no statistically significant association was found 
between these metabolic responses (beta=0.39 [-0.31;1.08]). In contrast, for 
women with DM2, GL-iAUC and TG-iAUC were associated (beta=0.26 
[0.002;0.53]). The latter association was in part dependent of fasting 
triglycerides; the regression coefficient reduced to 0.18 [-0.10;0.45] when fasting 
triglycerides were added to the model with age and GL-iAUC.  
 
Discussion 
The present study is to our knowledge the first to assess both postprandial 
triglyceride and glucose responses at two separate occasions in one study 
population. We demonstrated that fasting triglycerides were associated with 
both TG-iAUC and GL-iAUC, but other potential determinants of TG-iAUC and 
GL-iAUC differed. In spite of similar TG-iAUC responses in NGM and DM2, 
determinants of TG-iAUC and also of GL-iAUC clearly differed between women 
with NGM and DM2.  
We expected a more markedly prolonged triglyceride response 
especially after the second meal in patients with DM2 (19). The relative lack of 
exaggerated triglyceride response in women with DM2 might be the result of 
the meal-composition. The substantial amount of carbohydrates in the fat-rich 
mixed meal might suffice to elicit an insulin response. Indeed, attenuation of the 
triglyceride response was previously shown when glucose was added to a liquid 
fat-load (20). Also, the patients with DM2 included in the present study were 
well-controlled, possibly contributing to an ameliorated response of the liver to 
the meal-induced insulin response. On the other hand, since the women with 
DM2 were more insulin resistant than women with NGM (HOMA-IR), an elevated 
TG-iAUC was expected (21). Finally, we cannot exclude the possibility that a 
prolonged triglyceride response in patients with DM2 might have become 
evident with a longer observation period (22).  
A common mechanism for elevated postprandial triglyceride and glucose 
responses? 
Insulin resistance or central obesity, both components of the metabolic 
syndrome, might contribute to increased postprandial triglyceride and glucose 
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levels. Resistance to the suppressive effect of insulin on hepatic VLDL-production 
results in exaggerated postprandial triglyceride responses (23,24). We found 
that fasting insulin and HOMA-IR, as a reflection of insulin resistance and in 
particular hepatic insulin resistance, were associated with TG-iAUC in women 
with NGM, but the association disappeared when fasting triglycerides were 
added to the model. Furthermore, no association of HOMA-IR and fasting insulin 
with TG-iAUC in women with DM2 was found. However, also fasting triglycerides 
are a recognized component of the metabolic syndrome (25), and the 
association between fasting triglycerides and TG-iAUC might, at least in part, be 
the result of underlying hepatic insulin resistance.  
Impaired glucose tolerance has been attributed to a combination of  
peripheral insulin resistance and beta-cell dysfunction, whereas impaired fasting 
glucose is mainly associated with hepatic insulin resistance and impaired insulin 
secretion (26). This corroborates our finding that fasting glucose was associated 
with GL-iAUC in women with DM2, but not in NGM. The combination of hepatic 
insulin resistance and beta-cell dysfunction, reflected by elevated fasting and 
postprandial glucose levels, is common in DM2, but not in NGM. 
Central obesity as a component of the metabolic syndrome may be the 
common mechanism for elevated postprandial triglyceride and glucose 
concentration. The increased flux of free fatty acids in central obesity and 
elevated levels of pro-inflammatory adipocytokines result in so-called ectopic 
fat depositions in liver, muscle and beta-cells contributing to the development 
of hepatic and peripheral insulin resistance, and beta-cell dysfunction (27). 
Studies in men reported an association between visceral obesity and TG-iAUC 
(28,29). In line with these observations, a study among obese women showed 
that abdominal obesity, but not obesity as such, was associated with TG-iAUC. 
In the present study, the association between waist circumference and TG-iAUC 
was, although not statistically significant, stronger than the association between 
BMI and TG-iAUC. Furthermore, we found that hip circumference was inversely 
associated with TG-iAUC in women with NGM. An inverse relationship between 
larger hip circumference and fasting triglycerides was previously found in both 
men and women (30,31), and may be explained by an enhanced buffering 
capacity for triglyceride storage which prevents from fat deposition in other 
organs (32). The findings for GL-iAUC are comparable to those for TG-iAUC; 
central obesity seemed to be more strongly associated with elevated 
postprandial glucose than BMI in NGM women.  
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The present data also suggest that an elevated postprandial triglyceride 
response might be part of a dyslipidaemic lipid profile in women with NGM. 
Independent of fasting triglycerides, total cholesterol was positively and fasting 
HDL-cholesterol concentration was inversely associated with TG-iAUC. It is 
known that high levels of triglycerides and low HDL-cholesterol concentrations 
are associated (33) and postprandial lipaemia might be another feature of this 
so-called ‘diabetic’ dyslipidaemia. 
An important observation is that TG-iAUC was associated with GL-iAUC in 
DM2, but not in NGM. This suggests that the underlying mechanisms, e.g. 
hepatic insulin resistance and/or beta-cell dysfunction, is present in DM2, but 
not (yet) in NGM.  
Other potential mechanisms for postprandial triglyceride and glucose 
responses. 
An interesting finding was that HbA1c was strongly associated with TG-
iAUC in women with NGM. It is known that improvement of glycaemic control 
also improves postprandial triglyceride concentrations in patients with DM2 (34). 
This effect is attributed to the lipoprotein lipase (LPL) mediated clearance of TG-
rich lipoproteins, which is hampered when insulin action and/or secretion is 
inadequate (35). Since we did not measure LPL activity in this study, we cannot 
verify this assumption.  
The proportion of variance explained by the multivariate model for TG-
iAUC is lower for patients with DM2 (R2=0.29) compared to women with NGM 
(R2=0.52). In DM2, insulin resistance, only partly reflected by fasting triglycerides 
possibly plays an important role in increasing postprandial triglycerides, 
including the earlier discussed decreased LPL activity. The proportion of 
variance explained (R2) by the multivariate model for GL-iAUC was 0.51 for DM2 
and 0.24 for the NGM group. Obviously, the range in GL-iAUC is much smaller in 
women with NGM. Furthermore, we did not consider the effect of gut hormones 
(incretins), rate of gastric emptying and peripheral insulin resistance on GL-iAUC, 
which play important roles in glucose regulation. 
Study limitations 
A number of potential limitations of this study should be considered. First, 
the population consisted of Caucasian post-menopausal women aged 50 to 
65, and caution should be exercised to generalize our findings to other 
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populations. Second, the cross-sectional design limits us to assess causal 
relationships. Third, as a result of the smaller sample size of the DM2 population 
as compared to the NGM study population, less associations in the DM2 study 
population might have reached statistical significance. 
Conclusion 
In conclusion, GL-iAUC and TG-iAUC were interrelated in women with 
DM2 and fasting triglycerides were associated with both abnormalities. These 
findings suggest, at least partly, a common underlying mechanism for 
postprandial increments in glucose and triglycerides, especially occuring in 
women with DM2 and not in NGM. In healthy women, elevated TG-iAUC may 
belong to a dyslipidaemic lipid profile whereas fasting triglycerides were related 
to GL-iAUC, suggestive for an association with insulin resistance. 
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Abstract 
Objective: The present study aimed to compare the associations of 
postprandial glucose (ppGL) and postprandial triglycerides (ppTG) 
with carotid intima media thickness (cIMT) in women with normal 
glucose metabolism (NGM) and type 2 diabetes (DM2).  
Methods: Postmenopausal women (76 with NGM, 78 with DM2), 
received two consecutive fat-rich and two consecutive 
carbohydrate-rich meals on separate occasions. Blood samples 
were taken before and 1, 2, 4, 6 and 8 hours following breakfast; 
lunch was given at t=4. Ultrasound imaging of the carotid artery 
was performed to measure cIMT. 
Results: In women with NGM, an increase of 1.0 mmol/l glucose 
following the fat-rich meals was associated with a 50 µm cIMT 
increase (P=0.04), and following the carbohydrate meals, an 
increase of 1.8 mmol/l glucose was associated with a 50 µm larger 
cIMT (P=0.08). These associations were not explained by classical 
cardiovascular risk factors. However, no association between ppGL 
and cIMT was found in women with DM2 and ppTG were not 
associated with cIMT.  
Conclusion: The association between ppGL and cIMT in 
normoglycaemic women suggests that ppGL in the normal range is 
a marker or a risk factor for atherosclerosis. Postprandial glucose 
levels might be a better indicator of risk than post-OGTT glucose 
levels or triglyceride levels. 
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Introduction 
Men with type 2 diabetes mellitus (DM2) have a two- to three-fold and 
women a three- to four-fold increased risk of cardiovascular disease (CVD) 
(1,2). The increased risk for CVD in patients with DM2 is only partly explained by 
the classical CVD risk factors hypertension, high LDL-cholesterol, low HDL-
cholesterol and smoking (3). 
Disturbances in the postprandial metabolism are hypothesized to 
contribute to the excess risk of CVD, because of the elevated concentrations of 
glucose, triglyceride-enriched lipoproteins and inflammatory markers in the 
postprandial period (4). Glucose levels after an oral glucose tolerance test 
(OGTT) have been shown to be better indicators of CVD risk than fasting 
glucose levels in the general population and in subjects with a family history of 
DM2 (5-7). Also, postprandial triglyceride levels were more strongly related to 
cIMT than fasting triglyceride levels in both healthy subjects (8-10) and in 
patients with DM2 (11,12). However, the relative contributions of postprandial 
glucose (ppGL) levels and postprandial triglyceride (ppTG) levels to 
atherosclerosis are not clarified yet. 
Most postprandial studies applied a single fat-rich liquid-formula or an 
OGTT, but the association of the more physiological meal-related glucose and 
triglyceride responses with CVD might be more relevant. Furthermore, during 
daytime, glucose excursions following a first meal are known to affect the 
responses after a second meal (13). A cumulative effect of the triglyceride 
excursions following breakfast and lunch is likely to occur, especially in subjects 
with DM2 (14).  
The aim of the present study was to investigate the relation of ppGL and 
ppTG following two consecutive fat-rich meals or two consecutive 
carbohydrate-rich meals on two separate days, to cIMT, and to investigate 
whether these associations differ between women with normal glucose 
metabolism (NGM) and women with DM2.  
 
Methods 
Study population  
Women with DM2 (n=522), from the registry of the Diabetes Care System 
in the city of Hoorn, the Netherlands, and women who were randomly selected 
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from the municipal registry of Hoorn (n=541) aged 50-65 years at the beginning 
of the study, were invited to participate in the study.  
Exclusion criteria were non-postmenopausal status (menses in the last 12 
months), smoking, untreated endocrine disorder other than DM2, use of short 
acting insulin analogues, use of PPAR-α and -γ agonists, use of oral 
corticosteroids, use of hormone replacement therapy, fasting cholesterol >8.0 
mmol/l, fasting triglycerides >4.0 mmol/l, systolic blood pressure>190 mmHg, liver 
or renal impairment (liver derived enzymes >2.5 time the upper limit of the 
laboratory reference range, creatinine >120 µmol/l). Women who were 
selected from the municipal registry underwent a 75-g OGTT to verify their 
glucose tolerance status (fasting glucose <6.1 mmol/l and 2-hour post-load 
glucose <7.8 mmol/l (15)). Women with DM2 were excluded if they had HbA1c 
>9.0%. Women with NGM were excluded if they used HMG-CoA reductase 
inhibitors (statins), and women with DM2 who used statins were considered as a 
separate study group. 
Of the 1,063 women who were invited, 431 women were complete non-
responders and 258 women were not willing to participate. A total of 220 
women did not meet the inclusion criteria. Reasons for exclusion were: smoking 
n=65, elevated fasting and/or post-load glucose levels (NGM only) n=33, pre-
menopausal n=28, drop-out n=22, failure to draw blood samples from a canula 
n=19, use of hormone replacement therapy n=13, use of short acting insulin 
analogues n=12, illness during study participation n=6, elevated triglycerides 
n=4, use of PPAR-γ agonists n=4, use of statins (NGM only) n=3, blood pressure 
n=3, miscellaneous reasons n=4, cholesterol n=1, creatinine n=1, liver enzymes 
n=1 and missing cIMT n=1.  
Finally, 76 women with NGM and 78 women with DM2 completed the 
study protocol. All women gave written informed consent. The study was 
approved by the ethics committee of the VU University Medical Center.  
Screening visit 
The study consisted of three separate visits, i.e. a screening visit and two 
visits for the test-meals, with a maximum of one month apart. On the screening 
visit, fasting blood samples were drawn after a 12-h overnight fast.  
Blood pressure was measured at the left arm three times with 5 minutes 
intervals with an oscillometric blood pressure measuring device (Collin Press-
mate BP-8800, Colin, Komaki-City, Japan) after a 15-minute supine rest. Weight 
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and height were measured twice in barefooted participants wearing light 
clothes only. BMI was calculated as weight (in kg) divided by the square of 
height (in m). Waist circumference was measured twice at the level midway 
between the lowest rib margin and the iliac crest, and hip circumference was 
measured at the widest level over the greater trochanters. Medical history, 
medication, smoking and alcohol consumption were assessed by a 
questionnaire (16). Finally, physical activity was assessed by the Short 
Questionnaire to Assess Health-enhancing physical activity (17). 
Ultrasound imaging 
A single observer (MA) performed ultrasound imaging with an ultrasound 
scanner (350 Series, Pie Medical, Maastricht, The Netherlands), equipped with a 
7.5-MHz linear probe. Measurements were performed in the right common 
carotid artery at 10 mm proximal to the carotid bulb. Images were registered 
and analyzed by a personal computer equipped with vessel wall movement 
detection software and an acquisition system (Wall Track System, Pie Medical, 
Maastricht, the Netherlands).  
After a 15-minute supine rest, the artery was visualized in B-mode. After 
defining the segment, 10 mm proximal to the carotid bulb, the screen was 
switched to the M-mode and data acquisition in real-time presentation on the 
computer screen was enabled. Data were obtained by three consecutive 
measurements of 4 seconds each, triggered by the R-top of a simultaneously 
recorded ECG (18). Carotid IMT was measured from the posterior wall, as the 
distance from the first to the second echogenic line (19).  
Reproducibility of scanning was assessed in 7 women with DM2 and in 5 
women with NGM, who were examined twice, two weeks apart. The intra-
observer coefficient of variation (SD of the mean difference / (√2 * pooled 
mean) * 100%) for cIMT was 5.2%. 
Test meals 
All participants received two consecutive fat-rich meals on one occasion 
and two consecutive carbohydrate-rich meals on another occasion, in random 
order. Women arrived at the test facility in the morning after an overnight fast. 
Blood samples were taken before and at t=1, t=2, t=4, t=6 and t=8 hour after 
ingestion of the first test meal (breakfast). Lunch was given at t=4, immediately 
after a blood sample was taken. The nutrient composition of the meals was 
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calculated from the Dutch Nutrient Database (20). The fat-rich meals consisted 
of croissants, butter, cheese and fat-rich milk (3349 kJ; 50 g fat; 56 g 
carbohydrates and 28 g proteins). The carbohydrate-rich meals consisted of 
bread, marmalade, cooked chicken breast, ginger bread and drinkable yogurt 
enriched with soluble carbohydrates (3261 kJ; 4 g fat, 162 g carbohydrates and 
22 g proteins). Meals were eaten within 10 minutes. Apart from the test meals 
and water (ad libitum), participants refrained from food and drinks. In addition, 
throughout the visit, physical activity was limited to a short walk between two 
adjacent rooms.  
Laboratory analysis 
All laboratory analyses were performed at the VU University Medical 
Center in Amsterdam, the Netherlands. Serum total cholesterol, HDL-cholesterol 
and triglycerides were measured by enzymatic colorimetric assays (Roche, 
Mannheim, Germany). The inter-assay coefficients of variation for the 
triglyceride levels were 2.2% at a mean level of 1.0 mmol/l and 1.8% at a mean 
level of 1.9 mmol/l. Fasting LDL-cholesterol was calculated according to the 
Friedewald-formula (21). Plasma glucose levels were determined with a glucose 
oxidase method (Granutest, Merck, Darmstadt, Germany) and HbA1c was 
measured with reversed-phase cation exchange chromatography (Menarini 
Diagnostics, Florence, Italy). The inter-assay coefficients of variation for the 
glucose levels were 1.2% at a mean level of 4.9 mmol/l and 1.3% at a mean 
level of 19.0 mmol/l. Specific insulin was measured in serum by an 
immunometric assay in which proinsulin did not cross-react (Advia Centaur, 
Bayer Diagnostics, Mijdrecht, The Netherlands). The intra- and inter-assay 
coefficients of variation for insulin were <4% and <7%, respectively.  
Statistical analyses 
Analyses were performed in SPSS 12.0.1 for Windows (SPSS Inc. Chicago, 
IL). Differences in baseline characteristics between the three groups (NGM, DM2 
and DM2-ST) were tested with ANOVA with post-hoc analyses (LSD) for 
continuous variables that were ln-transformed in case of skewed distribution. 
Dichotomous variables were tested with χ2-test.  
Postprandial responses were calculated with the trapezoid method as 
total area under the curve (AUC) divided by 8 (hours). Insulin resistance was 
estimated by homeostasis model assessment (HOMA-IR), calculated as (mean 
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fasting insulin (mU/ml) * mean fasting glucose (mmol/l))/22.5 (22). Means for 
glucose and insulin were derived from fasting measurements on two separate 
study days. 
To study the possible associations between risk factors and cIMT and 
between postprandial responses and cIMT, we performed linear regression 
analysis with adjustment for age. The associations were expressed as regression 
coefficients per 1 SD (of the total study population) increase in independent 
variable. We tested for possible interactions of independent variables with DM2 
and use of statins by calculating the P-values of the interaction terms.  
Subsequently, regression coefficients for ppGL and ppTG were adjusted 
for fasting levels to investigate whether fasting levels explained the possible 
association between postprandial response and cIMT. To investigate the 
relative contribution of ppTG and ppGL to cIMT, we also made a mutually 
adjusted model for ppTG and ppGL. Finally, we tested BMI, total cholesterol, 
fasting insulin, HOMA-IR, systolic blood pressure, smoking, LDL-cholesterol and 
HDL-cholesterol as potentially confounding factors. We considered a two-sided 
P-value <0.05 to indicate statistical significance. For interaction terms, we 
considered P<0.15 statistically significant. 
 
Results  
Population characteristics assessed at the screening visit and fasting and 
postprandial glucose and triglycerides were presented separately for women 
with NGM, DM2 and women with DM2 using statin medication (DM2-ST, Table 1). 
Fasting and postprandial triglycerides and glucose, were similar in the DM2 
group and in the DM2-ST group, but were higher compared to the NGM group 
(all P<0.01, Table 1). Carotid IMT was increased and CVD was more prevalent in 
women with DM2 who were not using statins, but these differences did not 
reach statistical significance. In Table 2, results of linear regression analysis of 
known CVD risk factors with cIMT are shown. Because no interaction with DM2 
status or use of statins was found for most of the risk factors, we combined the 
subgroups for these analyses. Age was associated with cIMT: the estimated 
beta of 20.2 indicates that a 4 year difference in age is associated with a 20 µm 
larger cIMT (P=0.02). Also systolic blood pressure was associated with cIMT, a 
difference of 16 mmHg in systolic blood pressure was associated with a 19 µm 
difference in cIMT (P=0.04, model 1).  
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Table 1. Population characteristics (n=154) 
 NGM (n=76) DM2 (n=41) DM2-ST (n=37) 
Age (years) 60.1 (4.0) 58.9 (3.7) 61.1 (4.0) a
Duration of DM2 (years) - 5 (3-9) 4 (2-9) 
BMI (kg/m2) 26.3 (3.6) 32.7 (6.0) b 30.6 (4.6) b
Waist (cm) 88 (10) 104 (14) b 102 (13) b
Hip (cm) 104 (8) 112 (12) b 108 (10) b  
2-h post-load glucose (mmol/l) 5.4 (1.0) - - 
HbA1c 5.6 (0.3) 6.6 (0.6) b 6.8 (0.7) b
Fasting insulin (pmol/l) c,d 33.2 (25.5-47.5) 82.7 (38.8-122.5) b 82.3 (53.3-107.3) b
HOMA-IR c,d  1.29 (0.94-1.95) 4.05 (1.92-7.07) b 4.33 (2.53-6.61) b
Total cholesterol (mmol/l) c 5.7 (0.8) 5.5 (1.0) 4.4 (0.8) a,b
HDL-cholesterol (mmol/l) c 1.62 (0.42) 1.36 (0.29) b 1.33 (0.29) b
LDL-cholesterol (mmol/l) c 3.5 (0.8) 3.4 (0.9) 2.3 (0.7) a,b
Systolic blood pressure (mmHg) 131 (15) 143 (16) b 134 (16) a
Former smoking (%) 49 39 43 
Physical activity (hours/week) 37 (19) 36 (17) 31 (21) b
Alcohol intake >0gram/day (%) 78 37 b 46 b
Antihypertensive medication (%) 16 66 b 62 b
Diabetes treatment (%)    
  Diet/Metformin/Sulfonylureas only - 24/39/7 14/35/14 
  Metformin+sulfonylureas/    
metformin+acarbose/insulin 
- 10/2/17 19/0/19 
Meal measurements    
  Fasting triglycerides (mmol/l) c 1.2 (0.5) 1.7 (0.6) b 1.8 (0.6) b
  Fasting glucose (mmol/l) c 5.2 (0.4) 7.1 (1.4) b 7.5 (1.2) b
Fat-rich meals    
    PpTG (mmol/l)  2.1 (0.9) 2.7 (1.0) b 2.7 (0.9) b
    PpGL (mmol/l) 5.4 (0.5) 7.9 (1.8) b 7.8 (1.6) b
Carbohydrate-rich meals    
    PpTG (mmol/l) 1.4 (0.7) 2.0 (0.6) b 2.0 (0.7) b
    PpGL (mmol/l) 5.7 (0.8) 10.7 (3.5) b 11.5 (3.6) b
Cardiovascular disease (%) e 22 34 26 
Carotid IMT (µm) 764 (110) 790 (107) 769 (121) 
Data as means (SD) or percentages. In case of skewed distribution, medians (interquartile range) are 
presented and Ln-transformed values were tested. a P<0.05 compared to DM2 group. b P<0.05 compared to 
NGM group. c mean of 2 measurements. d women using insulin excluded. e Cardiovascular disease defined 
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as ankle-brachial-index <0.90, ECG-abnormalities (1.1-1.3, 4.1-4.3, 5.1-5.3 or 7-1), history of arterial surgery, 
cerebral vascular event, angina, amputation, claudication or possible myocardial infarction. 
Table 2. Linear regression analysis (beta (95% CI)) of risk factors and carotid 
intima media thickness (n=154) 
Variable  SD Model 1 Model 2  
Age  4.0 years 20.2 (2.6;37.8) a 22.7 (4.8;40.6) a
DM2  (yes versus no) 17.2 (-17.9;52.3) 33.1 (-9.3;75.5) 
DM2 duration b 4.7 years 12.7 (-11.1;36.5) 11.0 (-12.5;34.5) 
BMI  5.4 kg/m2 11.4 (-6.2;29.0) 7.7 (-13.0;28.3) 
Waist c 14.0 cm 13.0 (-31.6;57.6) 16.6 (-30.6;63.8) 
Hip c 10.3 cm -8.3 (-45.4;28.8) -8.7 (-47.6;30.3) 
2-hour post-load glucose d 1.0 mmol/l 2.1 (-22.8; 27.0) - 
HbA1c  0.76 % 12.4 (-5.2;29.9) 16.1 (-10.2;42.3) 
Fasting insulin b,e 59 pmol/l 1.7 (-19.2;22.6) -4.1 (-28.8;20.6) 
HOMA-IR b,e  3.4 5.0 (-15.3;25.2) -0.1 (-26.8;26.7) 
Total cholesterol 1.01 mmol/l 6.7 (-10.9;24.3) 7.4 (-13.6;28.3) 
HDL-cholesterol 0.39 mmol/l -8.0 (-25.8;9.8) -5.6 (-24.6;13.5) 
LDL-cholesterol 0.93 mmol/l 10.1 (-7.5;27.6)  12.4 (-9.1;33.9) 
Systolic blood pressure f  16 mmHg 18.9 (0.6;37.1) a 17.1 (-1.8;35.9) 
Former smoking g  (yes versus no) 23.5 (-25.6;72.5) - 
Alcohol intake b  63 gram/week 11.5 (-6.4;29.4) 17.7 (-1.1;36.6) 
Physical activity  19 hours/week -12.3 (-31.7;7.0) -12.0 (-31.5;7.4) 
Beta in µm intima media thickness per 1 SD increase in independent variable. Model 1: Adjusted for age. 
Model 2: Adjusted for age, DM2 and use of statins. a P<0.05. b Ln-transformed for analyses. c Waist and hip 
are additionally adjusted for each other and for BMI. d After an OGTT in women with NGM only. e Women 
using insulin excluded. f Additionally adjusted for use of antihypertensive medication. g Interaction with DM2 
(P=0.08) and use of statins (P=0.03), betas for women with NGM only. Other betas were: -50.6 (-117.4;16.1) 
and 59.2 (-22.4;140.7) for women with DM2 with DM2-ST, respectively. 
Results of linear regression analysis of fasting and postprandial glucose 
and triglycerides are shown in Table 3. Because we observed different 
associations of ppGL with cIMT for women with DM2 and women with NGM 
after both the fat-rich (P-value for interaction P=0.12) and the carbohydrate-
rich meals (P-value for interaction P=0.15), results are presented separately for 
women with NGM and DM2. We also found an interaction between fasting 
glucose and use of statin medication (P=0.07). Therefore, we performed the 
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regression analysis of fasting glucose with cIMT for women in the DM2-ST group 
separately. Fasting levels of glucose were statistically significantly associated 
with cIMT in women with DM2. In women with NGM, this association was of 
similar magnitude, although not statistically significant (Table 3). After mutual 
adjustment of fasting glucose and fasting triglycerides, the association between 
fasting glucose and cIMT in women with DM2 became stronger. After 
adjustment for CVD risk factors, (BMI, total cholesterol, fasting insulin, HOMA-IR, 
systolic blood pressure, smoking, LDL-cholesterol or HDL-cholesterol) the 
association between fasting glucose and cIMT remained statistically significant 
(data not shown). 
PpTG after both the test meals was not associated with cIMT in women 
with NGM and not in women with DM2. However, PpGL after both the fat-rich 
meals (P=0.04) and the carbohydrate-rich meals (borderline significant P=0.08) 
was associated with cIMT in women with NGM. A 1.0 mmol/l higher glucose 
level during the day of the fat-rich meals was associated with a 50 µm larger 
cIMT. In addition, after the carbohydrate meals, a 1.8 mmol/l higher glucose 
level was associated with a 50 µm larger cIMT. These associations only slightly 
changed after adjustment for fasting glucose or ppTG. Also adjustment for BMI, 
total cholesterol, fasting insulin, HOMA-IR, systolic blood pressure, smoking, LDL-
cholesterol or HDL-cholesterol as potentially confounding factors did not alter 
the associations between ppGL and cIMT (data not shown). Age-adjusted IMT 
in quartiles of ppGL for women with NGM is shown in Figure 1.  
To further explore the association between ppGL and cIMT, we 
performed regression analyses for each of the glucose measurements 
separately (1,2 and 4 hour) and for ppGL after breakfast only (AUC 0-4 hour) 
with regard to cIMT. Although borderline significant, glucose levels at t=1 and 
t=2 hour after the fat-rich meal were associated with cIMT (1.0 mmol/l glucose 
associated with a 19 µm larger cIMT at t=1 and 32 µm at t=2, both P=0.05). 
PpGL, after one meal (AUC 0-4 hour) was associated with cIMT similar to ppGL 
calculated after two consecutive meals. A 1.0 mmol/l higher glucose level after 
the fat-rich breakfast was associated with a 44 µm larger cIMT (P=0.03). 
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Figure 1. Age-adjusted cIMT (±SEM) in quartiles of mean postprandial glucose levels (mmol/l, 0-8 hour) 
following fat-rich meals (upper) and following carbohydrate-rich meals (lower) for women with NGM. P for 
trend derived from linear regression analyses with postprandial glucose levels as continuous variable: P<0.05 
and P=0.08 for fat-rich and carbohydrate-rich meals, respectively. 
Discussion 
In the present cross-sectional study, we compared the relative 
contribution of ppGL and ppTG to cIMT as an early marker of atherosclerosis. 
We found that ppGL, irrespective of the meal composition, was associated with 
cIMT in women with NGM but not in women with DM2. The association between 
ppGL and cIMT remained unaltered after adjustment for ppTG or other CVD risk 
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factors.  
Mild hyperglycaemia has previously been discussed as an 
underestimated cardiovascular risk factor (23). However, in the present study, 
we also included women with NGM, confirmed by OGTT. Remarkably, only in 
this normal range of fasting and postprandial glucose levels, ppGL was 
associated with cIMT. In the women with DM2, an association was found with 
fasting glycaemia but not with ppGL. Possibly, a high biological variation in 
ppGL has obscured the association with cIMT in these patients with DM2. 
Another possibility is that treatment with glucose lowering medication or dietary 
intervention in the women with DM2 might have influenced the association 
between ppGL levels and cIMT (24).  
Based on previously published papers, we would have expected an 
association between ppTG and cIMT, especially in patients with DM2 (11,12), 
but also in healthy subjects (8-10). Moreover, postmenopausal women have 
been shown to have higher postprandial lipaemia (25), which could potentially 
contribute to the high risk of CVD in these women (26,27). However, no 
associations between ppTG and cIMT were found in the present study. As to 
ppTG, no differences were found in a study with persons with and without CVD 
(28). In contrast, in another study, patients with coronary heart disease were 
found to have higher fasting triglycerides and higher ppTG than subjects 
without coronary heart disease (29). In the Atherosclerosis Risk in Communities 
Study, ppTG levels were found to be associated with early atherosclerosis, but 
only in non-obese subjects (8) and the investigators suggested that this 
association might be explained by high levels of atherogenic triglyceride-rich 
lipoprotein remnants in the postprandial state. These lipoprotein remnants were 
indeed related to cIMT, independent of ppTG (30). Since we did not measure 
lipoprotein remnant particles in the present study, we cannot address this 
question. It should furthermore be considered that gender-specific studies on 
the relation between ppTG and cardiovascular risk are scarce. The above 
mentioned Atherosclerosis Risk in Communities Study reported an association 
between ppTG and cIMT in both men and women, but an association with 
exercise-induced myocardial ischaemia was only present in men and not in 
women (8,31). Because of the increased risk for CVD converted by DM2 in 
postmenopausal women, studies in older women are urgently needed. 
 
Our fat-rich meal should be considered as a mixed meal because it 
contained carbohydrates, through which beta-cell stimulation will be induced. 
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Our data show that despite differences in test-meal composition and 
carbohydrate content (56 g or 162 g) an association between average ppGL 
levels and cIMT can be found. We also found that measuring glucose after one 
meal was enough to assess the association between ppGL and cIMT. However, 
glucose measured two hours after an OGTT, did not give a similar strong 
association with cIMT in women with NGM. This could not be due to limited 
precision of the single glucose measurement after the OGTT compared to the 
multiple postprandial glucose measurements, because we found a single 2-hour 
glucose measurement after a meal, although borderline significant, associated 
with a relevant increase in cIMT. This leads us to the conclusion that ppGL 
following a meal gives additional clinical relevant information compared to 2-
hour post-load glucose following a glucose solution. First of all, we should 
consider that the OGTT contained 75 gram glucose whereas the carbohydrate-
rich meal contained 162 gram carbohydrates which takes longer to digest due 
to higher carbohydrate load and the more complex molecular structure of 
carbohydrates in the meals. Secondly, it has been suggested that the relation 
between hyperglycaemia and cardiovascular disease is mediated by oxidative 
stress. Ceriello et al. showed a cumulative effect of postprandial 
hyperglycaemia and postprandial hypertriglyceridaemia on oxidative stress 
generation (32). Although a cumulative effect was possible after the mixed 
meal, we cannot confirm this because we did not find an independent 
association between ppTG and cIMT.  
Carotid IMT is a well-accepted marker for atherosclerosis and 
cardiovascular risk (33). Age and systolic blood pressure were associated with 
cIMT in our study. The estimated age-related increase of 50 µm per ten years is 
similar to that observed in a European study population (34) and is comparable 
to the age-effect in a study among women of the same age (35). Probably due 
to limited power, other CVD risk factors, systolic blood pressure excepted, were 
not statistically significantly associated with cIMT. Although the direction of the 
associations with cIMT were as expected, it should be noticed that not only 
atherosclerosis but also other mechanisms (thrombosis) play a role in 
development of CVD.  
The cross-sectional study design is a potential limitation to our study. We 
assumed that cIMT reflects the cumulative effect of previous atherogenic 
processes. However, cIMT is a result of dynamic processes over time: progression 
as well as regression due to treatment or lifestyle interventions occurs (24). 
Especially in the present population of women with DM2, who were treated 
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intensively, the treatment-related modification of the cIMT might have led to an 
underestimation of the true association between metabolic responses and 
atherosclerosis.  
The relative paucity of data in women and the disproportionately high risk 
of CVD in the present study population prompted us to perform the study. 
However, we should be careful in extrapolating the present results to other 
populations. In addition, the present study population cannot be viewed as a 
population-based cohort of postmenopausal women because from the 24% 
who agreed to participate, 40% did not meet the inclusion-criteria or dropped 
out of the study.    
The association of ppGL with cIMT in women with NGM was stronger than 
that of ppTG. The association between ppGL and cIMT in women with NGM 
suggests that ppGL, in the normal range, is a marker or a risk factor of CVD. 
Postprandial glucose measured after a fat-rich or a carbohydrate-rich meal, 
might give more information about development of atherosclerosis than 2-hour 
glucose, measured after an OGTT. 
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Abstract 
Aims: To compare the effects of a fat-rich and a carbohydrate-rich 
mixed meal on insulinogenic index as a measure of early insulin 
secretion in normoglycaemic women (NGM) and in women with 
type 2 diabetes (DM2). In addition, we assessed the relationship of 
anthropometric and metabolic factors with insulinogenic index.  
Methods: Postmenopausal women, 76 with NGM and 64 with DM2, 
received a fat-rich meal and a carbohydrate-rich meal on 
separate occasions. Early insulin response was estimated as 
insulinogenic index (∆Insulin0-30 min/∆Glucose0-30 min) derived from an 
isocaloric fat-rich (∆I30/∆G30(Fat)) and carbohydrate-rich 
(∆I30/∆G30(CH) meal. Associations of fasting triglycerides, 
postprandial triglycerides, BMI, waist and hip circumference and 
alanine aminotransferase (ALT) with insulinogenic indices were 
determined with adjustment for insulin sensitivity (estimated by 
homeostasis model assessment (HOMA-IR)) and age.  
Results: ∆I30/∆G30(Fat) was higher than ∆I30/∆G30(CH) in women with 
DM2 (60%, P<0.05) but not in women with NGM. In both groups, a 
higher insulinogenic index was correlated with lower glucose levels 
later following the meals. In women with DM2, HOMA-IR was 
positively associated with ∆I30/∆G30(CH). In women with NGM, waist 
circumference was independently and inversely associated with 
∆I30/∆G30(Fat) and with ∆I30/∆G30(CH); hip circumference was 
positively associated with ∆I30/∆G30(Fat).  
Conclusions: In women with DM2, the insulinogenic index following 
the fat-rich meal was higher than following the isocaloric 
carbohydrate-rich meal, which might favourably affect 
postprandial glucose excursions. The inverse association between a 
larger waist circumference and meal-induced insulinogenic index 
in women with NGM requires further mechanistic studies. 
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Introduction  
Insulin resistance and a decline in beta-cell function contribute to the 
development of type 2 diabetes (DM2) (1,2). Especially impairment of first-
phase insulin secretion as measured by an intravenous glucose tolerance test 
has been shown to be predictive for the development of DM2 (1,2). This first-
phase insulin response does not appear in physiological circumstances; i.e. 
following a meal or oral glucose ingestion (3). Therefore, to estimate early insulin 
secretion in physiological circumstances, the insulinogenic index (∆Insulin0-30 
min/∆Glucose0-30 min) is frequently used (4). Early insulin secretion is relevant for the 
control of postprandial glucose concentrations (5,6). The insulin response to an 
oral load is partly determined by secretion of incretins and by the rate of gastric 
emptying (7). In addition, meal composition affects these metabolic 
mechanisms (8). For these reasons, a mixed meal-induced beta-cell response is 
more representative for normal physiology than an oral glucose load. To our 
knowledge, no studies assessed differences in early insulin secretion induced by 
ingestion of isocaloric meals of different composition in persons with DM2. 
Factors affecting first-phase insulin secretion, include genetic factors and 
various environmental and metabolic factors, like in utero environment, diet 
high in saturated fat, obesity, body fat distribution, weight gain and elevated 
levels of free fatty acids (FFA) (9).  
In the present study, which includes post-menopausal women with normal 
glucose metabolism (NGM) and DM2, we firstly address the question whether 
isocaloric meals of different composition induce different glucose and insulin 
responses, expressed as the insulinogenic index. In addition, we aimed to assess 
the determinants of the insulinogenic index. 
 
Methods 
Study population  
The study population of the Hoorn prandial study has been described in 
detail previously (10). In brief, women with DM2 were randomly selected from 
the registry of the Diabetes Care System in the city of Hoorn, the Netherlands, 
and women with NGM were randomly selected from the municipal registry of 
Hoorn. All women were between 50 and 65 years of age, were post-
menopausal, non-smokers, had no untreated endocrine disorder other than 
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DM2, did not use PPAR-α and/or -γ agonists, oral corticosteroids or hormone 
replacement therapy. Women who were selected from the municipal registry 
underwent an oral glucose tolerance test (OGTT) to verify their glucose 
tolerance status (fasting glucose <6.1 mmol/l and 2-hour post-load glucose <7.8 
mmol/l (11)). Women with DM2 were excluded if they had HbA1c >9.0%. For the 
present analysis, women who used insulin analogues were also excluded. 
Finally, 76 women with NGM and 64 women with DM2 were included. All 
women gave written informed consent and the study was approved by the 
ethics committee of the VU University Medical Center.  
Study protocol 
On the first visit, fasting blood samples were drawn after a 12-h overnight 
fast. Weight and height were measured twice in barefooted participants 
wearing light clothes only. BMI was calculated as weight (in kg) divided by the 
square of height (in m). Waist circumference was measured twice at the level 
midway between the lowest rib margin and the iliac crest, and hip 
circumference was measured at the widest level over the greater trochanters. 
Medical history and medication were assessed by a questionnaire (12).  
On the second and the third visit, participants received either a fat-rich 
meal or a carbohydrate-rich meal after a 12-h overnight fast, in random order. 
Blood samples were taken before (t=0) and at t=30, t=60, t=120 and t=240 min 
after ingestion of the test meal. The fat-rich meal contained 3349 kJ; 50 g fat; 56 
g carbohydrates, 28 g proteins and 3 g fiber. The isocaloric carbohydrate-rich 
meal contained 3261 kJ; 4 g fat, 162 g carbohydrates, 22 g proteins and 5 g 
fiber (13).  
Laboratory analysis 
All laboratory analyses were performed at the VU University Medical 
Center in Amsterdam, the Netherlands. Plasma glucose levels were determined 
with a glucose oxidase method (Granutest, Merck, Darmstadt, Germany). 
Specific insulin was measured in serum by an immunometric assay in which 
proinsulin does not cross-react (Advia Centaur, Bayer Diagnostics, Mijdrecht, 
The Netherlands). Triglycerides were measured by an enzymatic colorimetric 
assay (Roche, Mannheim, Germany). Alanine aminotransferase (ALT) was 
determined by an enzymatic assay (Roche, Mannheim, Germany) according to 
the method proposed by the International Federation of Clinical Chemistry and 
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Laboratory Medicine (14). 
Statistical analyses 
Analyses were performed in SPSS 12.0.1 for Windows (SPSS Inc., Chicago, 
IL). Differences between participants with NGM and DM2 were tested with t-
test. Differences between meals were tested with a paired samples t-test.  
The insulinogenic index following the carbohydrate-rich meal 
∆I30/∆G30(CH)) and following the fat-rich meal ∆I30/∆G30(Fat)) was calculated 
by dividing the increment in insulin at t=30 by the increment in glucose at t=30 
(4). In case of negative ∆G30 values (n=5 for ∆I30/∆G30(CH) and n=14 for 
∆I30/∆G30(Fat), all women with NGM) we replaced these values by 0.1 mmol/l, 
which is the smallest difference in glucose that was measured. Mean 
postprandial insulin, glucose and triglycerides (total and incremental area 
under the curve (tAUC and iAUC)) were calculated by the trapezium rule and 
divided by 4 (hours) (15). Insulin resistance was estimated by homeostasis model 
assessment (HOMA-IR) and beta-cell function in the fasting state was estimated 
by HOMA-B (16). To study the possible associations with insulinogenic index, we 
performed linear regression analysis for ln-transformed insulinogenic indices with 
fasting and postprandial triglycerides, BMI, waist and hip circumference and 
ALT. Since age and HOMA-IR are strong determinants of insulin secretion (17), 
we adjusted for these variables and for use of statin medication (model 1). In an 
additional model (model 2), we included variables that had a strong 
association with insulinogenic index in model 1, and adjusted these variables for 
age, HOMA-IR, use of statin medication and for each other. We tested for 
possible interactions with DM2 and use of statin medication by calculating the 
p-values of the interaction terms. We considered a two-sided P-value <0.05 to 
indicate statistical significance. For interaction terms, we considered P<0.10 
statistically significant. 
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Results 
Characteristics of the study population are presented in table 1. In Figure 
1, glucose and insulin responses following the carbohydrate-rich and the fat-rich 
meal are shown. Glucose and insulin iAUC following the carbohydrate-rich meal 
were higher than after ingestion of the fat-rich meal (both, P<0.01). 
∆I30/∆G30(CH) and ∆I30/∆G30(Fat) were significantly lower in DM2 as compared 
to NGM women (both P<0.01, Figure 2). When comparing the indices of 
different meals, ∆I30/∆G30(Fat) was significantly higher than ∆I30/∆G30(CH) in 
women with DM2, but not in women with NGM (60% increase, P<0.01 versus 22% 
increase, P=0.46, Figure 2). 
 
Table 1. Characteristics of the study population  
 NGM (n=76) DM2 (n=64) 
Age (years) 60.1 (4.0) 60.3 (4.0) 
BMI (kg/m2) 26.3 (3.6) 31.3 (5.2) a
Waist (cm) 87.6 (9.6) 101.8 (12.7) a
Fasting glucose (mmol/l) b 5.2 (0.4) 7.4 (1.3) a
Fasting insulin (pmol/l) b 33.2 (25.5-47.5) 82.7 (48.8-115.5) a
Fasting triglycerides (mmol/l) c 1.2 (0.5) 1.8 (0.6) a
Triglycerides-tAUC (mmol/l) 2.1 (0.9) 2.3 (0.7) a
ALT (U/l) 20 (16-26) 26 (19-34) a
HOMA-IR b 1.3 (0.9-1.9) 4.1 (2.4-6.8) a
HOMA-B b  65.7 (54.7-87.0) 69.1 (44.2-93.5) 
Use of metformin (%) - 64 
Use of sulfonylureas (%) - 30 
Use of statins (%) - 47 
Means (SD). In case of skewed distribution medians (interquartile range) are presented and ln-transformed 
values are tested.  a P<0.05. b Based on the mean of two separate study days. c Based on the mean of three 
separate study visits. 
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Figure 1. Glucose and insulin responses (means ± SEM) following ingestion of a carbohydrate-rich meal or a 
fat-rich meal in women with NGM (•) and in women with DM2 (○).  
Since the associations between nearly all potential determinants and the 
insulinogenic indices differed between women with NGM and DM2, we 
performed regression analysis for NGM and DM2 study groups separately. Two 
interactions were found with use of statin medication (Table 2) and for all other 
regression analyses, we adjusted for the use of statin medication. In model 1 it is 
shown that BMI, waist and hip circumference were all negatively associated 
with ∆I30/∆G30(CH) in women with NGM, but not with ∆I30/∆G30(Fat). For women 
with NGM, model 2 included age, HOMA-IR, use of statins, waist and hip 
circumference, BMI and fasting triglycerides. In this multivariate model, waist 
circumference was inversely associated with ∆I30/∆G30(CH) and with 
∆I30/∆G30(Fat). Hip circumference became positively associated with 
∆I30/∆G30(Fat). In women with DM2, HOMA-IR was associated with a higher 
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∆I30/∆G30(CH). In women with DM2 who do not use statin medication, waist 
circumference was negatively associated with ∆I30/∆G30(CH) (Table 2). In a 
multivariate model with age, HOMA-IR, TG-tAUC, BMI, waist and hip 
circumference, all variables lost statistical significance. 
0
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P =0.46
 
Figure 2. Geometric means (68% CI) of ∆I30/∆G30 (pmol/mmol) following a carbohydrate-rich meal (white 
bars) and a fat-rich meal (grey bars) in women with NGM and DM2. Geometric means ± 68%CI are derived 
from the means ± SEM of the ln-transformed data. 
Additional analyses 
To explore the possible relation between insulinogenic index and the 
following postprandial glucose levels, we calculated Pearson's correlation 
coefficients with ln-transformed insulinogenic indices. In women with NGM, after 
both the fat-rich and the carbohydrate-rich meal, insulinogenic index was 
inversely correlated with glucose levels at t=120 (r=-0.52 and r=-0.42, both 
P<0.05, fat-rich and carbohydrate-rich meal, respectively), but not at t=240 (r=-
0.17, and r=-0.22, both N.S., for fat-rich and carbohydrate-rich meal, 
respectively). In DM2, an inverse correlation between insulinogenic index and 
glucose levels was present at t=120 (r=-0.43 and r=-0.56, both P<0.05, fat-rich 
and carbohydrate-rich meal, respectively) and t=240 (r=-0.32 and r=-0.54, both 
P<0.05, fat-rich and carbohydrate-rich meal, respectively). 
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Discussion  
In the present study, we compared beta-cell responses to two isocaloric 
meals of different composition. The fat-rich mixed meal resulted in lower 
glucose and insulin responses than the carbohydrate-rich meal as can be 
expected from the lower carbohydrate content in the fat-rich meal. However, 
the insulinogenic index following the fat-rich meal was higher than following the 
carbohydrate-rich meal in women with DM2 but not in women with NGM. 
Furthermore, in women with NGM, waist circumference was independently 
associated with a lower insulinogenic index. In women with DM2, HOMA-IR was 
associated with higher insulinogenic index.  
Insulin secretion and insulin sensitivity are tightly interrelated in healthy 
persons; such that the insulin response in insulin resistant persons is higher than in 
insulin sensitive persons (17). The relationship between insulin sensitivity and 
insulin secretion has been described by a hyperbolic function which suggests 
that insulin sensitivity * insulin secretion (= disposition index) is constant (18). 
However, in the present data, the relationship between ∆I30/∆G30 and HOMA-IR 
was not hyperbolic. Indeed, not all indices of insulin secretion and sensitivity can 
be described by a hyperbolic function (19). Furthermore, given the fact that 
disposition index reflects glucose tolerance status rather than beta-cell function 
(19), we chose not to use (∆I30/∆G30)/HOMA-IR, as an estimate of disposition 
index, but to use ∆I30/∆G30 as outcome variable and to adjust the regression 
models for HOMA-IR. We found a positive linear relationship between ∆I30/∆G30 
and HOMA-IR in DM2 when both variables were ln-transformed before analysis, 
but no clear association was present in NGM (Table 2).  
Meal-induced insulin secretion 
  The postprandial blood glucose and insulin responses highly depend on 
type and amount of carbohydrates in a meal. The postprandial glycaemic 
response can be quantified by the amount of carbohydrates and the 
glycaemic index of a meal (20). Both the amount of carbohydrates and the 
glycaemic index were higher for the carbohydrate-rich meal as compared to 
the fat-rich meal (glycaemic index data not shown), which partly explains the 
higher glucose responses following the carbohydrate-rich meal. The meal-
composition related differences in insulinogenic index were present in DM2 but 
were much less pronounced in NGM women. Therefore, we suggest that the 
lower insulinogenic index after the carbohydrate-rich meal as compared to the 
 64
 Meal-composition and insulin secretion 
fat-rich meal in women with DM2, is possibly the result of beta-cell insensitivity to 
the high glucose levels, a well-described characteristic of DM2. 
 Besides the amount of carbohydrates, the amount of fat and protein 
might have affected early insulin secretion. It has previously been demonstrated 
that adding fat to a carbohydrate-rich meal decreases the rate of gastric 
emptying (8), resulting in lower glucose and insulin responses. It is also well 
established that proteins can enhance insulin secretion (21, 22), the magnitude 
of the reponse being dependent on the amino acid composition (23). The 
difference in protein content between the fat-rich and the carbohydrate-rich 
meal was small (28 g versus 22 g), but the type of proteins may have differently 
affected the insulin response. However, in the present study, we chose to apply 
mixed meals in order to mimic normal physiology. This unabled us to distinguish 
separate effects of macronutrients on insulin secretion.  
 The higher insulinogenic index following the fat-rich meal was, as 
expected (24), inversely associated with the glucose concentration later 
following the meal. As previously suggested by Gannon et al., changing meal 
composition in patients with DM2 might be an opportunity to improve 
postprandial hyperglycaemia (25). However, it is of importance to consider 
other metabolic effects of a fat-rich or protein-rich diet besides 
hyperglycaemia. 
Associations with insulinogenic index 
Waist circumference, reflecting visceral fat, was independently 
associated with a lower early insulin response in women with NGM, irrespective 
of the meal composition. Visceral fat accumulation is accompanied by a 
higher lipolytic rate and flux of FFA in the portal circulation (26). A higher 
availability of FFA may result in ectopic triglyceride accumulation, e.g. in liver, 
muscle and pancreas, leading to insulin resistance and diminished beta-cell 
function. Several studies in humans have shown that insulin secretion is inhibited 
after chronic exposure to FFA (27-29). Some observations support the hypothesis 
that the adverse effects of lipids on insulin secretion only occur in the presence 
of hyperglycaemia, also referred to as gluco-lipotoxicity (30-32). Despite this 
hypothesis, in the present study, we found an association between waist 
circumference and diminished early insulin secretion in women with NGM, and 
only weakly in women with DM2. In agreement with this, changes in beta-cell 
function due to elevation of FFA has previously been shown in non-diabetic 
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individuals, while no effect was seen in individuals with DM2 (33). The authors 
argued that accounting for differences in insulin sensitivity would result in an 
inverse relationship between FFA and insulin secretion in DM2 patients. We 
adjusted the regression models for HOMA-IR, which did not result in an inverse 
relation between waist circumference and insulin secretion. Instead, we found 
that HOMA-IR was the most important determinant for the early insulin response 
in the present well controlled patients with DM2.  
 An alternative pathway for the association between waist 
circumference and decreased insulin secretion is by chronic low-grade 
inflammation due to so-called adipocyte derived adipocytokines, as for 
example tumor necrosis factor-alpha (34). In our study, the association between 
fasting triglycerides and insulinogenic indices in women with NGM completely 
disappeared after entering waist circumference in the model. Apparently, a 
higher waist circumference is associated with both impaired beta-cell function 
(lipotoxicity) and insulin resistance-induced dyslipidaemia (26).  
Limitations 
Although the insulinogenic index derived from an OGTT (35) and a meal 
(9) correlates with first-phase insulin secretion measured with the 
hyperglycaemic clamp, the insulinogenic index is not analogous to insulin 
secretion measured by the hyperglycaemic clamp (36). The insulinogenic index 
following a meal is dependent on the meal-induced release of incretins in the 
gut and the rate of gastric emptying (37). Therefore, the insulinogenic index 
may be considered as an important representative for normal physiology.  
 Sulfonylureas enhance insulin secretion in patients with DM2. This might 
have resulted in an augmented early insulin secretion in these patients (38). 
Indeed, patients with DM2 who used sulfonylureas had slightly higher 
insulinogenic indices (data not shown). This difference did however not affect 
our data on differences in insulinogenic indices between meals and 
insulinogenic index-related variables.  
 Because of the cross-sectional study design, we cannot assess the true 
effect of, for example, chronic exposure to triglycerides on early insulin 
secretion. Furthermore, FFA were not measured in the present study, which limits 
our ability to interpret our data in the context of the lipotoxicity model. Finally, 
the two standardized meals differed in both fat and carbohydrate content, 
which limits our conclusions about the separate effects of the meal 
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components on beta-cell response. However, by using the insulinogenic index, 
glucose increments are accounted for.  
Conclusion 
In conclusion, in the present study, the higher insulinogenic index 
following the fat-rich meal compared to the isocaloric carbohydrate-rich meal 
in women with DM2 may contribute to a more favourable postprandial 
glycaemic response. The inverse association between waist circumference and 
meal-related insulinogenic index in women with NGM warrants further 
mechanistic studies.  
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Chapter 5 
Abstract                    
Objective: High proinsulin concentration may be a better predictor 
for cardiovascular (CVD) mortality than insulin concentration. 
Previous observations may have been confounded by glucose 
tolerance status or lack of precision due to high intra-individual 
variability. We investigated the longitudinal relation of means of 
duplicate measurements of insulin and proinsulin with all-cause and 
CVD mortality in a population-based cohort taking glucose 
tolerance status into account. 
Research design and methods: Fasting and post 75 gram glucose-
load (2-hour) glucose, insulin and proinsulin values were determined 
in duplicate on 2 separate days, in 277 participants with normal 
glucose metabolism (NGM), 208 participants with impaired glucose 
metabolism (IGM) and 119 newly detected patients with type 2 
diabetes mellitus of the Hoorn Study. Insulin resistance and beta-cell 
function were estimated by homeostasis model assessment (HOMA-
IR and HOMA-B) and the fasting proinsulin/insulin ratio was 
calculated. Subjects were followed with respect to mortality until 
the first of January of 2003.  
Results: Fasting proinsulin levels were significantly associated with 
all-cause and CVD mortality, the hazard ratios per increase in 
interquartile range adjusted for age and gender were, 1.21 (95% 
confidence interval (CI): 1.04-1.42) for all-cause mortality and 1.33 
(1.06-1.66) for CVD mortality. Adjustment for glucose tolerance 
status and HOMA-IR did not substantially change the associations.  
Conclusions: Fasting proinsulin was associated with all-cause and 
CVD mortality, independent of glucose tolerance status and insulin 
resistance and largely independent of other CVD risk factors. 
Proinsulin might play a role in the relation between insulin resistance 
and CVD. 
 
 
 
 
 72
Proinsulin and (cardiovascular) mortality 
Introduction 
Hyperinsulinaemia is a marker of insulin resistance and was associated 
with all-cause mortality (1) and cardiovascular disease (CVD) mortality in 
prospective studies in the general population (2,2-6). The association between 
post-load insulin and CVD mortality was found to be weaker than the 
association between fasting insulin and CVD mortality (2,7,8).  
A number of population based studies showed that proinsulin, the 
precursor of insulin, is a better predictor of coronary heart disease than insulin (9-
12). However, in these studies, glucose tolerance status may have confounded 
this relationship. So, less is known about the role of insulin or proinsulin in the 
pathway to CVD. It has been suggested that proinsulin as a molecule might be 
atherogenic (13). In addition, higher proinsulin levels may also be attributed to 
beta-cell dysfunction (14). Another explanation is that insulin resistance explains 
the relation of both insulin and proinsulin with (CVD) mortality.   
Differences in the predictive value of insulin and proinsulin in the fasting 
and the post-load state, are difficult to interpret because of the inherent 
differences in variability. Insulin and proinsulin concentrations have been shown 
to be highly variable, in particular in the post-load state (15) and random 
misclassification leads to an underestimation of the true association with CVD. In 
the present study, in a subsample of the population based Hoorn study cohort, 
stratified for glucose tolerance status, fasting and post-load insulin and proinsulin 
levels were determined twice on 2 separate days, 2 weeks apart. HOMA-IR (16) 
was used as a marker of insulin resistance. To study the possible role of beta-cell 
dysfunction, disproportionately elevated proinsulin/insulin ratio (17) and HOMA-
B (16) are calculated. 
The aim of this study was, firstly, to investigate the longitudinal association 
of the mean of duplicate measures of fasting and post-load, insulin and 
proinsulin concentration and insulin resistance, estimated by HOMA-IR value 
with all-cause and CVD mortality. Secondly, to study the role of insulin resistance 
and glucose tolerance status in the relation between insulin or proinsulin and 
mortality. All analyses were done in a population-based cohort, which was 
stratified for glucose tolerance status. 
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Research design and methods 
Study population 
The Hoorn Study is a population-based cohort study on type 2 diabetes in 
the general Dutch population. The study population and research design have 
been described in detail previously (15). In summary, in 1989 3553 men and 
women, aged 50-75 years, were randomly selected from the population register 
of the middle-sized Dutch town of Hoorn. Of the 2540 subjects (71.5 %) who 
agreed to participate, 56 non-Caucasians were excluded. Therefore, the study 
cohort consisted of 2484 men and women. All subjects gave their written 
informed consent. The Ethics Committee of the VU University Medical Center 
approved the study. After exclusion of patients with known diabetes (n=90), as 
defined by use of insulin or blood glucose lowering agents, or a prescribed diet 
for diabetes, a subgroup of 1109 participants from the initial study cohort, 
stratified by age, gender, and 2-hour post-load glucose values, was invited for a 
second oral glucose tolerance test. For reasons of efficiency, insulin and 
proinsulin were measured in duplicate (approximately 2 weeks apart) in a 
subsample of 630 participants of the stratified sample of 1109 participants, 
including participants with impaired glucose tolerance and all participants with 
newly detected diabetes (15). Subjects with values below the lower limit of 
sensitivity of the insulin or proinsulin assay were excluded. For the present 
analyses, subjects were included if either insulin or proinsulin values were 
available in duplicate (n=605). Of these 605 subjects, one subject was lost to 
follow-up. Thus, the present study population comprised 604 subjects. 602 
participants have duplicate insulin values and proinsulin values were available 
for 511 participants.  
Measurements 
Anthropometric measurements were obtained from all participants. 
Weight was measured while participants were wearing light clothes only. 
Participants were not wearing shoes while height was measured. Body mass 
index (BMI) was calculated as weight (kg) divided by height (metres) square. 
Waist circumference (cm) was measured following a standardized procedure 
(15). Systolic and diastolic blood pressures were determined at the right upper-
arm, after 5 min of rest in seated participants, with a random-zero 
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sphygmomanometer (Hawksley-Gelman, Lancing, UK). The average of 
duplicate measurements was used.  
All laboratory analyses were performed at the VU University Medical 
Center in Amsterdam. Fasting plasma glucose concentration and 2-hour post-
load plasma glucose concentration were determined by the glucose 
dehydrogenase method (Merck, Darmstadt, Germany). Immuno-specific insulin 
was measured in serum by a double antibody radio immunoassay (lot SP21, 
Linco Research, St. Louis, U.S.A.) in which proinsulin and 32,33 split proinsulin 
cross-reacts by less than 0.2%. Proinsulin was measured by a double-antibody 
radioimmunoassay (Lilly Laboratory for Clinical Research, Indianapolis, U.S.A.) in 
which 31,32-proinsulin crossreact by 63% (18). Triglycerides, total cholesterol and 
HDL-cholesterol, measured on the first visit, were determined by enzymatic 
techniques (Boehringer-Mannheim, Mannheim, Germany).  
Mortality follow-up 
There is a continuous follow-up to register mortality from the participants 
of the Hoorn Study with the municipal register of the city of Hoorn providing 
information about the vital status of the participants. Information of causes of 
death was obtained from medical records of general practitioners and from the 
local hospital. Causes of death were coded according to the International 
Classification of Diseases, Ninth Revision (19). CVD mortality was defined as ICD-
9 codes 390-459 (Diseases of the circulatory system) or 798 (sudden death, 
cause unknown), because generally, sudden death is of cardiovascular origin 
(20). The mortality follow-up was completed until the first of January of 2003.  
Statistical methods 
Glucose tolerance status (based on fasting and post-load glucose 
values), fasting and post-load insulin and proinsulin values were based on the 
mean of two measurements. If only one value was determined, values were 
based on one measurement. This was done for one subject for fasting plasma 
glucose, for 16 subjects for post-load plasma glucose, for 16 subjects for fasting 
insulin and for 61 subjects for fasting proinsulin. The mean fasting and post-load 
glucose values of duplicate oral glucose tolerance tests were used to define 
the glucose tolerance status of the participants (21). Insulin resistance was 
estimated by HOMA-IR, calculated as (fasting insulin (µU/ml) * fasting glucose 
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(mmol/l))/22.5. Beta-cell function was estimated by HOMA-B, calculated as 
(fasting insulin (µU/ml) * 20) / (fasting glucose (mmol/l) - 3.5)(16). 
Differences in baseline measurements for groups of glucose tolerance 
status were examined using linear regression for continuous data and logistic 
regression for dichotomous data, adjusted for age. Correlations between insulin, 
proinsulin, HOMA-IR and HOMA-B were calculated by Spearman correlation 
coefficients, because of skewed distribution of insulin and proinsulin. 
Hazard ratios (HR) and 95% confidence intervals (CI) were obtained from 
multivariate Cox proportional hazards models. Hazard ratios are calculated for 
one increase in interquartile range value, which is calculated for each variable. 
All models were adjusted for age and gender. We tested for possible interaction 
between insulin, proinsulin, HOMA-IR and glucose tolerance status by adding 
two product terms to the survival models; insulin*impaired glucose metabolism 
(IGM) and insulin*type 2 diabetes. We also tested for possible interaction 
between insulin, proinsulin, HOMA-IR and gender, because this was found in 
some studies (2). In the second model we additionally adjusted for glucose 
tolerance status as a potential confounding factor. Thirdly, we additionally 
adjusted for insulin resistance, calculated as HOMA-IR, to investigate the effect 
of insulin and proinsulin levels on (CVD) mortality, independent of HOMA-IR. To 
find other potential confounding or mediating factors, we added fasting and 
post-load glucose, BMI, triglycerides, HDL-cholesterol, total cholesterol, 
hypertension and current smoking one by one to the third model. We adjusted 
our model for the variables that affected the estimated association. A P-value 
<0.05 was considered to be statistically significant. Testing for interaction, we 
considered a P-value <0.10 to be statistically significant. Statistical analyses were 
performed with the SPSS software package for Windows (version 10.1.4).  
Results 
The characteristics of the study cohort stratified for glucose tolerance 
status are shown in Table 1. Of the 609 participants, 156 died, of whom 59 died 
from CVD or sudden death during 11 years of follow-up. There was an 
increasing risk of all-cause mortality over the glucose tolerance groups (P=0.04). 
For CVD mortality, increase in risk over glucose tolerance groups was not 
statistically significant (P=0.10). All other variables except gender and total 
cholesterol, differed statistically significant (P<0.05) over glucose tolerance 
groups. 
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TABLE 1. Baseline characteristics and mortality, in categories of glucose 
tolerance status (n=604) 
Variable NGM a
N=277 
IGM 
N=208 
New DM 
N=119 
Baseline    
Age (years) 63.4 (7.3) 64.5 (7.2) 66.0 (6.4) 
Gender (% male) 48.4 48.6 47.9  
Body mass index (kg/m2) 25.9 (3.3) 27.9 (4.1) 28.6 (4.0) 
Waist circumference (cm) 89 (10) 96 (12) 99 (10) 
Fasting glucose (mmol/l) b 5.3 (0.4) 6.0 (0.5) 8.0 (2.5) 
2-hour post-load glucose (mmol/l) 
b
5.6 (1.4) 8.5 (1.4) 14.3 (5.2) 
Triglycerides (mmol/l) 1.3 (1.0-1.8) 1.7 (1.2-2.3) 2.0 (1.3-2.8) 
HDL-cholesterol (mmol/l) 1.38 (0.38) 1.26 (0.38) 1.14 (0.27) 
Total Cholesterol (mmol/l) 6.6 (1.1) 6.8 (1.2) 6.6 (1.3) 
Diastolic blood pressure (mmHg) b 81 (10) 85 (10) 85 (9) 
Systolic blood pressure (mmHg) b 133 (18) 143 (20) 145 (17) 
Hypertension (%) c 27.5 48.6 55.5 
Current smoker (%) 31.4 21.6 21.0 
Fasting specific insulin (pmol/l) b 72.1 (56.1-92.9) 88.6 (69.8-123.7) 117.2 (89.3-159.7) 
Fasting proinsulin (pmol/l) b 9.5 (5.6-13.5) 14.2 (8.5-21.3) 21.7 (11.8-31.9) 
Proinsulin/insulin ratio b 0.12 (0.07-0.19) 0.14 (0.10-0.22) 0.16 (0.11-0.24) 
Post-load specific insulin (pmol/l) b 311 (182-443) 533 (345-888) 601 (353-921) 
Post-load proinsulin (pmol/l) b 49.8 (29.3-78.5) 74.9 (52.0-115.4) 93.4 (66.1-133.3) 
HOMA-IR 2.8 (2.1-3.7) 4.0 (3.0-5.5) 6.6 (5.0-9.5) 
HOMA-B 137 (105-181) 123 (90-175) 104 (63-145) 
11-year follow-up    
All-cause death [number of 
events (%)] 
59 (21.3%)  55 (26.4%) 42 (35.3%) 
CVD mortality or sudden death 
[number of events (%)] 
20 (7.2%) 22 (10.6%) 17 (14.3%) 
Data presented as means (SD), in case of skewed distribution as median values (interquartile range). Linear 
regression for continuous variables: P<0.05, except for total cholesterol (P=0.98). Logistic regression for 
percentages: P<0.05, except for gender (P=0.69) and CVD mortality (P=0.10). a Glucose tolerance status 
based on the mean fasting and 2-hour post-load glucose levels of 2 Oral Glucose Tolerance Tests. b Based 
on the mean of two measurements. c Hypertension (diastolic blood pressure ≥95 mmHg or systolic blood 
pressure ≥160 mmHg or medication). 
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Spearman correlation coefficients between insulin, proinsulin, HOMA-IR 
and HOMA-B are shown in Table 2. All shown variables were statistically 
significant correlated with each other (P<0.01), except fasting proinsulin with 
HOMA-B and proinsulin/insulin ratio with post-load insulin and with HOMA-IR. 
Proinsulin/insulin ratio was statistically significant but inversely related to fasting 
insulin and HOMA-B.  
TABLE 2. Spearman Correlation coefficients for insulin and proinsulin, HOMA-IR 
and HOMA-B 
 Fasting 
specific 
insulin 
Fasting 
proinsuli
n  
Proinsulin
/insulin 
ratio 
Post-
load 
specific 
insulin  
Post-
load 
proinsuli
n  
HOMA-IR 
Fasting proinsulin  0.47 a      
Proinsulin/insulin ratio -0.14 a 0.78 a     
Post-load specific insulin  0.67 a 0.43 a 0.04    
Post-load proinsulin  0.51 a 0.68 a 0.41 a 0.74 a   
HOMA-IR 0.95 a 0.53 a -0.04 0.63 a 0.52 a  
HOMA-B 0.63 a 0.09 -0.34 a 0.44 a 0.25 a 0.38 a
HOMA-IR: (fasting insulin (µU/ml) * fasting glucose (mmol/l)) / 22.5; HOMA-B: (fasting insulin (µU/ml) *20) / 
(fasting glucose (mmol/l) - 3.5). a Correlation is statistically significant (P<0.01). 
Hazard ratios for fasting insulin, fasting proinsulin and HOMA-IR, adjusted 
for age and gender were calculated for separate strata of glucose tolerance 
first. The hazard ratios for insulin and for HOMA-IR were the highest in the NGM 
group (data not shown). Proinsulin was associated with mortality in all groups of 
glucose tolerance status. Since the tests for interactions of insulin, proinsulin, 
HOMA-IR with glucose tolerance status were not statistically significant (P>0.10), 
these groups were combined for subsequent analyses. The associations with 
mortality did not differ between men and women (data not shown). 
In Table 3, hazard ratios per increase in interquartile range (IR), calculated 
from the present study population, for both all-cause and CVD mortality are 
shown. Fasting insulin, proinsulin/insulin ratio, post-load insulin and proinsulin 
levels, and HOMA-B were not significantly associated with all-cause or CVD 
mortality. Fasting proinsulin, however, was significantly associated with all-cause 
mortality (HR=1.21, CI: 1.04-1.42) and CVD mortality (HR=1.33, CI: 1.06-1.66), 
adjusted for age and gender. After adjustment for glucose tolerance status and 
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additionally for HOMA-IR, the hazard ratios for proinsulin were only slightly 
attenuated, and remained significant. HOMA-IR was associated with all-cause 
mortality (HR=1.16, CI: 1.01-1.32), but not with CVD mortality. By including fasting 
proinsulin in the model of HOMA-IR the association between HOMA-IR and all-
cause mortality disappeared (HR=1.00, CI: 0.83-1.20). Also, by including 
proinsulin in the model of insulin, hazard ratios for insulin became smaller (Table 
3) while hazard ratios for proinsulin did not substantially change (data not 
shown).  
TABLE 3. Hazard Ratios for fasting and post-load insulin and proinsulin, HOMA-IR 
and HOMA-B (n=604)  
 
                                
Interquartile 
range 
HR (95% CI) for all-
cause mortality 
HR (95% CI) for CVD 
mortality 
Fasting specific insulin  51.6 pmol/l   
   Model 1  1.15 (0.98-1.35) 1.14 (0.87-1.49) 
   Model 2  1.09 (0.91-1.31) 1.04 (0.77-1.40) 
   Model 3  - - 
   Model 1+ proinsulin  1.00 (0.81-1.22) 0.90 (0.65-1.25) 
Fasting proinsulin 12.8 pmol/l   
   Model 1  1.21 (1.04-1.42) 1.33 (1.06-1.66) 
   Model 2  1.19 (1.00-1.40) 1.27 (1.00-1.63) 
   Model 3  1.21 (1.00-1.46) 1.34 (1.01-1.76) 
   Model 3 + triglycerides  1.18 (0.97-1.43) 1.29 (0.97-1.72) 
   Model 3 + hypertension a  1.19 (0.98-1.44) 1.31 (0.99-1.73) 
   Model 3 + current smoking   1.23 (1.01-1.49) 1.37 (1.03-1.81) 
Proinsulin/insulin ratio 0.12   
   Model 1  1.11 (0.96-1.28) 1.19 (0.97-1.47) 
   Model 2  1.10 (0.95-1.28) 1.17 (0.95-1.45) 
   Model 3  1.11 (0.95-1.29) 1.18 (0.95-1.47) 
Post-load specific insulin 408 pmol/l   
   Model 1  1.06 (0.95-1.19) 1.10 (0.93-1.31) 
   Model 2  1.03 (0.91-1.17) 1.06 (0.87-1.28) 
   Model 3  1.01 (0.88-1.16) 1.04 (0.85-1.28) 
Post-load proinsulin 57.5 pmol/l   
   Model 1  1.12 (0.92-1.37) 1.26 (0.93-1.70) 
   Model 2  1.07 (0.87-1.33) 1.16 (0.84-1.61) 
   Model 3  1.06 (0.85-1.31) 1.15 (0.82-1.60) 
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HOMA-IR 2.82   
   Model 1  1.16 (1.01-1.32) 1.16 (0.94-1.44) 
   Model 2  1.10 (0.93-1.30) 1.07 (0.82-1.40) 
   Model 3  - - 
   Model 1 + proinsulin  1.00 (0.83-1.20) 0.97 (0.73-1.29) 
HOMA-B 82.3   
   Model 1  0.99 (0.83-1.19) 0.94 (0.69-1.28) 
   Model 2  1.03 (0.86-1.24) 0.99 (0.73-1.35) 
   Model 3  0.99 (0.81-1.21) 0.95 (0.68-1.34) 
Hazard ratios per increase in interquartile range. a Hypertension: Diastolic blood pressure ≥95 mmHg or 
systolic blood pressure ≥160 mmHg or medication. Model 1: Adjusted for age and gender. Model 2: Adjusted 
for age, gender and glucose tolerance status. Model 3: Adjusted for age, gender, glucose tolerance status 
and HOMA-IR. 
In addition, we tested for other potential confounding risk factors (Table 
3) in the relation between proinsulin and (CVD) mortality. Only triglycerides and 
hypertension slightly attenuated the association between proinsulin and all-
cause mortality. Other risk factors i.e. fasting and post-load glucose, BMI, HDL-
cholesterol, total cholesterol and HOMA-B did not change the association 
between proinsulin and mortality (data not shown).  
 
Discussion 
In the present study, in a subsample of a population-based prospective 
study, we found that proinsulin was an independent risk factor for both all-cause 
and CVD mortality, also after adjusting for both insulin resistance and glucose 
tolerance status. 
An increase of 12.8 pmol/l proinsulin was associated with a 21% higher all-
cause mortality and a 33% higher CVD mortality. The association of proinsulin 
with mortality risk appeared stronger than that of insulin with mortality risk. This 
has also been observed in another longitudinal study (9) and in cross-sectional 
studies (22,23). Moreover, in a model which included both proinsulin and insulin 
or HOMA-IR, proinsulin remained significantly associated with (CVD) mortality, 
whereas insulin or HOMA-IR did not. Only one previous study considered insulin 
as a covariate (11). In that study, proinsulin remained an independent risk factor 
for stroke and the excess risk of insulin disappeared when proinsulin was added 
to the model. 
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High proinsulin levels can be a result of insulin resistance or beta-cell 
failure, and both may contribute to the association between proinsulin and 
CVD. Proinsulin has been shown to be strongly associated with insulin resistance 
in a recent study (24), which may at least partly explain the association with 
CVD and mortality (25,26). A strong correlation between proinsulin and HOMA-
IR can cause multi-colinearity when both variables are included in the same 
model. In the present study, the Spearman Correlation coefficient between 
proinsulin and HOMA-IR was 0.53, which is substantially lower than the 0.90 cut-
off value, which is often used as a rule of thumb to define multi-colinearity. We 
found that the association between proinsulin and (CVD) mortality was 
independent of insulin resistance. In contrast, the association between HOMA-IR 
and CVD mortality disappeared following adjustment for proinsulin. Therefore, 
high proinsulin levels might be an intermediate factor in the association 
between insulin resistance and CVD risk, in which high proinsulin levels are more 
closely related to CVD than insulin resistance.  
High proinsulin levels may also be attributed to beta-cell dysfunction or an 
increased demand on the beta-cell (14). In the present study, 
disproportionately elevated proinsulin/insulin ratio or HOMA-B (16) were not 
associated with an increased risk of CVD mortality. This suggests that proinsulin 
per se may contribute to the atherogenic or thrombogenic process. Indeed, a 
clinical study in which human proinsulin was administered for at least one year 
was stopped when 6 patients, treated with human proinsulin, had adverse 
cardiovascular events (13), whereas subjects treated with insulin had no 
adverse events.  
In the IRAS study, plasminogen-activator inhibitor-1 (PAI-1) was suggested 
to play a role in the association between proinsulin and CVD (22). Increased 
PAI-1 activity promotes both fibrosis and thrombosis and is associated with CVD 
(27). It was already shown that PAI-1 activity increased after insulin or proinsulin 
was administered in vitro (28) and in vivo (29). Unfortunately, in the Hoorn Study, 
data on PAI-1 are not available.  PAI-1 levels are elevated in subjects with insulin 
resistance, impaired glucose metabolism and the metabolic syndrome (27). 
Therefore, the metabolic syndrome which is defined by high triglycerides, 
impaired glucose metabolism, hypertension, abdominal obesity and/or low HDL 
(30), is another potential confounding factor in the relation between proinsulin 
and CVD risk. However, in our data, triglyceride concentration, glucose 
tolerance status and hypertension explained only a small part of the association 
between proinsulin and CVD risk.  
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Hyperinsulinaemia has been shown to predict all-cause (1) and CVD 
mortality in the general population (2,4,5,8). We did find an association 
between insulin and CVD mortality, similar to the findings in the meta-analysis of 
the DECODE Insulin Study Group. However, in the present study, the association 
between insulin and CVD mortality was not significant, probably because of the 
relatively small number of cases.  
In a number of studies, the association between insulin and coronary 
heart disease was J-shaped (3) or U-shaped (31). In the present sub-population 
of the Hoorn Study, the number of cases was too small to explore this. When we 
analysed the entire Hoorn Study population, baseline insulin levels were 
available for 1806 participants with normal glucose metabolism. Indeed, the 
hazard ratios for fasting specific insulin of the lowest quintile against the middle 3 
quintiles, adjusted for age and gender, were 1.10 (95% CI: 0.81- 1.50) for all-
cause mortality and 1.07 (95% CI: 0.65-1.75) for CVD mortality (unpublished 
data). For the present analysis, we did not consider this as a relevant deviation 
of a linear association.  
In some studies, post-load insulin levels, two hours following a 75 gram 
glucose load, have been associated with coronary artery disease (7,8). In the 
present study, post-load insulin levels were not significantly associated with 
mortality and the association was weaker than between fasting insulin and 
mortality. These results are consistent with findings from a recent meta-analysis 
(2). The weaker association between post-load insulin and mortality was 
explained by the larger biological variation of post-load insulin levels. In our 
study, biological variation was reduced by measuring insulin levels in duplicate, 
but this still could play a role in attenuating the association between post-load 
insulin and mortality.  
We did not use gold standard techniques for measuring insulin sensitivity 
(i.e. the hyperinsulinaemic euglycaemic clamp) and for beta-cell function (i.e. 
the hyperglycaemic clamp) (32). Instead, HOMA-IR was used as an estimate of 
insulin resistance (16). In previous studies, HOMA-IR was found to be a predictor 
of CVD in diabetic patients (25,33). However, HOMA-IR cannot be used to 
estimate insulin resistance in diabetic patients (34). Therefore, patients with 
known diabetes were excluded in the present study. Our observation that insulin 
levels and HOMA-IR were the strongest predictors of all-cause and CVD 
mortality in subjects with a normal glucose tolerance status, might be explained 
by the fact that insulin and HOMA-IR are less accurate indices of insulin 
resistance in patients with IGM or newly detected diabetes. 
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Strength of our study is that levels of insulin, proinsulin and glucose were 
measured twice to improve the precision. We included participants with newly 
diagnosed diabetes and with IGM, to enlarge the range of distribution of insulin, 
proinsulin, HOMA-IR and HOMA-B. Also, these subjects are especially important 
to include because of their enhanced CVD risk. 
In our study, proinsulin concentration was associated with both all-cause 
and CVD mortality independent of glucose tolerance status and insulin 
resistance. In addition, we showed that the association between HOMA-IR and 
all-cause mortality disappeared by entering proinsulin to the model. High 
proinsulin levels might therefore play a role in the atherothrombotic process, 
possibly as an intermediate in the association between insulin resistance and 
CVD risk.  
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Abstract 
Objective: Cholesteryl ester transfer protein (CETP) concentration 
strongly influences HDL metabolism and it might affect diabetic 
dyslipidaemia. We investigated potential determinants of CETP 
concentration in subjects with normal glucose metabolism (NGM), 
impaired glucose metabolism (IGM) and type 2 diabetes mellitus 
(DM2).  
Methods and results: CETP concentration was determined in 241 
persons with NGM, 147 with IGM and 243 with DM2 during the 2000-
2001 follow-up examination of the Hoorn Study.  
As potential determinants of CETP concentration, we considered 
age, gender, smoking, alcohol intake, physical activity, glucose 
metabolism, triglycerides, total cholesterol, and the -629C/A 
polymorphism in the CETP gene promoter. Female gender (beta, 
adjusted for all other potential determinants [95% CI] was 0.17 
[0.07;0.28]), prevalence of IGM (0.14 [0.02;0.26]), alcohol intake (-
0.05 [-0.08;-0.01]), total plasma cholesterol (0.14 [0.09;0.19] and the -
629 C-allele (0.17 [0.13;0.21]) were associated with CETP 
concentration. 
Conclusions: Female gender, impaired glucose metabolism and 
total plasma cholesterol and the -629 C-allele were all associated 
with higher CETP concentration, and alcohol intake was inversely 
associated with CETP concentration, irrespective of all other 
potential determinants. Differences in gender, concentrations of 
total plasma cholesterol, alcohol intake or -629 C-alleles might 
explain differences in CETP concentration between patients with 
and without DM2. 
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Introduction  
Cholesteryl ester transfer protein (CETP) plays a key role in the reverse 
cholesterol transport (RCT) (1,2) which returns cholesterol from peripheral tissues 
to the liver for elimination from the body (3). In this pathway CETP mediates the 
transfer of cholesteryl ester (CE) from high density lipoprotein (HDL) particles and 
low density lipoprotein (LDL) particles to very low density lipoprotein particles 
(VLDL) in exchange for triglycerides (4,5). Previous studies have suggested that 
increased CETP concentration is associated with an increased risk of 
cardiovascular disease (CVD) by reducing HDL-c levels and enriching VLDL with 
CE. The latter can be metabolized to atherogenic small dense LDL (6-8). This 
may be particularly important in the presence of diabetic dyslipidaemia (9). 
Previous studies have shown decreased, normal or elevated CETP 
concentration in type 2 diabetes (DM2) (9-16). These unequivocal results 
indicate the need to understand the determinants of CETP concentration, and 
particularly in DM2 patients. Previous studies described the effects of plasma 
cholesterol in normal and hypercholesterolaemic subjects, triglycerides in DM2 
subjects, smoking in subjects with insulin dependent diabetes, alcohol intake of 
alcohol abusers compared to control subjects, physical activity in healthy 
normolipidaemic subjects and -629C/A polymorphism in patients with coronary 
artery disease on CETP concentration (12,17-22). This is the first study to 
investigate in depth the determinants of CETP concentration with a special 
focus on the role of glucose metabolism. 
 
Subjects and methods 
Study Population 
For the present study, we used data from the 2000-2001 Hoorn Study 
follow-up examination (23) and the Hoorn Screening Study (24), which were 
both population-based studies. From the participating 836 participants, we 
excluded individuals with missing data on primary variables of interest (glucose 
metabolism (n=12), CETP concentration (n=29) and total plasma cholesterol 
(n=37)). We furthermore excluded persons who used lipid-lowering medication 
(n=127). The resulting study population (n=631) consisted of 241 persons with 
normal glucose metabolism (NGM), 147 persons with impaired glucose 
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metabolism (IGM=impaired fasting glucose and/or impaired glucose tolerance) 
and 243 persons with type 2 diabetes mellitus (DM2). Categories of glucose 
metabolism were defined according to the WHO-99 criteria (25). All persons 
gave written informed consent. The ethics committee of the VU University 
Medical Center approved the study. 
Laboratory analyses 
HbA1c was measured by ion-exchange high performance liquid 
chromatography (reference range 4.3-6.1 %). Fasting and post-load plasma 
glucose concentrations were determined by the glucose dehydrogenase 
method. Triglycerides, total plasma cholesterol and HDL-c were determined by 
enzymatic techniques (Roche, Mannheim, Germany). LDL-cholesterol was 
directly determined by the N-geneousTM assay (Genzyme, Cambridge MA). 
Non-HDL-c was calculated as the difference between total cholesterol and 
HDL-c. CETP concentration was measured by a two-antibody sandwich 
immunoassay which was developed and described by Niemeijer-Kanters et al 
(26,27). Inter-assay and intra-assay coefficients of variation were 7.8 and 6.0%, 
respectively. As a standard, pool plasma containing 2 mg CETP/ml was taken. 
The alleles of the -629C/A polymorphism in the promoter regions of the CETP 
gene were determined by extracting DNA from white blood cells for PCR 
genotyping, as previously described in detail (22).  
Questionnaires 
Habitual physical activity and alcohol intake were measured by 
validated questionnaires (28,29). 
Cardiovascular disease 
Prevalent CVD was defined as self-reported history of arterial surgery, 
cerebral vascular event, amputation, angina, claudication, possible infarction, 
measured ankle-brachial-pressure index <0.90 or ECG-abnormalities (Minnesota 
codes 1-1, 1-2, 1-3, 4-1, 4-2, 4-3, 5-1, 5-2, 5-3 or 7-1). Resting 12-lead ECGs were 
recorded by a standardized procedure as previously described (30). Doppler-
assisted systolic blood pressure measurements were performed to calculate 
ankle-brachial-pressure index (30). The Rose questionnaire (31) was used to 
determine presence of angina, claudication or possible myocardial infarction.  
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Statistical analyses  
Screening the literature, age, gender, glucose metabolism, triglycerides, 
total plasma cholesterol, smoking, alcohol use, physical activity and the -
629C/A polymorphism of the CETP gene promoter were considered to be 
possible determinants of CETP concentration. Prevalent CVD, Hba1c, insulin, 
LDL-c, HDL-c and non-HDL-c were described but not considered as potential 
determinants. Differences in characteristics between men and women were 
tested with t-test and dichotomous variables with a non-parametric test. For 
men and women separately, differences in characteristics between tertiles of 
CETP concentration were tested with linear or logistic regression analyses for 
continuous and dichotomous variables, respectively, with tertiles of CETP 
concentration as independent variable (P for trend). For frequencies of the -
629C/A polymorphism, chi-square test was used to test deviation from the 
Hardy-Weinberg equilibrium.  
In a multivariate linear regression model with CETP concentration as 
dependent variable, we first studied all potential determinants separately 
adjusted for age, gender and glucose metabolism. We tested for interactions of 
the potential determinants with study population (Hoorn Study and Hoorn 
Screening Study), gender and glucose metabolism by adding an interaction 
term in the regression model. To investigate independent associations of the 
potential determinants with CETP concentration, we subsequently adjusted for 
all potential determinants. Results were reported as unstandardized betas (95% 
confidence interval (CI)) which implies that a beta of 0.5 indicates that CETP 
concentration increases by 0.5 mg/L if a parameter increases by 1 unit (i.e. one 
mmol/L or one -629 C-allele).   
A P-value <0.05 was considered statistically significant, except for 
interaction, where we used P-value <0.10 as statistically significant. All analyses 
were performed in SPSS (Version 11.0, Chicago, Ill.). 
 
Results 
Table 1 shows the characteristics of the entire study population stratified 
for gender and tertiles of plasma CETP concentration. Women had higher CETP 
concentration, total cholesterol, LDL-cholesterol, HDL-cholesterol and non-HDL-
cholesterol concentration than men (p<0.01 for all, data not shown). The -
629C/A polymorphism of the CETP gene promoter was in Hardy Weinberg-
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equilibrium in the total study population. In both men and women, total plasma 
cholesterol (P<0.01), LDL-c (P<0.05 for men, <0.01 for women), non-HDL-c 
(P<0.01) and the number of C-alleles of -629C/A (P<0.01), increased with 
increasing CETP tertiles. In men, also Hba1c differed between tertiles of CETP 
concentration (P<0.05). No other differences in characteristics were observed.  
Because there were no statistically significant interactions of the potential 
determinants with gender and glucose metabolism (P-value for interaction 
>0.10), we performed the multivariate regression analyses in the total study 
population (Table 2). Female gender, prevalent CVD, current smoking 
(inversely), triglycerides, total cholesterol, LDL-cholesterol, non-HDL-cholesterol, 
and the number of C-alleles of the -629C/A polymorphism were all significantly 
associated with CETP concentration (P<0.05). 
Table 3 shows results of a multivariate linear regression model (R²=0.22) of 
all potential determinants of CETP concentration. Triglycerides and smoking 
showed no independent associations with CETP concentration. Female gender, 
total plasma cholesterol and the number of C-alleles of the -629C/A 
polymorphism remained strongly and independently associated with CETP 
concentration. Also, prevalence of IGM and alcohol intake (inversely) proved 
to be independently associated with CETP concentration in this model. This 
means that a 10-fold increase in alcohol consumption (which is the difference in 
intake between men and women in the present study) is associated with a 
decrease of 0.05 mg/L CETP concentration. Furthermore, an increase of 1.0 
mmol/L total cholesterol concentration is associated with an increase of 0.14 
mg/L CETP concentration. If the number of C-alleles of the -629C/A 
polymorphism increases with one, CETP concentration increases with 0.17 mg/L. 
Finally, women have an on average 0.17 mg/L higher CETP concentration and 
persons with IGM have an on average 0.14 mg/L higher CETP concentration. 
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Table 2. Associations (Beta (95% CI)) with CETP concentration: linear regression 
analysis 
Regression coefficient adjusted for age, gender and glucose metabolism 
Age (years) 0.00 (-0.01 ; 0.00) 
Female gender (yes vs no) 0.30 ( 0.20 ; 0.39) 
Prevalent CVD (yes vs no) 0.10 ( 0.01 ; 0.20) 
Current smoking (yes vs no) -0.12 (-0.26 ; -0.01) 
Alcohol intake (g/day) a -0.02 (-0.06 ; 0.02) 
Habitual physical activity (h/week) a  0.00 (-0.07 ; 0.07) 
IGM (yes vs no) 0.10 (-0.02 ; 0.22) 
DM2 (yes vs no) -0.04 (-0.15 ; 0.07) 
Triglycerides (mmol/L) a  0.47 ( 0.07 ; 0.86) 
Total cholesterol (mmol/L) 0.13 ( 0.09 ; 0.18) 
LDL-c (mmol/L) 0.10 ( 0.05 ; 0.15) 
HDL-c (mmol/L) -0.06 (-0.18 ; 0.07) 
Non-HDL-c (mmol/L) 0.14 ( 0.09 ; 0.18) 
Number of C-alleles (0,1 or 2) b 0.15 (0.11 ; 0.19) 
a Data were log-transformed for analyses. b number of C-alleles, AA or AC or CC allelic combination of the –
629C/A polymorphism. 
 
 
Table 3 Associations (Beta (95% CI)) with CETP concentration: linear regression 
analysis 
Mutually adjusted regression coefficient 
Age (years) 0.00 (-0.01 ; 0.00) 
Female gender (yes vs no) 0.17 (0.07 ; 0.28) 
Current smoking (yes vs no) -0.10 (-0.22 ; 0.03) 
Alcohol intake (g/day) a  -0.05 (-0.08 ; -0.01) 
Habitual physical activity (h/week) a  -0.01 (-0.08 ; 0.06) 
IGM (yes vs no) 0.14 (0.02 ; 0.26) 
DM2 (yes vs no) -0.02 (-0.13 ; 0.09) 
Triglycerides (mmol/L) a  0.00 (-0.43 ; 0.43) 
Total cholesterol (mmol/L) 0.14 ( 0.09 ; 0.19) 
Number of C-alleles (0,1 or 2) b 0.17 ( 0.13 ; 0.21) 
a Data were log-transformed for analyses. b number of C-alleles, AA or AC or CC allelic combination of the –
629C/A polymorphism. 
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Discussion 
In this population-based study, female gender, prevalence of IGM, but 
not DM2, plasma cholesterol levels, the number of C-alleles of the -629C/A 
polymorphism and alcohol intake (inversely) were associated with CETP 
concentration, independent of other potential determinants. This is the first 
study assessing independent determinants of CETP concentration. 
Cholesterol 
Previous studies showed that plasma CETP concentration was increased 
in patients with hypercholesterolaemia (5,8,32,33). Also dietary cholesterol has 
been reported to increase plasma CETP concentration (33,34), an effect that 
was shown to be related to increased CETP gene expression through sterol 
responsive DNA elements in the CETP gene promoter (18,35,36). In line with this, 
the use of cholesterol lowering agents, like statins, causes a decrease of CETP 
concentration (37,38). Our data from a population consisting of subjects with 
NGM, IGM and DM, agree with the notion that increased cholesterol levels are 
associated with increased CETP concentration. 
To study the association of LDL-c, VLDL-c and HDL-c with CETP 
concentration is complicated. As described above, cholesterol in these 
lipoproteins can induce CETP gene transcription (39). On the other hand, CETP 
affects cholesterol content in the distinct lipoproteins by transfer of CE from HDL 
to LDL and VLDL. This leads to an ambiguous interpretation of the associations 
between these distinct lipoproteins and CETP concentration. Therefore, we 
considered total plasma cholesterol as a more appropriate potential 
determinant of CETP concentration.  
Gender 
Other studies found that women had higher CETP concentration than 
men (17,40). We showed that female gender was strongly and independently 
associated with CETP concentration. A sterol, like oestrogen may stimulate CETP 
gene transcription by the sterol responsive DNA elements and therefore 
increase CETP concentration. Indeed, a positive association between 
oestrogen and CETP concentration has been previously described (41). 
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Alcohol intake 
The inverse association between alcohol intake and CETP concentration 
is in line with an earlier observation that CETP concentration was decreased in 
alcohol abusers (20,42). The decrease of 0.05 mg/L in CETP concentration 
associated with a 10-fold increase in  alcohol consumption might indicate a 
relevant reduction in CETP concentration in alcohol abusers. The present data 
show that the lower CETP concentration in men as compared to women is not 
the result of a higher alcohol consumption, because of the independent 
relationship of gender and alcohol intake with CETP concentration. 
-629C/A polymorphism 
We have investigated the -629C/A polymorphism as a genetic 
determinant of CETP concentration, because -629C/A is considered to be a 
strong genetic marker in the promoter region of the CETP gene (22). Results of 
the present study confirm the strong association between the presence of the C 
-allele of this polymorphism and CETP concentration.   
Glucose metabolism 
In line with previous studies, we did not identify an independent 
association between prevalence of DM2 and CETP concentration (10,14,43). 
Some investigators, however, reported elevated CETP concentration in patients 
with DM2 as compared to NGM (16,17,44). However, in these studies, 
differences in total cholesterol, alcohol intake and -629C/A polymorphism were 
not taken into consideration. The present association between prevalence of 
IGM and elevated CETP concentration has not been described before. A linear 
association of fasting or post-load glucose levels with CETP concentration was 
not present, as no association between DM2 and CETP concentration was 
found. It might be hypothesized that lower levels of total cholesterol in patients 
with DM2, as compared to persons with IGM and even NGM (data not shown), 
caused the lower CETP concentration in patients with DM2. However, the 
association between IGM and CETP concentration was independent of total 
levels of cholesterol. Another possibility is that, although most of the patients 
with DM2 were newly diagnosed, differences in dietary habits underlie the 
association between IGM and CETP concentration. For example, it has been 
found that consumption of monounsaturated fatty acids reduces CETP 
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concentration, whereas a high consumption of saturated fatty acids increases 
CETP concentration (45). 
 
Triglycerides, smoking and physical activity did not show an independent 
association with CETP concentration. Although these potential determinants 
have an important influence on lipid metabolism and therefore on RCT, they 
may have a minor role in determination of CETP concentration.  
Potential weaknesses of the study 
The cross-sectional design of our study restrained our conclusions with 
regard to causal relationships. 
Instead of measuring the neutral lipid transfer activity of CETP, we have 
measured CETP concentration. Several studies have shown, however, that CETP 
activity and CETP concentration are strongly correlated (6,9,14). Additionally, 
some studies reported that the presence of high triglycerides, such as in DM2, 
results in even higher correlations between CETP concentration and CETP 
activity (4,17,32). Therefore, we regarded CETP concentration as a suitable 
indicator of CETP function.  
The final multivariate linear regression model had a relatively low 
explained variance (R²=0.22). Possibly, other undetected determinants exist. 
Apparently, more research to determinants of CETP is needed to get a better 
understanding of the mechanisms behind differences in plasma CETP levels.  
Conclusions  
This is the first study to examine independent associations of potential 
determinants of CETP concentration in subjects with normal and abnormal 
glucose metabolism. First of all, we noted the absence of a relation between 
CETP concentration and DM2, although persons with IGM had higher CETP 
concentration. Second, female gender, the -629 C-allele and total plasma 
cholesterol were independently associated with increased CETP concentration 
and alcohol intake was associated with decreased CETP concentration. 
Differences in gender, total plasma cholesterol concentration, alcohol intake or 
-629 C-alleles might explain previous inconsistent results regarding CETP 
concentration in patients with DM2.   
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Abstract 
Background: Dietary intake has a strong influence on lipid 
metabolism and the risk of type 2 diabetes (DM2). However, there is 
no information available about the effects of food consumption 
patterns on cholesteryl ester transfer protein (CETP) and there is little 
information about the effects of population-based food 
consumption patterns on the risk of DM2. 
Objective: The objective of the present study is to examine food 
consumption patterns in relation to CETP concentration and 
prevalence of DM2.  
Methods: The present study consisted of cross-sectional data from a 
population-based cohort study. From the 2000-2001 Hoorn Study 
follow-up examination 754 subjects were recruited. Individuals were 
categorized into glucose metabolism subgroups based on their 
fasting and post-load glucose concentrations (WHO-99 criteria). 
The habitual food intake was measured with a food frequency 
questionnaire. Explorative factor analysis was used to identify food 
consumption patterns. CETP concentration was measured by two-
body sandwich immunoassay.  
Results: Five food consumption patterns were identified: the 
"Cosmopolitan", "Meat", "Sweet beverages", "Sugary foods" and 
"Traditional Dutch" pattern. The "Meat pattern" score was inversely 
associated with CETP concentration (beta, -0.15 [95% CI, 0.24 to -
0.06]). The "Meat" and "Sweet beverages" pattern scores were both 
associated with a higher risk of DM2 (odds ratio, 1.39 [95% CI, 1.09 
to 1.77], 1.27 [95% CI, 1.03 to 1.56] respectively).  
Conclusions: Higher scores of the "Meat pattern" were associated 
with higher prevalence of DM2 and unexpectedly with lower CETP 
concentration. 
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Introduction 
Cholesteryl ester transfer protein (CETP) exchanges cholesterol esters from 
high density lipoproteins (HDL) for triglycerides (TG) from very low density 
lipoproteins (VLDL) and low density lipoproteins (LDL). Although CETP has an 
important role in the reverse cholesterol transport (1-3), high CETP 
concentrations are thought to promote atherosclerosis and therefore increase 
the risk of cardiovascular disease (CVD) (4-6).  
Dietary intake is an important determinant of cardiovascular risk factors, 
such as plasma lipids (7-10) and the risk of type 2 diabetes (DM2) (11-14). In 
several intervention studies, changing the macronutrient composition of the diet 
affected CETP concentration (15-17). For example, lowering the energy 
percentage of total fat in the diet or replacing saturated fatty acids by 
unsaturated fatty acids, decreased the CETP concentration (15;16). It has been 
suggested that not only macronutrient composition, but also the combination 
with micronutrients, and possible interactions between nutrients can affect the 
lipid metabolism (18). By investigating food consumption patterns, these effects 
will be taken into account. Furthermore, food consumption patterns reflect the 
habitual dietary intake. In several studies, food consumption patterns have 
shown to be associated with plasma lipids (19;20) and the risk of DM2 (21-24). 
However, only a few studies investigated the association with DM2 in the 
general population (22;24) and the association of food consumption patterns 
with CETP has never been investigated.  
The objective of the present study was to identify food consumption 
patterns in a general population and to examine these patterns in relation to 
CETP concentration and DM2. 
 
Methods 
Study population  
The Hoorn Study is a population-based cohort study of glucose 
metabolism and cardiovascular risk factors in the general Dutch population. The 
population and the study design have been described in detail previously (25). 
In 2000-2001, a follow-up examination took place in a subsample of the original 
study population, stratified for glucose tolerance status as the previous 
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examination in 1990-1998. The present study consisted of cross-sectional data 
from the Hoorn Study follow-up examination. Individuals were excluded if there 
were missing data of CETP or the food-frequency questionnaire (FFQ). Finally, 
754 subjects were included in the factor analysis. For the association of the food 
consumption patterns with CETP and risk of DM2, subjects who used lipid 
lowering drugs were excluded, because these drugs disturb the association 
between diet and lipids. Furthermore, subjects who were diagnosed with DM2 
before entering the study were excluded. After these exclusions, the study 
population consisted of 571 individuals: 283 men and 288 women. The number 
of individuals with NGM, IGM and DM2 were 248, 139 and 184, respectively. All 
subjects gave written informed consent. The ethics committee of the VU 
University Medical Center approved the study.  
Laboratory analyses  
Fasting and post-load plasma glucose concentration was determined by 
the glucose dehydrogenase method. Fasting and post-load glucose 
concentration were used to categorize individuals according to the WHO-99 
criteria (26). CETP concentration was measured by two-antibody sandwich 
immunoassay, which was developed and described by Niemeijer-Kanters et al 
(27). Inter-assay and intra-assay coefficients of variation were 7.8 and 6.0%, 
respectively. As a standard, pool plasma containing 2 mg CETP/ml was taken. 
TG and total cholesterol (TC) were determined by enzymatic techniques 
(Roche, Mannheim, Germany).  
Dietary assessment, medical examination and physical activity  
A validated semi-quantitative FFQ (28;29) was used to determine the 
consumption of 178 food items during the previous year. The questionnaire has 
been described in detail previously (29). The relative validity of the FFQ was 
assessed among 121 men and women. The median Spearman correlation 
coefficients between the dietary intake based on 24-hours recalls and the 
questionnaires was 0.61 for men and 0.53 for women. BMI was calculated by 
dividing weight by height square. Subjects were wearing light clothes, only. 
Physical activity was measured using the 'Short questionnaire to assess health-
enhancing physical activity' (SQUASH) (30).  
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Statistical analysis 
For the identification of the food consumption patterns, we used factor 
analysis (principal components analysis). Factor analysis is a multivariate data 
reduction method, which reduces the many original variables (food groups) 
into a limited number of factors (food patterns) that maximally explain the 
variation in the original variables. Firstly, food items were combined that were 
similar in nutrient profile and culinary use according to a previous study (20), 
resulting in 46 food groups (for example, fried onion and fried tomato were 
combined into fried vegetables). Food group variables that had a skewed 
distribution were Ln-transformed. Food group variables were adjusted for total 
energy intake using the residual method (31), because we were not interested 
in the quantity of intake, but in the effect of the combinations of food groups.  
Next, we used the principal component factor analysis (32) to the 46 food 
group variables to identify food consumption patterns (factors). We used the 
checklist of De Vet et al (33) to evaluate whether the choice for exploratory 
factor analysis was justified: no previous study had been performed in a similar 
study population and therefore we had no prior hypothesis about the factors 
that would be identified. To determine the number of factors we used the 
eigenvalue of the factors, the Scree plot, the interpretability of the identified 
food consumption patterns and consistency of the identified factors in sex 
stratified analysis. Varimax rotation was used to obtain uncorrelated factors (32).  
The factor loadings are the correlation coefficients between each food 
group variable with the food consumption pattern factors of issue. For each 
participant, factor scores were computed for all five food consumption patterns 
by summing the standardized intake of the food groups, weighted by the factor 
loadings. The factor scores show to what degree the diet of participants 
conformed to the food consumption patterns.  
The association between macro- and micronutrient intake and the food 
consumption patterns were expressed as Pearson's correlation coefficients. For 
the analysis of population characteristics according to food consumption 
patterns, the pattern scores were age-adjusted using linear regression analysis. 
Next, food patterns were categorized in tertiles for men and women separately 
to distribute men and women evenly over the tertiles. P-values for trend for 
continuous and categorical data were calculated using linear regression 
analysis and P-values for binary data were calculated using logistic regression 
analysis. 
To examine the associations between food consumption patterns and 
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CETP concentration, we performed linear regression analysis. Age, physical 
activity, smoking, alcohol intake, educational level, BMI, glucose metabolism, 
TC, TG and total energy intake were considered as potential confounders. We 
adjusted for all potential confounders combined in a multivariate model with 
and without TG and TC. Results were reported as betas and 95% confidence 
interval (CI). For CETP, all betas were reported per intertertile range (difference 
between the median of the third and first tertile) increase in factor score of 
each food consumption pattern. For example, a beta of 0.5 indicates that if a 
pattern increased one intertertile range, CETP concentration increased by 0.5 
mg/l. We tested for possible interaction with glucose metabolism by adding 
interaction terms. To examine the association of food consumption patterns 
and the risk of DM2, we performed logistic regression analysis. The pattern 
scores were divided in tertiles and the first tertile was used as reference group. 
We considered age, physical activity, smoking, alcohol intake, total energy 
intake, history of hypertension, history of hypercholesterolaemia, family history of 
DM2 and BMI as potential confounders. We adjusted for all potential 
confounders combined in a multivariate model with and without BMI. Results 
were reported as relative risk and 95% CI. All P-values were for 2-sided tests. P-
values <0.05 were considered statistically significant, except for tests of 
interaction, for which we considered P-values <0.10 statistically significant. All 
analyses were performed using SPSS (version 11.0, Chicago, Ill) for Windows. 
 
Results 
Food consumption patterns 
Because there was no interaction between glucose metabolisms and 
food consumption patterns in the association with CETP concentration, we 
combined the glucose metabolism subgroups for these analyses. Five factors 
(food consumption patterns) were identified. The factor loadings for each food 
group for these food consumption patterns are given in Table 1. The five factors 
were labeled: "Cosmopolitan", "Meat", "Sweet beverages", "Sugary foods" and 
"Traditional Dutch" pattern. The five patterns together explained 28% of the total 
variance in the original food group variables. 
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Table 1. Factor loading matrix for identified food consumption patterns (n=754)a
  Pattern 1 
Cosmopoli
tan 
Pattern 2 
Meat 
Pattern 3 
Sweet 
beverages 
Pattern 4 
Sugary 
foods 
Pattern 5 
Tradition
al Dutch 
Salad vegetables 0.67    0.17 
Fried vegetables 0.61     
Mayonnaise 0.54 0.25    
Warm sauces 0.52    -0.27 
Pasta 0.51 0.24    
Oils 0.50     
Brown rice 0.49 -0.20  0.16  
Garlic 0.43   -0.19  
Pizza 0.43  0.17   
White rice 0.39 0.17  0.17 -0.17 
Wine 0.35     
Fish 0.30     
Soup 0.25 0.23    
Water 0.21     
Added fats, highly 
saturated 
-0.31 0.31 -0.16 0.22 -0.20 
Processed meat  0.65    
Red meat, fat   0.62   0.18 
Red meat, lean   0.60   0.26 
Potatoes -0.35 0.37  0.17 0.27 
Salty snacks 0.28 0.35 0.29  -0.21 
French fries 0.23 0.35   -0.27 
Chicken 0.30 0.32    
Eggs  0.30    
Organ meat  0.28    
Spirits  0.28  -0.23 -0.17 
Beer  0.28    
Coffee  0.28    
Soy products 0.19 -0.57    
Low-sugar beverages   0.90   
High-sugar beverages   0.89   
Juice   0.35  0.15 
Added sugar -0.20   0.55  
Pastry    0.52  
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High-fat dairy -0.19   0.44 0.18 
Candy    0.40 -0.20 
Refined bread   0.21 0.36 -0.18 
Tea  -0.27  0.36  
Breakfast cereals 0.16 -0.17  0.30  
Legumes    0.29  
Nuts 0.25   0.26  
Boiled vegetables -0.18    0.55 
Fruit  -0.32   0.48 
Low-fat dairy   0.23 0.18 0.45 
Wholegrain bread     0.43 
Added fats, highly 
unsaturated 
    0.37 
Cheese 0.19   -0.19 0.26 
Factor loadings between -0.15 and 0.15 are not shown for simplicity. a Food consumption patterns were 
identified with factor analysis on energy-adjusted food groups, using the varimax rotation.  
Population characteristics 
Higher scores for the "Cosmopolitan", "Meat" and "Sweet beverages" 
patterns were associated with a younger age, whereas higher scores for the 
"Sugary foods pattern" were associated with an older age (data not shown). 
Men had higher scores for the "Meat pattern" than women, while women had 
higher scores for the "Traditional Dutch pattern" than men (data not shown). 
Table 2 shows the population characteristics according to tertiles of age-
adjusted food pattern scores.  
Correlation between macro-, micronutrients and food consumption patterns 
The correlations between macro-and micronutrient intakes and the 
identified food consumption pattern scores are shown in Table 3. Briefly, the 
"Cosmopolitan pattern" score was associated with a higher intake of poly-
unsaturated fatty acids, whereas the "Meat pattern" score was associated with 
higher intake of saturated fatty acids and mono-unsaturated fatty acids. The 
"Cosmopolitan", the "Sugar" and the "Traditional Dutch" pattern scores were 
associated with a higher intake of fibers. In contrast, the "Meat" and "Sweet 
beverages" pattern scores were associated with lower intakes of fibers.  
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Table 2. Population characteristics according to tertiles of the food consumption 
pattern scoresa
 Pattern 1 
Cosmopolitan 
Pattern 2 
Meat 
Pattern 3 
Sweet beverages 
 1 2 3 1 2 3 1 2 3 
BMI (kg/m2) 27.6 27.2 27.5 26.6 27.3 28.5 b 27.0 27.2 27.5 b
Habitual physical 
activity (h/wk) d
19.4 19.3 23.0 22.1 18.3 20.3 20.0 21.0 21.0 
Smokers (%) 23 12 13 c 12 16 20 c 21 14 13 c
Education (%) e          
   Low 65 47 39 c 44 51 57 c 55 45 52 
   Medium 28 42 44 c 41 39 34 34 40 41 
   High 7 11 16 c 15 10 9 c 12 15 7 
Alcohol intake (g/day) 
d
3.7 5.8 10.1b 3.8 5.8 8.8 b 5.7 5.8 6.7 
Cholesterol (mmol/l) 5.8 5.8 5.8 5.8 5.8 5.9 5.8 5.9 5.8 
Triglycerides (mmol/l) d 1.3 1.3 1.4 1.4 1.2 1.3 1.3 1.3 1.4 b
 
 Pattern 4 
Sugary foods 
Pattern 5 
Traditional Dutch 
 1 2 3 1 2 3 
BMI (kg/m2) 28.0 27.3 27.0 b 27.5 27.4 27.5 
Habitual physical activity (h/wk) d 20.2 21.0 19.6 20.2 21.5 20.1 
Smokers (%) 16 18 14 19 16 13 c
Education (%) e       
   Low 48 53 50 57 50 44 c
   Medium 37 37 40 36 35 44 c
   High 14 10 10 7 15 12 
Alcohol intake (g/day) d 12.5 5.8 2.9 b 5.5 6.2 6.1 
Cholesterol (mmol/l) 5.8 5.7 5.9 5.8 5.9 5.8 
Triglycerides (mmol/l) d 1.4 1.3 1.3 1.3 1.3 1.4 
a Patterns scores were adjusted for age and divided in tertiles. To distribute men and women evenly over the 
tertiles, tertiles were derived for men and women separately. b P-value for trend <0.05 calculated with linear 
regression using pattern scores as continuous data adjusted for gender and age. c P-value for trend <0.05 
calculated with logistic regressing using pattern scores as continuous data adjusted for gender and age. d 
Median reported. e Education: low, junior high school or less; medium, high school; high, vocational college 
or university. 
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Table 3. Pearson’s correlation coefficients (r) between macro- and 
micronutrients and the food consumption pattern scores a
 Pattern 1 
Cosmop
olitan 
Pattern 2 
Meat 
Pattern 3 
Sweet 
beverages 
Pattern 4 
Sugary 
foods 
Pattern 5 
Traditional 
Dutch 
Total fat (E%)  .29 -.12  -.20 
Saturated fat (E%) -.23 .24 -.11  -.22 
Mono unsaturated fat (E%) .12 .34 -.11 -.08 -.25 
Poly unsaturated fat (E%) .23    .08 
Cholesterol  (mg/d) .04 .53    
Carbohydrates (E%) -.11 -.42 .13 .47 .14 
Mono- and disaccharide 
(g/d) 
-.15 -.39 .20 .37 .12 
Polysaccharide (g/d) .10 .08  .29 .12 
Fiber (g/d) .13 -.13 -.13 .13 .57 
Protein (E%) .07 .11  -.26 .44 
Plant protein (g/d) .09 -.38 -.12 .08 .08 
Animal protein (g/d)  .38 .09 -.17 .39 
Calcium (mg/d)  -.22 .10  .46 
Magnesium (mg/d) .17 -.32 -.10 -.12 .39 
Vitamin B6 (mg/d)   -.17 -.17 .37 
Vitamin C (mg/d) .27 -.24 .09  .42 
Vitamin E (mg/d)  -.24  -.11  
Alcohol  (g/d)  .11  -.39 -.13 
E%, percentage of total energy intake. a Food consumption patterns were identified with factor analysis on 
energy-adjusted food groups and micronutrients were adjusted for total energy intake. All correlations are 
significant at P<0.05. 
Associations between food consumption patterns and CETP 
Table 4 shows the standardized regression coefficients of CETP in relation 
to the factor scores for the food consumption patterns. We presented both 
crude estimates and estimates adjusted for age, physical activity, smoking, 
educational level, BMI, total energy intake and glucose metabolism. The "Meat 
pattern" score was inversely associated with CETP concentration (beta, -0.15 
[95% CI, -0.25 to -0.04]. Additionally adjusting for TG and TC did not attenuate 
this association. No consistent associations were observed for the other food 
consumption patterns. 
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Table 4. Associations (beta’s (95% CI)) between food consumption pattern 
scores and CETP concentration a
 Pattern 1 
Cosmopolitan 
Pattern 2 
Meat 
Pattern 3  
Sweet beverages 
Univariate 0.06 (-0.04;0.16) -0.15 (-0.24;-0.06) -0.01 (-0.12;0.10) 
Model 1 0.11 (-0.01;0.22) -0.15 (-0.25;-0.04) -0.02 (-0.14;0.10) 
Model 2 0.03 (-0.06;0.12) -0.15 (-0.24;-0.06) -0.02 (-0.13;0.08) 
 
 Pattern 4  
Sugary foods 
Pattern 5 
Traditional Dutch 
Univariate 0.03 (-0.05;0.12) 0.04 (-0.05;0.14) 
Model 1 -0.02 (-0.12;0.09) 0.01 (-0.09;0.11) 
Model 2 0.05 (-0.04;0.13) 0.04 (-0.05;0.13) 
Model 1: adjusted for age, physical activity, smoking, alcohol intake, educational level, BMI, BMI2, glucose 
metabolism and energy intake. Model 2: model 1 + total cholesterol and triglycerides (log-transformed).     a 
For standardization, the betas are expressed per intertertile range (median of the third tertile minus the 
median of the first tertile) of the food consumption pattern scores.  
Association between food consumption patterns and type 2 diabetes 
Table 5 shows the association between food consumption pattern scores 
and DM2, adjusted for age, physical activity, smoking, alcohol intake, BMI, total 
energy intake, history of hypercholesterolaemia and hypertension and family 
history of DM2. The "Meat pattern" score was associated with a higher risk of 
DM2 (odds ratio, 1.55 [95% CI, 1.22 to 1.95]). A high score for the "Sweet 
beverages pattern" was also associated with a higher risk of DM2 (odds ratio, 
1.27 [95% CI, 1.03 to 1.56]. After additional adjustement for BMI, the association 
with DM2 slightly attenuated for both the "Meat pattern" and the "Sweet 
beverages pattern" scores. 
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Table 5. Odds ratio (95% CI)  of type 2 diabetes, according to tertiles of the food 
consumption pattern scores 
 Tertiles OR lineair a
 1  2 3  
Cosmopolitan pattern score     
  % of type 2 diabetes 33 35 32  
  Model 1 1 0.98 (0.60;1.62) 0.73 (0.43;1.24) 0.97 (0.79;1.20) 
  Model 2 1 1.02 (0.61;1.71) 0.74 (0.43;1.27) 0.95 (0.76;1.18) 
Meat pattern score     
  % of type 2 diabetes 28 29 44  
  Model 1 1 0.96 (0.58;1.58) 2.26 (1.33;3.84) 1.55 (1.22;1.95) 
  Model 2 1 0.85 (0.51;1.44) 1.73 (0.99;3.00) 1.39 (1.09;1.77) 
Sweet beverages pattern score     
  % of type 2 diabetes 28 32 41  
  Model 1 1 1.10 (0.67;1.82) 1.54 (0.94;2.53) 1.27 (1.03;1.56) 
  Model 2 1 1.14 (0.68;1.91) 1.47 (0.88;2.47) 1.23 (0.99;1.53) 
Sugary foods pattern score     
  % of type 2 diabetes 38 31 31  
  Model 1 1 0.78 (0.47;1.28) 0.66 (0.39;1.12) 0.87 (0.69;1.09) 
  Model 2 1 0.79 (0.47;1.32) 0.77 (0.44;1.33) 0.91 (0.72;1.16) 
Traditional Dutch pattern score     
  % of type 2 diabetes 34 34 32  
  Model 1 1 0.97 (0.60;1.56) 0.66 (0.41;1.07) 0.93 (0.76;1.13) 
  Model 2 1 0.94 (0.57;1.55) 0.67 (0.40;1.10) 0.93 (0.75;1.15) 
Model 1: adjusted for age, physical activity, smoking, alcohol intake, energy intake, hypertension, 
hypercholesterolaemia, family history of diabetes. Model 2: model 1 + BMI, BMI2. a Odds ratios calculated 
with pattern scores as continuous data.  
Discussion 
In the present study, we identified five major food consumption patterns: 
the "Cosmopolitan", "Meat", "Sweet beverages", "Sugary foods" and "Traditional 
Dutch" patterns. Higher scores of the "Meat pattern" were associated with lower 
CETP concentration. The "Meat" and "Sweet beverages" pattern scores were 
both associated with a higher risk of DM2. Strengths of our study included the 
population-based design, the extensive information on potential confounders, 
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and the detailed information on parameters of the glucose metabolism. 
Limitations of the study 
Factor analysis requires several arbitrary decisions. Because of a large 
number of food items assessed by the used food frequency questionnaire, we 
combined the food items into 46 food groups. This classification has been used 
in a previous study (20). Other possibly arbitrary choices in the factor analysis 
were the number of factors to retain, the rotation technique chosen, the 
adjustment for total energy intake and the choice to conduct the factor 
analysis for men and women combined. 
To study the impact of these arbitrary decisions on the resulting food 
consumption patterns, we performed several sensitivity analyses with Pearson's 
correlation analysis. We found strong correlations between the selected food 
consumption pattern scores and the food consumption pattern scores, which 
were obtained with the other mentioned choices (r=0.81 to r=1.00). Therefore, 
we concluded that the food consumption patterns were robust in our 
population. The variance explained by the five food patterns was 28%, which is 
comparable with the explained variance in previous studies with factor analysis 
of food consumption data (19;20;34). Habitual food intake is difficult to assess, 
but the used FFQ has previously been shown to be reproducible and valid for 
estimating food intake, such as bread, cereals, meat and milk products (29). In 
addition, underreporting is known to be a common feature in dietary studies 
(35-37). To take general underreporting into account, we adjusted for total 
energy intake. Since we excluded individuals who were aware of having DM, it 
is unlikely that glucose metabolism affected diet or reporting of diet.  
Results in the light of other studies 
Experimental studies have shown that a change in macronutrient 
composition of the diet affects CETP concentration (15;16). However, in daily 
life, individuals do not choose a combination of macronutrients, but a 
combination of food groups resulting in several changes in macro- and 
micronutrients. In experimental studies, it is difficult to assess the combined 
effect of macro- and micronutrients on CETP concentration. This is possible by 
investigating food consumption patterns. This is the first study to examine the 
association between food consumption patterns and CETP concentration in the 
general population. In experimental studies, replacement of saturated fatty 
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acids for mono-unsaturated fatty acids (MUFAs) or carbohydrates resulted in a 
decrease in CETP concentration (15;16). In this study, the "Meat pattern" 
contains a high proportion of both saturated fatty acids and MUFAs. Therefore, 
it is difficult to predict the effect of this diet on CETP concentration. Alternatively, 
the inconsistency in effects on CETP concentration may reflect differences in 
duration of dietary exposure. Food consumption patterns reflect the habitual 
dietary intake and may have influenced biological variables for years instead of 
the short exposure in the experimental studies.  
The interpretation of the health consequences of the observed 
associations with CETP concentration is difficult. Others have shown that 
individuals with higher CETP concentration have a higher risk of atherosclerosis 
(4-6), which indicates that a decrease in CETP concentration could be 
favourable. However, the "Meat pattern" appeared to be associated with 
detrimental effects on glucose metabolism that should be taken into account.  
The association between a high “Meat pattern” score and DM2 is in line 
with prospective studies (21;23) in which a “Western dietary pattern” and high 
consumption of red and processed meat was associated with DM2. The “Sweet 
beverages pattern” score was also associated with DM2. This pattern was 
mainly characterized by refined grains and sweet beverages and higher 
pattern scores were associated with low fiber intake. In a case-control study, a 
similar pattern has been found to be directly associated with DM2 (38) and 
results of other studies have indicated a protective effect of whole grains and 
fibers (11;13;14;39). In the current study, the association of the “Meat pattern” 
and “Sweet beverages pattern” score with DM2 was somewhat weaker after 
adjustment for BMI, suggesting that effects of these diets on DM2 may be partly 
mediated by effects on BMI.   
Conclusions  
This is the first population-based study that examined the associations of 
food consumption patterns with CETP concentration. The potentially unhealthy 
"Meat pattern" score was inversely associated with CETP concentration, which 
was unexpected given the results of experimental studies of macronutrient 
intakes. Therefore, more research is needed to examine the effect of food 
consumption patterns on CETP concentration. Our results suggest that both the 
"Meat pattern" and the "Sweet beverages pattern" scores have adverse effects 
on glucose metabolism. Therefore, restriction of the food combinations that 
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characterize the "Meat" and "Sweet beverages pattern" may contribute to the 
prevention of DM2. 
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Abstract 
Aims: Cholesteryl ester transfer protein (CETP) exchanges neutral 
lipids between lipoproteins. Since the role of CETP in the 
atherogenic process is still not fully clarified, we studied the 
association of CETP concentration with the prevalence of 
cardiovascular disease (CVD) and with intima media thickness of 
the carotid artery (IMT) in subjects with normal glucose metabolism 
(NGM), impaired glucose metabolism (IGM) and type 2 diabetes 
mellitus (DM). 
Methods: Subjects (n=566) were recruited from the 2000-2001 
follow-up examination of the Hoorn study. CETP concentration was 
determined by an immunoassay. Prevalent CVD was defined as 
self-reported history of arterial surgery, cerebral vascular event, 
amputation, angina, claudication, possible infarction, measured 
ankle-brachial index <0.90 or ECG-abnormalities. The right common 
carotid artery IMT was measured by ultrasound at 10 mm proximal 
to the carotid bulb. 
Results: In men, CETP concentration was not associated with 
prevalent CVD, irrespective of glucose tolerance status. In women 
with NGM or IGM, we also noted the absence of such a relation. 
However, in women with DM, CETP concentration was strongly and 
independently associated with a 3.3-fold increased CVD risk 
(OR=3.34 (1.56;7.14)). No statistically significant association was 
found between CETP concentration and IMT in the entire cohort. 
Conclusions: In an elderly Caucasian population, associations of 
CETP concentration with prevalent CVD were dependent on 
glucose tolerance status and gender. The finding that high CETP 
concentration was strongly associated with increased prevalence 
of CVD in women with DM warrants further investigation. 
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Introduction 
Disturbances in lipoprotein metabolism play a major role in atherogenesis. 
Increased levels of LDL-cholesterol (LDL-c) and triglycerides, associated with the 
occurrence of small dense LDL, and decreased levels of HDL-cholesterol (HDL-
c) characterize dyslipidaemia. Cholesteryl ester transfer protein (CETP) plays an 
important role in lipid metabolism by mediating the transfer of esterified 
cholesterol (CE) from HDL to apolipoprotein B-containing lipoproteins in 
exchange for triglycerides (1).  
To date, it has been difficult to define the role of CETP in atherogenesis. A 
high CETP activity decreases HDL-c levels and lowering CETP activity by 
investigational drugs has been shown to increase HDL-c concentration (2) and 
to decrease LDL-c concentration (3). On the other hand, CETP plays an 
important role in the reverse cholesterol transport by promoting the transport of 
CE to the liver by LDL or VLDL (4). In the presence of an efficient hepatic uptake 
of the latter lipoproteins or their contents, this may be favourable. Probably, the 
individual lipid profile determines in which way CETP affects atherogenesis (5). In 
a number of previous studies, high CETP concentration was shown to be 
associated with increased risk of coronary artery disease in the context of 
increased triglyceride levels (6), familial hypercholesterolaemia (7), in men with 
established coronary artery disease(8) and in type 2 diabetic patients (9). One 
study showed that the association between CETP and coronary artery disease 
was explained by decreased HDL-c levels (6), while other studies did not (7-9). 
Disturbances in lipid metabolism are a common feature of diabetes as 
well as a high susceptibility for atherosclerosis and cardiovascular disease 
(CVD). Little is known about the association between CETP concentration and 
CVD in these patients. Therefore, we studied the associations of CETP 
concentration with prevalent CVD and intima media thickness (IMT) of the 
carotid artery in subjects with normal glucose metabolism (NGM), impaired 
glucose metabolism (IGM) and type 2 diabetes mellitus (DM).  
In addition, we investigated the association of the –629C/A polymorphism 
in the promotor region of the CETP gene with prevalence of CVD and with IMT.  
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Subjects and Methods 
Study population 
The Hoorn Study is a population-based cohort study of type 2 DM in the 
general Dutch population. The population and the study design have been 
described in detail previously (10). Briefly, in 1989, 3553 men and women, aged 
50-74 years, were randomly selected from the population register of the middle-
sized Dutch town of Hoorn. 2484 Caucasian subjects agreed to participate. In 
the 2000-2001 Hoorn Study Follow-up examination, 1074 individuals of the 
original Hoorn Study cohort were re-invited. We invited all surviving subjects with 
type 2 diabetes (n=176), and random samples of individuals with normal 
glucose metabolism (n=705) or impaired glucose metabolism (n=193) based on 
their glucose tolerance status at the previous examination (WHO-99 criteria) 
(11). Of these 1074 subjects, 648 (60.3%) subjects participated in the follow-up 
examination. To increase the number of DM individuals, we additionally invited 
217 participants from the Hoorn Screening Study (12), of whom 188 agreed to 
participate. Among the 455 non-participants, 13% were complete non-
responders. Other reasons not to participate were lack of interest (30%), 
comorbidity (23%), age (7%), unwillingness to travel (6%), participation too time-
consuming (6%), and miscellaneous reasons (15%)(13). Finally, 836 subjects 
participated in the study. The study was approved by the ethics committee of 
the VU University Medical Center. All subjects gave written informed consent.  
From the participating 836 subjects, we excluded subjects with missing 
data on primary variables of interest (glucose metabolism (n=24), CETP 
concentration (n=52), ultrasound examination of the carotid artery (n=76) 
mainly because of unsatisfactory definition of the arterial wall due to obesity 
(13)). Subjects who used medication which is known to affect lipid metabolism 
(n=118) and CETP concentration (14) were also excluded. The resulting 
complete dataset for primary values of interest consisted of 566 subjects (231 
with NGM, 127 with IGM and 208 with DM). Glucose tolerance status was 
defined again at the follow-up examination according to the WHO-99 criteria 
(11). 
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Anthropometric measurements and questionnaires 
Anthropometric measurements were obtained from all participants. 
Weight and height was measured in barefooted participants wearing light 
clothes only. BMI was calculated as weight (kg) divided by the square of height 
(m). Information about alcohol intake was obtained from a validated food-
frequency questionnaire (15). 
Laboratory analyses 
Fasting and 2-hour post-load plasma glucose concentrations were 
determined by the glucose dehydrogenase method and triglycerides, total 
cholesterol and HDL-c were determined by enzymatic techniques (Roche, 
Mannheim, Germany).  
LDL-c was directly determined by the N-geneousTM assay (Genzyme, 
Cambridge MA). LDL-size was measured by high performance gel-filtration 
chromatography as previously described in detail (16,17). 
CETP concentration was measured by a two-antibody sandwich 
immunoassay, which was developed and described by Niemeijer-Kanters et al 
(18). Inter-assay and intra-assay coefficients of variation were 7.8 and 6.0%, 
respectively. As a standard, pool plasma containing 2 mg/ml CETP was taken. 
DNA was extracted from white blood cells for genotyping. We used the 
polymerase chain reaction method as described by Klerkx and coworkers to 
assess the presence of the C>A variance in the promoter region of the CETP 
gene (19). 
Cardiovascular disease 
Resting 12-lead ECGs were recorded and automatically coded 
according to the Minnesota code (20) with an automated diagnostic 
classification system (Modular ECG Analysis System) (21). An ECG was 
considered abnormal with Minnesota codes 1-1, 1-2, 1-3, 4-1, 4-2, 4-3, 5-1, 5-2, 5-
3 or 7-1.  
Doppler-assisted systolic blood pressure measurements were performed in 
duplicate, from brachial, posterior tibial and dorsalis pedis arteries on both the 
left and the right side. Ankle-Brachial-index was calculated for each leg by the 
highest of the posterior tibial and the dorsalis pedis average pressure divided by 
the brachial pressure on the same side.  
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The Rose questionnaire (22) was used to determine presence of angina, 
claudication or possible myocardial infarction. Prevalent CVD was defined as 
self-reported history of arterial surgery, cerebral vascular event, amputation, 
angina, claudication or possible infarction or measured ankle-brachial-index 
<0.90 or ECG-abnormalities. 
Ultrasound imaging 
Procedures and reproducibility of scanning are described in detail 
elsewhere (13). In summary, an ultrasound scanner (350 Series, Pie Medical), 
equipped with a 7.5-MHz linear probe, was operated by a single observer. Three 
measurements, 4 seconds each, were performed in the right common carotid 
artery at 10 mm proximal to the carotid bulb. Images were registered and 
analysed by a computer equipped with vessel wall movement detection 
software and an acquisition system (Wall Track System, Pie Medical, Maastricht, 
the Netherlands).  
Statistical analyses 
All analyses were performed in SPSS (Version 10.1). Characteristics of the 
study population were divided according to categories of glucose tolerance 
status and gender. Data were presented as means (SD) or for skewed data, as 
medians (interquartile range). Differences in baseline measurements between 
categories of glucose tolerance status and gender were examined using 
ANOVA for continuous data and Kruskal Wallis analysis for dichotomous data. 
All ANOVA analyses were adjusted for age. Deviation from the Hardy-Weinberg 
equilibrium for frequencies of the –629C/A polymorphism was tested by chi-
square.  
Logistic regression was used to examine the association of CETP 
concentration with CVD. Age-adjusted odds ratios (OR) with 95% CI were 
obtained from logistic regression analysis. Linear regression analysis was used to 
examine the association of CETP concentration with IMT; results were reported 
as betas (95% CI). A beta of 10 would indicate that if CETP concentration 
increases 1 mg/l, IMT increases by 10 µm. We tested for possible interactions of 
CETP concentration with glucose tolerance status, gender, smoking, 
triglycerides and study population (original Hoorn Study cohort or Hoorn 
Screening Study) by calculating the P-values of the interaction terms.  
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Subsequently, we adjusted for HDL-c and triglycerides, which were 
considered as possible confounding factors. Finally, BMI, total cholesterol, 
systolic blood pressure, alcohol intake, smoking, LDL-c, LDL-size, waist 
circumference and fasting insulin were considered as possible confounding 
factors and were added to a multivariate model. The final multivariate model 
included the factors that altered the estimated beta for prevalent CVD or IMT. 
For interaction, a P-value<0.10 was considered statistically significant, whereas 
we used P<0.05 as statistically significant for all other analyses. 
 
Results 
Characteristics of the study population 
Results were reported in groups of glucose tolerance status and for men 
and women separately because of observed interactions between CETP 
concentration and gender and between CETP concentration and glucose 
tolerance status with regard to prevalent CVD. Table 1 shows the characteristics 
of the study population stratified for categories of glucose tolerance status and 
gender. CETP concentration was higher in women than in men (P<0.01, all men 
compared to all women), but did not differ significantly between categories of 
glucose tolerance. IMT was higher and CVD was more prevalent in subjects with 
IGM and DM in both sexes, although this increase did only reach statistical 
significance in women (P<0.01 and P=0.01 for IMT and for prevalent CVD, 
respectively). The total prevalence of CVD was 48.9%. In the majority of these 
subjects, CVD was defined as ECG-abnormalities, ankle-brachial-index<0.90, 
amputation or arterial surgery. The prevalence of self-reported CVD based on 
the Rose questionnaire only (angina, claudication and possible myocardial 
infarction) was 3% in the entire study population.  
 
 
 
 
 
 
 
127 
Chapter 8 
D
M
 
10
4 
69
.7
 (7
.5
) 
7.
6 
(1
.8
) 
12
.1
 (2
.9
) 
1.
6 
(1
.1
-2
.0
)  
1.
39
 (0
.3
4)
 
3.
7 
(0
.9
) 
21
.4
4 
(0
.4
8)
 
6.
0 
(1
.0
) 
28
.5
 (4
.1
) 
95
.5
 (1
0.
9)
 
14
7 
(2
1)
 
84
 (1
0)
 
11
.7
 
0.
4 
(0
-5
.9
) 
2.
02
 (0
.6
8)
 
28
/5
1/
21
 
88
5 
(1
56
) 
61
.0
 
IG
M
 
63
 
70
.9
 (5
.7
) 
6.
0 
(0
.5
) 
8.
0 
(1
.5
) 
1.
3 
(0
.9
-1
.8
) 
1.
63
 (0
.4
5)
 
4.
0 
(1
.0
) 
21
.5
8 
(0
.4
4)
 
6.
3 
(1
.0
) 
27
.9
 (4
.6
) 
93
.1
 (1
0.
9)
 
14
4 
(1
9)
 
81
 (1
0)
 
11
.1
 
2.
9 
(0
.4
-1
1.
8)
 
2.
14
 (0
.5
6)
 
27
/4
1/
32
 
85
4 
(1
32
) 
45
.9
 
W
om
en
 
N
G
M
 
12
2 
68
.2
 (6
.1
)  
5.
4 
(0
.4
) 
5.
7 
(1
.1
)  
1.
1 
(0
.8
-1
.5
) 
1.
70
 (0
.4
1)
 
3.
9 
(0
.9
) 
21
.8
0 
(0
.3
2)
 
6.
2 
(0
.9
) 
26
.0
 (3
.0
)  
85
.7
 (9
.3
) 
13
7 
(2
2)
 
81
 (1
2)
 
13
.1
 
4.
4 
(0
.7
-1
2.
1)
 
2.
07
 (0
.5
8)
 
28
/5
1/
21
 
79
8 
(1
44
) 
41
.8
 
D
M
 
10
4 
67
.2
 (8
.4
)  
7.
7 
(1
.9
) 
11
.2
 (2
.6
) 
1.
5 
(1
.1
-2
.0
) 
1.
14
 (0
.3
0)
 
3.
4 
(0
.8
) 
21
.2
0 
(0
.4
4)
 
5.
3 
(0
.9
)  
28
.6
 (3
.4
) 
10
3.
5 
(1
0.
3)
 
14
5 
(2
0)
 
85
 (1
0)
 
13
.5
 
9.
4 
(2
.6
-2
6.
9)
 
1.
70
 (0
.5
9)
 
26
/4
7/
27
 
88
0 
(1
96
) 
52
.6
 
IG
M
 
64
 
68
.3
 (6
.2
) 
6.
1 
(0
.5
) 
7.
7 
(1
.8
) 
1.
3 
(1
.0
-1
.8
) 
1.
29
 (0
.3
4)
 
3.
8 
(0
.9
) 
21
.4
4 
(0
.3
8)
 
5.
7 
(1
.0
) 
26
.7
 (2
.9
) 
98
.8
 (9
.4
) 
14
0 
(1
6)
 
84
 (1
1)
 
21
.9
 
13
.3
 (4
.1
-3
3.
1)
 
1.
88
 (0
.6
1)
 
26
/4
0/
33
 
87
7 
(1
83
) 
47
.6
 
M
en
 
N
G
M
 
10
9 
69
.3
 (6
.3
) 
5.
5 
(0
.4
) 
5.
4 
(1
.1
) 
1.
3 
(0
.9
-1
.5
) 
1.
33
 (0
.3
7)
 
3.
6 
(0
.9
) 
21
.5
1 
(0
.3
4)
 
5.
5 
(0
.9
) 
25
.8
 (3
.1
) 
95
.2
 (9
.5
) 
14
0 
(1
8)
 
83
 (1
0)
 
18
.3
 
11
.1
 (2
.4
-2
7.
4)
 
1.
75
 (0
.5
2)
 
34
/4
3/
22
 
85
4 
(1
80
) 
44
.9
 
Ta
bl
e 
1.
 C
ha
ra
ct
er
ist
ic
s 
of
 th
e 
st
ud
y 
po
pu
la
tio
n 
st
ra
tif
ie
d 
fo
r g
lu
co
se
 to
le
ra
nc
e 
st
at
us
 a
nd
 g
en
de
r (
n=
56
6)
 
 
 n A
ge
 (y
ea
rs
) 
Fa
st
in
g 
gl
uc
os
e 
(m
m
ol
/l)
 
2-
ho
ur
 p
os
t-l
oa
d
 g
lu
co
se
 (m
m
ol
/l)
 
Tr
ig
ly
ce
rid
es
 (m
m
ol
/l)
 
HD
L-
ch
ol
es
te
ro
l (
m
m
ol
/l)
 
LD
L-
ch
ol
es
te
ro
l (
m
m
ol
/l)
 
LD
L-
siz
e 
(n
m
) 
To
ta
l C
ho
le
st
er
ol
 (m
m
ol
/l)
 
BM
I (
kg
/m
2 )
 
W
ai
st
 (c
m
) 
Sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e 
(m
m
Hg
) 
D
ia
st
ol
ic
 b
lo
od
 p
re
ss
ur
e 
(m
m
Hg
) 
C
ur
re
nt
 sm
ok
er
 (%
) 
A
lc
oh
ol
 in
ta
ke
 (g
/d
ay
) 
C
ET
P 
(m
g/
l) 
-6
29
 C
C
/C
A
/A
A
 (%
) 
C
ar
ot
id
 IM
T 
(µ
m
) 
Pr
ev
al
en
t C
V
D
 (%
) a
a  
Pr
ev
al
en
t c
ar
d
io
va
sc
ul
ar
 d
ise
as
e 
d
ef
in
ed
 a
s a
nk
le
-b
ra
ch
ia
l-i
nd
ex
<0
.9
0,
 E
C
G
-a
bn
or
m
al
iti
es
, h
ist
or
y 
of
 a
rte
ria
l s
ur
ge
ry
, c
er
eb
ra
l v
as
cu
la
r e
ve
nt
, a
ng
in
a,
 
am
p
ut
at
io
n,
 c
la
ud
ic
a
tio
n 
or
 p
os
sib
le
 m
yo
ca
rd
ia
l in
fa
rc
tio
n.
 
 
 128
 CETP and cardiovascular disease 
Associations of CETP concentration with CVD and IMT 
In men, CETP concentration was not associated with the prevalence of 
CVD, independent of glucose tolerance status. In women with NGM or IGM, we 
also noted the absence of such a relation. However, in women with DM, CETP 
concentration was strongly associated with CVD risk (OR=3.34 (1.56;7.14); P-
value for interaction between DM and CETP concentration: P<0.01). 
Importantly, this association was not attenuated after adjustments for HDL-c, 
triglycerides or other CVD risk factors (Table 2). Also alcohol intake, LDL-c, LDL-
size, waist circumference and fasting insulin did not alter the estimate (data not 
shown). In women with NGM, high CETP concentration was inversely associated 
with prevalent CVD. However, this association was only borderline statistically 
significant.  
No association was found between CETP concentration and IMT in men 
with NGM, IGM or DM and neither for women with IGM or DM. However, CETP 
concentration was borderline statistically significantly associated with IMT in 
women with NGM (P=0.054, Table 3). Because no statistically significant 
interaction with glucose tolerance status or gender was found with regard to 
IMT, a regression coefficient for CETP in the combined study population is 
considered more appropriate. CETP was not statistically significant associated 
with IMT in the total study population (beta=15.0 (-6.6;36.7)), adjusted for age, 
gender and glucose tolerance status). 
No statistical significant interactions were found between CETP 
concentration and smoking, triglycerides or study population with regard to 
either prevalence of CVD or IMT. 
-629C/A polymorphism 
Frequencies of the –629C/A polymorphism were equally distributed over 
categories of glucose tolerance status. The number of A-alleles of the -629C/A 
polymorphism was associated with lower CETP concentration (P<0.01) and with 
higher HDL-c levels (P=0.01). The -629C/A polymorphism was not associated with 
prevalent CVD or IMT (data not shown). 
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Discussion 
This population-based study showed a strong and independent 
association between fasting CETP concentration and the prevalence of CVD in 
women with DM while no clear associations with IMT were observed. 
This is in line with the hypothesis that CETP should be more detrimental in 
patients with DM than in subjects with NGM (23). Subjects with DM or IGM have, 
besides their glucose abnormalities, elevated concentrations of triglycerides 
and decreased HDL-c levels (24). In patients with high triglyceride levels, CETP 
preferentially directs CE from HDL to larger VLDL (25). In this CETP-mediated 
transport, CE is exchanged for triglycerides, which are directed to LDL and HDL. 
These LDL and HDL particles become triglyceride-enriched providing a substrate 
for hepatic lipase to generate small dense LDL and HDL, which are considered 
to be atherogenic (4). In addition, CETP contributes to the atherogenity of small 
dense LDL in an indirect way by enrichment of VLDL particles with CE. These 
large, CE-enriched VLDL particles are a precursor of small dense LDL (23). 
Therefore, high levels of CETP concentration are expected to be atherogenic 
especially in subjects with a large pool of triglyceride-enriched lipoproteins, i.e. 
VLDL.  
However, despite the association with prevalent CVD in women with DM, 
we did not observe an association between CETP concentration and IMT. This 
may be related to a number of limitations of our study. Although several studies 
reported a high correlation between CETP concentration and CETP activity (26-
28), the weak associations between CETP concentration and IMT could be the 
result of measuring CETP concentration instead of CETP activity. Especially in 
subjects with DM, the relation between CETP activity and CETP concentration 
could differ compared to healthy subjects (29). Indeed, a recent study showed 
an association between CETP activity and IMT while no association was found 
between CETP concentration and IMT (29). Furthermore, measuring fasting CETP 
concentration may be less relevant than measuring postprandial CETP 
concentration regarding the risk of atherosclerosis and CVD, especially in DM. 
Postprandial changes in CETP concentration and activity were found in two 
studies (30,31), although not in one small study (32).  
Until now, no other studies examined the association between CETP 
concentration and CVD in different categories of glucose tolerance. The finding 
that CETP concentration and CVD are not related to each other in healthy 
subjects, is in line with previous studies (6-9). The beneficial effects of CETP in 
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reverse cholesterol transport might be dominant in healthy subjects with an 
efficient hepatic uptake of cholesterol. 
A gender difference regarding the association between CETP and 
prevalent CVD has not been observed previously. The association between 
CETP concentration and prevalent CVD in women with DM was however very 
strong and of similar magnitude in women from the Hoorn Screening Study and 
in women from the original Hoorn Study cohort. It has been previously showed 
that in women, the relative risk of CVD conferred by DM is greater than in men 
(33). Taken the gender difference regarding the association between CETP and 
prevalent CVD in the current study, CETP might be a mediator of CVD risk. In line 
with previous findings, the women studied here had significantly higher levels of 
CETP than men, which might reflect a higher neutral lipid exchange rate 
between lipoproteins. In the presence of a high concentration of VLDL particles, 
as in DM (34), a high CETP concentration may contribute to the high risk of CVD 
in diabetic women (35). An additional possible explanation of the lack of 
association in men may be selective survival. In this study population, women 
with DM were found to be older than men (men aged 67.2 years and women 
aged 69.7 years). This could imply that men who had an atherogenic lipid 
profile, high CETP concentration and CVD may already have deceased, in 
contrast to the surviving women.  
We also found the AA genotype associated with an anti-atherogenic lipid 
profile. As expected, the AA genotype of the C-629A gene was associated with 
lower CETP concentration and with higher HDL-c levels (19), which is generally 
regarded as an anti-atherogenic lipid profile. Other studies showed these 
differential effects on atherosclerosis and prevalent CVD (36,37). We found, 
however, no associations between the CETP gene and prevalent CVD or IMT. 
The lack of association in the present study may be due to a low statistical 
power. Indeed, in a recent meta-analysis (38), the TaqIB polymorphism of the 
CETP gene (acknowledged to be a marker for the functional –629C/A 
polymorphism) was associated with cardiovascular events, whereas no 
association was found in most of the individual studies included in the meta-
analysis.  
The current cross-sectional study design limits our scope of interpretation. 
Patients with DM, who have diabetes for several years, receive blood glucose-
lowering therapy and often change their lifestyle. As a consequence of these 
interventions, regression of IMT (39) and changes in CETP concentration may 
occur, while history of CVD remains unchanged. This could explain the 
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discrepancies observed in the association of CETP with IMT and with prevalent 
CVD in DM patients. In addition, exclusion of subjects who used lipid-lowering 
medication possibly resulted in a study population with a relatively low 
cardiovascular risk profile. This may have led to an underestimation of the true 
association between CETP concentration and prevalent CVD and/or IMT. Due 
to limited statistical power, we used a broad definition of CVD compared to 
other studies (6). Further study into more specific CETP-related cardiovascular 
abnormalities might be helpful to elucidate a possible mechanistic pathway 
between CETP and CVD. Furthermore, the current data warrant further 
investigation into the value of CETP concentration in larger prospective studies 
which are unfortunately very limited thus far (6-8). 
In summary, associations of CETP concentration with atherosclerosis and 
prevalent CVD were dependent on glucose tolerance status and gender. The 
finding that high CETP concentration was strongly associated with prevalent 
CVD in women with DM needs further investigation into CETP as a possible 
mediator for CVD risk in patients with DM.   
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Abstract 
Aim: The aim of the present study was to investigate the impact of 
two consecutive fat-rich meals compared to two consecutive 
carbohydrate-rich meals on cholesteryl ester transfer protein (CETP) 
concentration in women with and without type 2 diabetes (DM2).  
Methods: Postmenopausal women, 76 with normal glucose 
metabolism (NGM), 41 with DM2 and 42 with DM2 who were also 
using statins (DM2-ST) received two consecutive fat-rich meals on 
two consecutive carbohydrate-rich meals on separate occasions. 
Blood samples were taken at t=1, 2, 4 and 8 hours following 
breakfast, lunch was given at t=4. CETP concentration was 
measured by a two-antibody sandwich immunoassay.  
Results: Fasting CETP concentration was similar in the NGM and 
DM2 study groups, but lower in the DM2-ST group (P<0.05). 
Following the fat-rich meals, CETP concentration was increased in 
all study groups at t=4 and t=8 as compared to baseline (P<0.05). 
By contrast, no significant increases in CETP concentration were 
found following the carbohydrate-rich meals. The postprandial 
increase in CETP concentration was positively correlated with 
postprandial changes in triglycerides and total cholesterol levels.  
Conclusion: Fat-rich meals but not carbohydrate-rich meals induce 
a significant increase of CETP concentration in postmenopausal 
women. This effect is independent of diabetes status and use of 
statin.  
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Introduction 
Patients with type 2 diabetes (DM2), and in particular women, are subject 
to an increased risk of cardiovascular disease (CVD) (1). Especially in 
postmenopausal women, this increased risk can in part be ascribed to 
abnormalities in lipid metabolism (2). Elevated levels of triglycerides, low levels 
of HDL-cholesterol, and a preponderance of small, dense LDL particles 
characterize these abnormalities. A central regulator in lipid metabolism, which 
is associated with these lipid traits, is cholesteryl ester transfer protein (CETP). This 
protein mediates the transfer of esterified cholesterol (CE) from HDL to 
apolipoprotein B-containing lipoproteins in exchange for triglycerides (3). To 
date, the relations between CETP and atherosclerosis are unclear, but a recent 
prospective study showed that CETP concentration was positively related to 
future CVD (4). Small molecular inhibitors of CETP activity have moreover been 
reported to raise HDL-cholesterol concentrations (5, 6), however, it is yet to be 
clarified whether these novel drugs indeed decrease the risk of CVD. 
It has been suggested that the individual metabolic setting, especially the 
level of triglycerides, determines whether CETP concentration affects 
atherogenesis (4, 7). In this respect, the regulation of CETP after a meal can be 
relevant with regard to daytime changes of triglyceride concentrations. This in 
turn may be relevant to effective application of pharmaceutical CETP-inhibitors. 
Several investigators have reported an increase in CETP activity 4 to 6 hours 
after ingestion of a fat-load (8-10), although one study found no increase in 
CETP activity (11). It was observed that the number of triglyceride-rich 
lipoproteins (chylomicrons) and their triglyceride content, which is increased in 
the postprandial phase, enhance CETP activity, but the exact mechanism is 
unclear (12). Since a strong correlation between CETP activity and CETP 
concentration exists (13), an increase in CETP activity as measured with 
exogenous substrates is (in part) a reflection of an increase in CETP 
concentration in the circulation (8). Some investigators indeed support this 
notion with reporting a postprandial increase in CETP concentration in addition 
to an increase in CETP activity (9). Possibly, the lack of postprandial increase in 
CETP concentration together with CETP activity in other studies was due to the 
relatively small sample size (10, 12). 
Until now, the postprandial effects on CETP concentration have only 
been studied after a single, non-physiological liquid fat-load. The effects of 
carbohydrate-rich meals have not been investigated to date. Another aspect 
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that has not been addressed is the effect of multiple meals that are normally 
consumed over a day (14, 15). The aim of the present study was therefore to 
investigate the impact of two consecutive fat-rich and carbohydrate-rich meals 
on CETP concentration. To this purpose, we studied postmenopausal women 
with normal glucose metabolism (NGM), women with DM2, and women with 
DM2 who were using HMG-CoA reductase inhibitors (statins)(DM2-ST). 
 
Methods 
Study population  
Women, aged 50-65 years when the study was initiated, were invited to 
participate in the study and firstly attended a screening visit after a 12-hour 
overnight fast. Women with DM2 were recruited from the registry of the 
Diabetes Care System in the city of Hoorn, the Netherlands. Women with 
uncontrolled DM2 (Glycosylated Hemoglobin (HbA1c) >9.0%) were excluded. 
Women with DM2 using HMG-CoA reductase inhibitors (statins) were considered 
as a separate study group (denoted as DM2-ST). Women with NGM were 
randomly selected from the municipal registry of Hoorn. These individuals 
underwent a 75-g oral glucose tolerance test to verify their glucose tolerance 
status (fasting glucose <6.1 mmol/l and 2-hour post-load glucose <7.8 mmol/l 
(16)). Women with NGM were excluded if they used statins. 
For all study groups the following exclusion criteria were employed: pre-
menopausal status (menses in the last 12 months), smoking, untreated 
endocrine disorder other than DM2, use of short-acting insulin analogues, use of 
PPAR-α agonists, use of oral corticosteroids, use of hormone replacement 
therapy, fasting cholesterol >8.0 mmol/l, fasting triglycerides >4.0 mmol/l, systolic 
blood pressure >190 mmHg, liver or renal impairment.  
Weight and height were measured twice in barefooted participants 
wearing light clothes only. Body mass index (BMI) was calculated as weight (in 
kg) divided by the square of height (in m). Waist circumference was measured 
twice at the level midway between the lowest rib margin and the iliac crest, 
and hip circumference was measured at the widest level over the greater 
trochanters. All women gave written informed consent and the ethics 
committee of the VU University Medical Center approved the study.  
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Study design and test meals 
Following the screening visit, participants attended two test-meal visits, 
with a maximum of one month apart. In random order, the participants 
received two consecutive identical fat-rich meals and two consecutive 
identical carbohydrate-rich meals on separate occasions. Women arrived at 
the test facility in the morning after an overnight fast. Blood samples were taken 
before (t=0) using the first test meal (breakfast) and at t=1, t=2, t=4, t=6 and t=8 
hours after ingestion of the meal. Lunch was given at t=4, immediately after the 
blood sample was taken. The nutrient composition of the meals was calculated 
from the Dutch Nutrient Database (17). The fat-rich meals consisted of 2 
croissants, butter, cheese and fat-rich milk (3349 kJ; 50 g fat; 56 g 
carbohydrates, 28 g proteins and 171 mg cholesterol). The carbohydrate-rich 
meals consisted of bread, marmalade, cooked chicken breast, ginger bread 
and drinkable yogurt enriched with sugar (3261 kJ; 4 g fat, 162 g carbohydrates, 
22 g proteins and 15 mg cholesterol). Meals were eaten within 10 minutes time. 
Except from water (available ad libitum), participants refrained from other food 
and drinks. Throughout a visit day, physical activity was limited to a short walk 
between two adjacent rooms. 
Laboratory analysis 
CETP concentration was measured at t=0, t=2, t=4, and t=8 by a two-
antibody sandwich immunoassay, which was developed and described by 
Niemeijer-Kanters et al (18). Inter-assay and intra-assay coefficients of variation 
were 7.8 and 6.0%, respectively. As a standard, pool plasma containing 2 
mg/ml CETP was taken. Serum total cholesterol, HDL-cholesterol and 
triglycerides were measured by enzymatic colorimetric assays (Roche, 
Mannheim, Germany). LDL-cholesterol was calculated according to the 
Friedewald-formula (19). Plasma glucose levels were determined with a glucose 
oxidase method (Granutest, Merck, Darmstadt, Germany) and HbA1c was 
measured with cation-exchange chromatography (Menarini Diagnostics, 
Florence, Italy). Specific insulin was measured in serum by an immunometric 
assay in which proinsulin did not cross-react (Advia Centaur, Bayer Diagnostics, 
Mijdrecht, The Netherlands).  
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Statistical analyses 
Analyses were performed in SPSS 12.0.1 for Windows (SPSS Inc. Chicago, 
IL). Differences in characteristics between the three study groups were tested 
with ANOVA with post-hoc comparisons. In case of skewed distribution, 
variables were ln-transformed before analyses. Postprandial concentrations of 
CETP were tested with paired samples t-test for comparison with the 
concentration at t=0. We considered a two-sided P-value <0.05 to indicate 
statistical significance. 
 
Results 
Population characteristics 
Characteristics of the study population are described in Table 1. Overall, 
DM2 women were, irrespective of use of statins, more obese, had higher fasting 
plasma glucose, higher HbA1c and higher insulin levels than women with NGM. 
In addition, fasting triglycerides were higher and HDL-cholesterol concentrations 
were lower in women with DM2. In the DM2-ST group, total cholesterol and LDL-
cholesterol concentrations were lower as compared to the NGM and DM2 
groups. Of all the women with DM2 (n=83), 65% used anti-hypertensive 
medication, 75% used oral blood glucose lowering medication and 18% used 
insulin. Fasting CETP concentration was nearly identical in women with DM2 and 
NGM. In the DM2-ST group, however, CETP concentration was significantly lower 
compared to both former groups. Patients who used insulin had non-significant 
lower fasting CETP concentrations than patients who did not use insulin (1.62 
(0.42) versus 1.67 (0.39), P=0.67). 
Postprandial lipid metabolism 
The effects of two consecutive fat-rich meals or two consecutive 
carbohydrate-rich on triglycerides, total cholesterol, HDL-cholesterol, LDL-
cholesterol and CETP concentration in each of the three study groups are 
shown in Figure 1 and 2. The use of two consecutive fat-rich meals, resulted in 
an on average 76±52% increase of triglyceride levels at t=8 while both HDL-
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cholesterol and LDL-cholesterol levels were decreased by 11±6% and 11±10% at 
t=8, respectively. Similar, but less pronounced responses were found following 
the use of two carbohydrate-rich meals (23±25% increase for triglycerides and 
7±5% and 8±8% decrease for HDL-cholesterol and LDL-cholesterol, respectively). 
Total cholesterol did not change following the fat-rich meals (0±6%), but slightly 
decreased following the carbohydrate-rich meals (4±6%). Despite generally 
similar effects amongst the three groups, we noted a less pronounced decrease 
in HDL-cholesterol levels in women with DM2-ST at t=8 following the fat-rich meal 
(P<0.05) compared to women with NGM. Furthermore, the decrease of total 
cholesterol and LDL-cholesterol at t=8 following the carbohydrate-rich meal was 
less pronounced in women with DM2-ST (P<0.05) compared to women with 
NGM and DM2 who do not use statin medication. 
Table 1. Characteristics of the study population  
 NGM DM2 DM2-ST 
n 76 41 42 
Age (years) 60.1 (4.0) 58.9 (3.7) 61.1 (3.9) b
BMI (kg/m2) 26.3 (3.6) 32.7 (6.0) c 31.1 (4.8) c
Fasting glucose (mmol/l) a 5.2 (0.4) 7.1 (1.4) c 7.4 (1.2) c
HbA1c (%) 5.6 (0.3) 6.6 (0.6) c 6.8 (0.7) c
Fasting insulin (pmol/l) a 33.2 (25.5-47.5) 82.5 (39.3-127.0) c 83.2 (54.9-124.7) c
Use of insulin (%) - 17 19 
Triglycerides (mmol/l) a 1.2 (0.5) 1.7 (0.5) c 1.7 (0.6) c
Total cholesterol (mmol/l) a 5.7 (0.8) 5.5 (1.0) 4.3 (0.8) b,c
HDL-cholesterol (mmol/l) a 1.62 (0.42) 1.36 (0.29) c 1.33 (0.29) c
LDL-cholesterol (mmol/l) a 3.5 (0.8) 3.4 (0.9) 2.2 (0.7) b,c
CETP mg/l 1.77 (0.36) 1.80 (0.38) 1.52 (0.37) b,c
Means (SD). Median (interquartile range) in case of skewed distribution. a Mean of two fasting measurements 
derived from the two test-meal visits. b P<0.05 compared to DM2 group. c P<0.05 compared to NGM group. 
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Fat-rich meals 
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Figure 1. Triglyceride, total cholesterol and HDL-cholesterol concentrations (Means±SEM) after ingestion of 
two consecutive meals. B: breakfast, L: lunch. NGM: normal glucose metabolism (▼), DM2: type 2 diabetes 
mellitus (●), DM2-ST: type 2 diabetes mellitus, using statin medication (○). 
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Figure 2. LDL-cholesterol and CETP concentrations (Means±SEM) after ingestion of two consecutive meals. B: 
breakfast, L: lunch. NGM: normal glucose metabolism (▼), DM2: type 2 diabetes mellitus (●), DM2-ST: type 2 
diabetes mellitus, using statin medication (○). 
CETP concentration in the postprandial state 
DM2-ST women presented with both lower fasting and lower postprandial 
CETP concentrations compared to other groups (P<0.05 for both) on both meal 
interventions. In women with NGM and DM2, none of the fasting and 
postprandial CETP concentrations was statistically significantly different from 
each other. Taken this result, we felt safe to combine the NGM and DM2 study 
groups to increase statistical power for subsequent analyses (see Table 2). 
Following the fat-rich meals, CETP concentration was increased in the 
combined NGM+DM2 group and in the DM2-ST study group at t=4 and t=8 as 
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compared to t=0 (P<0.05, Table 2). Increase in the NGM+DM2 group was 5±19% 
at t=4 and 4±17% at t=8 and in the DM2-ST group, the mean increase was 8±21% 
at t=4 and 4±13% at t=8. In contrast to the fat-rich meals, no statistically 
significant increase in CETP concentration was observed after ingestion of the 
carbohydrate-rich meals in any of the study groups.  
Table 2. Postprandial CETP concentrations (mean (SD)) following two 
consecutive fat-rich and two consecutive carbohydrate-rich meals 
CETP (mg/l) t=0 t=2 t=4 t=8 ∆t0-8h
Fat-rich meals 
NGM+DM2  1.77 (0.39) 1.74 (0.39) 1.85 (0.43) a 1.84 (0.48) a 0.07 (0.30) 
DM2-ST 1.51 (0.40) 1.50 (0.39) 1.63 (0.35) a 1.58 (0.44) a 0.07 (0.20) 
t-test between 
groups 
P<0.01 P<0.01 P<0.01 P<0.01 NS 
      
Carbohydrate-rich meals 
NGM+DM2 1.79 (0.43) 1.77 (0.41) 1.82 (0.43) 1.84 (0.41) 0.05 (0.27) 
DM2-ST 1.53 (0.37) 1.54 (0.41) 1.60 (0.42) 1.57 (0.42) 0.04 (0.23) 
t-test between 
groups 
P<0.01 P<0.01 P<0.01 P<0.01 NS 
a P<0.05, paired samples t-test compared to t=0. 
Table 3. Pearson correlations between fasting and postprandial increment in 
CETP, and lipid concentrations following two consecutive fat-rich meals (women 
with NGM, DM2, DM2-ST combined; n=159) 
 Fasting    Postprandial (∆t0-8h) 
 TG T.Chol HDL-c LDL-c  TG T.Chol HDL-c LDL-c 
Fasting CETP 0.11 0.42 a -0.07 0.45 a  0.05 -0.05 -0.20 b -0.02 
Postprandial 
CETP (∆t0-8h) 
0.00 -0.06 -0.06 -0.04  0.17 b 0.24 a -0.07 0.03 
a P<0.01. b P<0.05. TG: triglycerides. T.Chol: total cholesterol.  
Correlation coefficients for fasting CETP concentration and postprandial 
increase (∆t0-8h) in CETP with fasting and increment in triglycerides, total 
cholesterol, HDL-cholesterol and LDL-cholesterol following the fat-rich meals did 
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not differ between the NGM, DM2 and DM2-ST subgroups. This enabled us to 
combine the complete study population for correlation analysis (Table 3). In this 
analysis, fasting CETP concentration appeared positively correlated with total 
cholesterol and LDL-cholesterol concentrations and interestingly with a 
decrease in HDL-cholesterol in the postprandial state. Furthermore, postprandial 
increase in CETP concentration seemed to be positively correlated with 
postprandial changes in triglycerides and total cholesterol concentration 
(P<0.05 for both).  
 
Discussion 
In the present study, we demonstrated for the first time that CETP 
concentration rises upon the use of fat-rich meals, while no increment in CETP 
concentration was observed following carbohydrate-rich meals. This increase 
did not differ between women with DM2 and women with NGM. The use of 
statins by women with DM2 decreased fasting and postprandial CETP 
concentrations; however, the postprandial increment in CETP concentration 
was similar to women with NGM and women with DM2 not using statins. The 
observed increase in CETP concentration proved independent of baseline lipid 
levels but was positively associated with postprandial changes in triglycerides 
and total cholesterol concentrations. 
Postprandial phase 
The present findings are in line with two previous studies demonstrating an 
increase in CETP concentration and, concomitantly, an increase in CETP activity 
following a liquid fat-load in normolipidaemic subjects (9) or after a fat-rich 
meal in hypercholesterolaemic women (12). Other investigators showed no 
significant difference between fasting and postprandial CETP concentration in 
DM2 patients (n=11) and not in healthy controls (n=10), possibly due to the 
limited number of subjects studied (10). No previous studies have shown that 
postprandial increases in CETP concentrations were similar among healthy 
individuals, patients with DM2 and patients with DM2 who use statin medication. 
Taken together, it is likely that the underlying mechanism leading to increment 
in plasma CETP concentration is a general mechanism that is independent of 
baseline plasma lipid and/or glucose concentrations. Speculating about an 
underlying mechanism, the increase in CETP concentration can either be result 
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of increased synthesis, cellular secretion or by decreased catabolic rate or a 
combination of these factors.  
Dietary cholesterol has been shown to increase CETP mRNA-synthesis in 
human adipose tissue biopsies concomitant with increased plasma CETP 
concentration (20). Earlier studies in rabbits already showed that a high 
cholesterol diet induces CETP mRNA expression in the liver (21). The 
responsiveness of the CETP gene for dietary cholesterol has been identified by 
the presence of cholesterol-response elements in the promoter region of the 
gene (22). In the present study, the fat-rich meal contained a 10-fold higher 
cholesterol content compared to the carbohydrate-rich meal. Thus, 
postprandial elevation of CETP concentration in plasma is possibly due to 
cholesterol-mediated stimulation of gene transcription. This is corroborated by 
the positive correlation between the postprandial changes in CETP and 
cholesterol concentration in the present study. Statins might reduce CETP gene 
expression in the liver by inhibiting cholesterol synthesis (23). In line with previous 
studies (24, 25), the present data showed that use of statins reduces fasting 
CETP concentration, however, it did not prevent the postprandial rise in CETP 
concentration.  
Another explanation for the increased postprandial CETP concentrations 
is that liver- and/or adipose tissue, the main CETP producing organs, might 
release stored pools of CETP. A close correlation between adipose tissue CETP 
mRNA abundance and plasma CETP concentrations (r=0.85) has been 
demonstrated by Radeau et al. (26), but this does not exclude the possibility 
that CETP protein is stored in adipose tissue or the liver. Evidence for a direct role 
of free fatty acids in this process comes from an in vitro study showing that free 
fatty acids have the ability to enhance secretion of CETP from an intestinal cell 
line (27). Another study showed that in fasting condition, free fatty acid 
concentrations were correlated with CETP concentrations (28). However, in vivo 
studies are required to elucidate whether CETP storage and/or release can for 
example be triggered by free fatty acids that are produced upon lipolysis of 
food born triglycerides.  
The insulin response following a meal has been shown to suppress lipid 
oxidation and to initially decrease levels of free fatty acids (29). The present fat-
rich meal contained carbohydrates, inducing a substantial insulin response. The 
insulin-mediated suppression of fatty acids can possibly explain the initial delay 
(up to two hours) in postprandial increment in CETP concentration. It can be 
hypothesized that the increase of CETP concentration would be greater after 
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consuming a fat-load lacking carbohydrates.  
Alternative explanations for the postprandial CETP increase such as 
attenuated clearance rates of circulating CETP by, for example, a longer CETP 
residence time on HDL, are speculative. 
Use of insulin and CETP concentration 
Hyperinsulinaemia, induced by daily insulin injection in transgenic mice 
expressing human CETP, has recently been found to down-regulate CETP gene 
expression (30). Some of the DM2-patients in the present study were insulin-
dependent. However, data from the current study, show that CETP 
concentration did not differ between insulin-dependent and independent DM2 
patients. In addition, daily use of insulin did not suppress the postprandial CETP 
increase following the fat-rich meal. However, these observations were 
obtained from a very limited number of patients in this study, and require larger 
in depth studies. 
Study limitations 
Only post-menopausal women were investigated. Caution should 
therefore be exercised in extrapolating the present data to effects in men, 
especially since it has been reported that CETP gene expression is possibly 
influenced by hormones (31). Women have, as compared to men, higher levels 
of CETP, although this difference is reduced after the menopause (32).  
A second point that needs attention is the lack of CETP concentration 
measurement at 6 hours after ingestion of the meals due to the lack available 
plasma samples. This is the time point at which the highest plasma triglyceride 
levels were noted and since the increase in triglycerides was correlated with the 
increase in CETP concentration, it is possible that we underestimated the true 
increase in postprandial CETP concentration. Finally, we measured CETP 
concentration and not activity. Although there exist strong correlations 
between CETP concentration and exogenous measured CETP activity (13) (in 
such assays, CETP protein concentrations determine the extend of neutral lipid 
transfer, i.e. CETP activity, between donor and acceptor particles), it is difficult 
to predict how these assays reflect the activity of HDL associated CETP in the 
circulation while using endogenous lipoproteins as substrates. It has for instance 
been shown that an increased concentration of apoB-containing particles and 
an increased binding of CETP to larger HDL-particles in the postprandial phase 
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increase CETP activity (8). 
Conclusions and implications 
To conclude, in a large group of postmenopausal women, we found that 
CETP concentration moderately increased following two consecutive fat-rich 
meals but not following two consecutive carbohydrate-rich meals. The increase 
in CETP concentration was irrespective of diabetes status and use of statin 
medication and was positively correlated with changes in total cholesterol and 
triglyceride levels. Because CETP concentration is elevated following a fat-rich 
meal, irrespective of use of statins, it would be of interest to study the effect of 
pharmaceutical CETP inhibition in the postprandial phase.  
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CHAPTER 10 
 
GENERAL DISCUSSION 
 
 
Chapter 10 
The main aim of the studies presented in this thesis was to investigate the 
role of postprandial metabolism (triglycerides, glucose, insulin and cholesteryl 
ester transfer protein (CETP)) in the development of cardiovascular disease. We 
assessed potential determinants of postprandial levels of glucose, triglycerides, 
insulin and CETP. The contribution of fasting and postprandial glucose, 
triglycerides and insulin levels, and of fasting CETP concentration to 
cardiovascular disease risk was investigated. Here we describe and discuss the 
main findings and make some recommendations as to future studies. 
 
Main findings 
Fasting, post-load and postprandial glucose 
Potential determinants of postprandial increase in glucose levels following 
ingestion of two consecutive carbohydrate-rich meals were described in 
Chapter 2. Fasting glucose was not associated with postprandial glucose levels 
in women with normal glucose metabolism (NGM), whereas age and fasting 
triglycerides were independently associated with postprandial glucose 
excursions. In contrast, in patients with diabetes, an association between fasting 
and postprandial glucose levels was present (Chapter 2).  
The postprandial glucose response was associated with intima media 
thickness (IMT) in women with NGM while no association of fasting glucose and 
2-hour post-OGTT glucose levels with IMT was found (Chapter 3). A mean 
increase of 1.0 mmol/l postprandial glucose following the fat-rich and of 1.8 
mmol/l following the carbohydrate-rich meal was associated with a 50 µm 
thicker IMT. To compare, the difference of 50 µm in IMT was associated with a 
difference of 10 years in age. However, no association between postprandial 
glucose levels and IMT was found in women with diabetes. By assessing the 
association between individual postprandial glucose measurements and IMT in 
NGM women, we found that postprandial glucose measurements at t=1 and 
t=2 hour were more strongly associated with IMT than later measurements (t=4) 
or measurements after the second meal (Chapter 3).   
Hyper(pro)insulinaemia and cardiovascular risk 
In chapter 5, we investigated whether fasting or post-load insulin and 
proinsulin levels predicted cardiovascular mortality or all-cause mortality. We 
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found that a 13 pmol/l higher fasting proinsulin level independently predicted a 
33% higher risk for cardiovascular mortality and a 21% higher risk for all-cause 
mortality. This association was independent of glucose tolerance status and 
insulin resistance. In contrast, the association between fasting insulin and 
mortality was weak and non-significant and was partly explained by glucose 
tolerance status and proinsulin concentration. Two-hour post-load insulin and 
proinsulin concentrations were not significantly associated with mortality. 
Meal-induced insulin secretion  
Early insulin secretion following a carbohydrate-rich and a fat-rich meal 
was estimated by the insulinogenic index (∆Insulin0-30 min/∆Glucose0-30 min) 
and results are described in Chapter 4. In women with type 2 diabetes, the 
insulinogenic index following the fat-rich meal was higher than following the 
carbohydrate-rich meal. In women with type 2 diabetes and in NGM, the 
insulinogenic index was inversely correlated with glucose levels following the 
meals. Furthermore, a higher waist circumference was associated with lower 
insulinogenic indices after the fat-rich and the carbohydrate-rich meals in 
women with NGM.  
Fasting and postprandial triglycerides 
In Chapter 2, we described that fasting triglyceride levels were strongly 
associated with postprandial triglycerides following two consecutive fat-rich 
meals, which was in line with earlier studies (1). Independent of fasting 
triglycerides, HbA1c, total cholesterol, and, inversely, high density lipoprotein 
(HDL)-cholesterol was associated with postprandial increase in triglycerides in 
women with NGM whereas no other variables than fasting triglycerides were 
associated with postprandial triglycerides in women with diabetes.   
No association of fasting and/or postprandial triglycerides with IMT was 
found in women with NGM or diabetes (Chapter 3).  
Fasting and postprandial Cholesteryl Ester Transfer Protein 
Genetic, metabolic and dietary determinants of fasting CETP 
concentration in the Hoorn Study were described in Chapter 6 and 7. We found 
that the C allele of the -629C/A polymorphism of the CETP gene was an 
important determinant of CETP concentration. Independent of this 
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polymorphism, women had higher CETP concentration and cholesterol levels 
were associated with increased CETP concentration, whereas alcohol intake 
was associated with lower CETP concentration (Chapter 6). Furthermore, a 
factor-analysis derived dietary pattern, the "Meat pattern", which was rich in fat, 
was associated with lower CETP concentrations but with a higher prevalence of 
type 2 diabetes (Chapter 7). These genetic, metabolic and dietary associations 
with fasting CETP concentration were all independent of glucose tolerance 
status. Besides these chronic effects on CETP concentration, in the Hoorn 
prandial study, we found that two consecutive fat-rich meals induced an acute 
increase in CETP concentration, while carbohydrate-rich meals did not 
(Chapter 9). This increase was similar in women with NGM and in women with 
diabetes and was correlated with postprandial changes in cholesterol and 
triglycerides.  
The association of CETP concentration with prevalent cardiovascular 
disease or carotid IMT is described in Chapter 8. These associations differed 
between men and women, and among glucose tolerance status. In women 
with diabetes, a high CETP concentration was associated with increased 
prevalence of cardiovascular disease. This association was independent of HDL-
cholesterol, triglycerides and other cardiovascular risk factors. No association 
was found in women without diabetes or in men. In addition, no association 
between CETP concentration and carotid IMT was found in any of the study 
groups. 
 
 
Methodological considerations  
In the following paragraphs, some strengths and weaknesses of the 
studies described in this thesis will be discussed. These considerations concern 
study design, study population, and measurement of postprandial metabolism, 
CETP and carotid IMT.  
Study design 
The Hoorn prandial study (Chapter 2-4 and 9) and all of the analyses of 
the Hoorn Study (Chapter 6-8) except one (Chapter 5) were performed in a 
cross-sectional setting, measuring potential determinants and outcome 
variables approximately at the same time. The cross-sectional design limits the 
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scope of interpretation with regard to causal relationships. Cross-sectional data 
on variables that can change in time should be interpreted with caution. For 
example, the lack of association of postprandial triglycerides with carotid IMT 
(Chapter 3) might be due to other factors that affect carotid IMT over time. 
Carotid IMT is a result of a dynamic process over time and it is known that 
regression of IMT can occur when glycaemia is well-controlled (2). Changes in 
lipid metabolism in postmenopausal women are also well known (3). The 
postprandial triglyceride excursions in postmenopausal women may not 
adequately reflect the changes in lipaemia and thus the long-term exposure to 
triglycerides  in these women. Prospective studies investigating the association 
between postprandial triglycerides and cardiovascular disease might resolve 
this limitation of cross-sectional data. However, it should also be noted that 
prospective studies do not conclusively prove causal relationship. In prospective 
associations, a common underlying factor might affect both the predictor and 
outcome variable.  
Hoorn prandial population  
Postmenopausal women with and without diabetes were invited for the 
Hoorn prandial study. We consider postmenopausal women and especially 
postmenopausal women with diabetes as a high-risk population for 
cardiovascular disease, which prompted us to invite postmenopausal women 
for the Hoorn prandial study. In men, cardiovascular disease has since long 
been recognized as the leading cause of death. Indeed, the risk for 
cardiovascular disease in younger women is lower than in men, but this does 
not hold for postmenopausal women. The menopause induces large changes 
in risk for women, probably because the protective effect of estrogens is lost in 
postmenopausal women (4). Furthermore, although most risk factors contribute 
to cardiovascular disease both in men and in women, the impact of some risk 
factors is greater in women than in men (5). Diabetes, for instance, confers a 
three- to four-fold increased risk for cardiovascular disease in women, while in 
men the risk is two- to three-fold increased (6). Also in the Hoorn Study, it was 
found that postmenopausal women with diabetes had a higher relative risk for 
cardiovascular disease than men of the same age (7). Besides the increased risk 
for cardiovascular disease, we invited postmenopausal women because of the 
relative paucity of data on postprandial metabolism in this population. 
The diabetes population of the Hoorn prandial study was recruited from 
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the Diabetes Care System in Hoorn. These patients were aware of their diabetes 
and were well treated. This is amongst other reflected by mean HbA1c levels 
<7.0 % and lower LDL-cholesterol levels than the women with normal glucose 
metabolism, also when no lipid-lowering medication was used. Treatment 
effects might have influenced our results in some important ways. First, fasting 
and postprandial glucose and triglyceride levels might be less pronounced and 
prolonged as can be expected in women who are not optimally treated or who 
have newly diagnosed diabetes. Second, during treatment, regression of 
carotid IMT might have occurred due to control of (postprandial) 
hyperglycaemia or use of lipid-lowering medication. We also reported a lower 
IMT in DM2 patients who used statin medication as compared to those who did 
not (Chapter 3). Third, insulin sensitivity might have been improved due to diet 
intervention or increased physical activity. As a result, the differences in 
postprandial metabolism between women with diabetes and NGM may be less 
pronounced than can be expected in patients who are not optimally treated. 
Consequently, associations of fasting or postprandial glucose and triglycerides 
with carotid IMT, if present, might have been underestimated.  
Hoorn Study population 
The Hoorn Study started in 1989 and is a cohort study from the Dutch 
population in the region of Hoorn. Participants were randomly selected from the 
population register and 70% (n=2484) agreed to participate. Therefore, it is 
justified to extrapolate the results to the general Dutch population of the same 
age. Data from the Hoorn Study as presented in Chapter 5 were derived from a 
subsample of the original Hoorn Study cohort (n=1109) that attended a second 
visit within two weeks following the first visit. This subsample was stratified for 2-h 
glucose levels and included all patients with type 2 diabetes and impaired 
glucose tolerance and a random sample of the subjects with normal glucose 
tolerance (2-h post-load glucose <7.8 mmol/l). The participation rate to the 
second visit was 92% (8), which allows us to consider this subsample as a 
representative sample of the general population of the same age in the region 
of Hoorn.  
The data from the Hoorn Study as described in Chapter 6-8 were 
measured in 2000-2001, at a follow-up examination of the subsample as 
described above. All participants were older than 60 years at this examination 
and 57% (631 out of 1109) of the participants who were invited did participate. 
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Therefore, we consider participants in the follow-up examination as a relatively 
healthy selection of the general population of that age and we should be 
cautious to extrapolate these data to the general population. The Hoorn 
Screening Study, carried out in 1998-2000, aimed to identify patients with 
diabetes in the age range of 50-75 years with a step-wise screening procedure 
(9). Patients with type 2 diabetes, identified by this screening procedure (n=217) 
were added to the participants of the follow-up examination of the Hoorn Study 
to increase the number of patients with diabetes. Hoorn Screening Study 
patients with recently detected type 2 diabetes had a different cardiovascular 
risk profile than patients with diabetes from the original Hoorn Study cohort. 
Therefore, in addition to the participants in the follow-up examination of the 
Hoorn Study, the combined population of patients with diabetes as described in 
Chapters 6-8 are a heterogeneous population of patients, which cannot be 
considered representative of the general diabetes population. 
Measuring postprandial metabolism 
The reason for using two consecutive meals in the Hoorn prandial study 
was to mimic daily food intake patterns. Postprandial glucose and triglyceride 
responses to a second meal differ from postprandial responses to a first meal. 
The ability of a first meal to attenuate glucose response to a second meal is 
known as the "second-meal effect" (10). Sequential meal ingestion also 
provokes a rapid release (within one hour) of triglycerides from a previous meal 
(11).  
However, we found that postprandial glucose concentration following 
the first meal (up to 4 hours) was associated with IMT to a similar extent as the 
total glucose response following two consecutive meals (Chapter 3). This implies 
that glucose levels following a single meal and glucose levels following two 
consecutive meals are similarily representative of the underling 
pathophysiology. Indeed, the correlation between postprandial glucose after 
the first meal and postprandial glucose levels after the second meal was high 
(r=0.83 for fat-rich meals and r=0.94 for carbohydrate-rich meals, unpublished 
data Hoorn prandial study). The same was the case for triglyceride levels 
following one meal and following two consecutive meals (r=0.91 for fat-rich 
meals and r=0.94 for carbohydrate-rich meals, unpublished data Hoorn prandial 
study). This indicates that daytime glucose and triglyceride excursions are well 
estimated by application of a single meal.  
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However, by measuring the triglyceride response of two consecutive 
meals up to 8 hours after breakfast (i.e. 4 hours after lunch), we did not fully take 
into account the clearance rate of triglycerides. In order to fully assess the 
effects of a delayed clearance rate and an increased triglyceride production, 
we should have extended the postprandial measurements until the levels of 
triglycerides returned to baseline.  
In considering the postprandial response of, for example, triglycerides or 
glucose we calculated total area under the curve or incremental area under 
the curve depending on the research question. When the postprandial 
response was considered as dependent variable, postprandial incremental 
area under the curve was calculated because we aimed to assess factors that 
contributed to the postprandial increase in triglycerides or glucose rather than 
to the fasting level, which is, in case of triglycerides, strongly correlated to the 
postprandial concentration. On the other hand, when the postprandial 
response was considered as an independent variable or determinant, we 
calculated total area under the curve because we supposed that the total 
exposure to glucose or triglycerides during the day accounts for potential 
atherogenic effects of these variables (12). 
Carbohydrate-load  
The widely accepted measurement of post-load plasma glucose levels 
for the assessment of glucose tolerance is the 2-hour value following an OGTT 
(75-gram glucose solution). This test is well standardized but does not necessarily 
reflect daytime glucose levels. Regular daytime glucose profiles are probably 
better reflected by the glucose levels following a meal (13). Indeed, for women 
with NGM, the correlation between 2-hour post-OGTT glucose values and 2-
hour postprandial glucose values was significant (r=0.38 and r=0.29, both P<0.05, 
for fat-rich and carbohydrate-rich meals respectively), but lower than the 
correlation between 2-hour postprandial glucose levels following the two meals 
of different composition (r=0.56, P<0.01, unpublished data Hoorn prandial 
study).  
Postprandial glucose levels are determined by several factors, including 
quantity and composition of the meal, previous consumed meals, rate of 
gastric emptying and insulin secretion. We found that postprandial glucose 
levels and IMT were associated, while no association between 2-hour post-OGTT 
glucose levels and IMT was found (Chapter 3). It should be noted that these 
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women were selected for normal glucose metabolism (fasting glucose <6.1 
mmol/l and 2-hour glucose levels <7.8 mmol/l). The range of post-OGTT glucose 
levels might have been too small to detect an association with IMT. On the 
other hand, despite this small range in post-OGTT glucose levels, postprandial 
glucose was associated with IMT. Therefore, we should consider some 
differences between post-OGTT and postprandial glucose levels. First, within-
subject variability of 2-hour post-OGTT glucose levels is higher than 2-hour 
glucose levels following a standardized mixed meal (14). The lower variability will 
give more statistical power for assessing the impact of glucose levels after the 
mixed meal on  IMT. It does however not explain the lack of association 
between 2-hour glucose levels and IMT in women with normal glucose 
metabolism. Second, and probably more important, the glucose response to 
the mixed meals results from mechanisms, which are not involved in the 
absorption of an oral glucose load. The composition of the meal is of 
importance in insulin stimulation and rate of gastric emptying. For example, 
some proteins can stimulate insulin secretion (15,16) and fat delays the rate of 
gastric emptying (17). The involvement of these mechanisms may result in a 
higher between-subject variation in postprandial glucose levels than after an 
OGTT. This is relevant for determining the cardiovascular risk profile. Although the 
exact role of separate micro- and macronutrients cannot be unravelled from 
the present data, in daily life, different nutrients are consumed together. Thus, a 
mixed meal potentially represents a better estimate of an individual's usual 
insulin secretion, glucose and triglyceride exposure than an oral glucose load.  
Fat-load  
The composition of the fat-rich meal determines the following metabolic 
responses and might potentially have influenced the results with regard to the 
association between postprandial triglycerides and cardiovascular risk (Chapter 
3). The amount of carbohydrates might have been important because glucose 
stimulation determines the height of the insulin response. In turn, insulin 
suppresses the fatty acid release from adipose tissue, stimulates lipoprotein 
lipase mediated clearance of triglyceride-rich lipoproteins (18) and suppresses 
the postprandial triglyceride response due to suppression of hepatic VLDL-
secretion (19). However, previous studies applied mixed meals with high (60 
energy%) or lower (27 energy%) amounts of carbohydrates and both studies 
showed an association between postprandial triglycerides and cardiovascular 
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risk (20,21). Furthermore, the amount of fat also ranged from 20-60 energy% in 
these previous studies. Therefore, it is unlikely that the amount of fat or 
carbohydrates in the fat-rich mixed meal as used in the Hoorn prandial study 
explained the lack of association between postprandial triglycerides and IMT 
(Chapter 3). We propose other possible explanations for this lack of association 
in the mechanistical pathways section. 
Besides the composition of the meal, the choice of a fat-rich meal 
instead of a liquid fat-load in the Hoorn prandial study also potentially affects 
the following metabolic response. A liquid meal passes the stomach faster than 
solid meals (22), resulting in higher glucose and insulin responses as compared 
to a solid meal. However, the metabolic response to a solid meal is a better 
reflection of usual daily exposure to triglycerides and of the possible contribution 
to atherosclerosis than the response to an oral liquid fat-load.  
CETP concentration or activity 
Plasma concentrations of CETP are tightly correlated with CETP mRNA 
expression in adipose tissue as demonstrated in a human study (23). Expression 
of CETP is responsive to a variety of genetic (Chapter 6) and environmental 
factors including plasma cholesterol concentrations and alcohol intake 
(Chapter 6). Whilst the CETP concentration mainly depends on CETP gene 
transcription, the activity of the protein can also be influenced by other factors. 
As already suggested in the eighties, CETP activity is affected by CETP 
concentration, an increase in triglyceride-rich lipoproteins, and redistribution of 
CETP to larger HDL particles (24). Despite this, strong correlations were found 
between CETP concentration and activity when measured with exogenous 
substrate (r=0.86) (25). However, these strong correlations were measured in the 
fasting state and not in the postprandial state. Therefore, the results of our 
postprandial data on CETP concentration (Chapter 9) cannot simply be 
extrapolated to CETP activity. Furthermore, it is difficult to predict the relation 
between postprandial CETP concentration and postprandial CETP activity when 
using endogenous substrate. By using endogenous substrate, CETP activity 
largely depends on the triglyceride concentration in the plasma, which varies in 
the postprandial state. Nevertheless, given the fact that CETP concentration 
increased following a fat-rich meal, together with an increase in triglycerides 
(Chapter 9), we would suppose an even higher postprandial increase in CETP 
activity than in concentration. 
 166
General discussion 
B-mode M-mode 
arterial   
diameter       IMT  
complex 
 
Figure 1. Measurement of carotid intima media thickness (IMT) in B-mode ultrasound. 
IMT as a measure of atherosclerosis  
Ultrasound imaging of the arterial wall is a non-invasive research tool to 
quantitate changes in the arterial wall. Measurement of carotid IMT by 
ultrasound imaging is widely used. A higher carotid IMT reflects thickening of the 
arterial wall (26) (Figure 1). Carotid IMT is a well-accepted marker for 
atherosclerosis and cardiovascular risk and it was shown to be predictive for 
incident coronary heart disease (27). Despite its predictive value for 
cardiovascular disease risk, some important limitations of IMT as a marker for 
atherosclerosis should be considered.  
First, carotid IMT can be assumed to reflect the cumulative effect of the 
atherogenic processes. Because of these dynamic processes over time, 
progression as well as regression due to drug treatment or lifestyle intervention 
can occur. Lipid-lowering therapy slows progression of IMT (28) and also the use 
of glucose lowering medication can reduce IMT (29). Especially in a cross-
sectional study design, treatment-related modification of the IMT might have 
led to an attenuation of the true association between metabolic responses and 
atherosclerosis. Second, since IMT is a continuous variable and there is no cut-
off point for IMT above which clinical manifestation of atherosclerosis can be 
considered present (30). Furthermore, plaque formation and the tissue type of 
the plaque are important in prediction of events. Lipid-rich plaques with a thin 
cap are more prone to rupture and to cause symptoms as compared to stable 
plaques (31). Finally, many other mechanisms, which are not accounted for 
when IMT is used as a measure of atherosclerosis, play a role in development of 
cardiovascular disease. Arterial and cardiac properties, as arterial stiffness, 
endothelial function and cardiac function as well as inflammation and 
thrombosis, all contribute to the occurrence of cardiovascular events. 
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Postprandial mechanistic pathways  
Fasting, post-load and postprandial glucose 
Elevated fasting and post-load glucose levels are considered to be the 
result of different mechanisms (32). Fasting glucose levels are mainly 
determined by beta-cell function and the hepatic glucose output whereas 
postprandial glucose levels are regulated by the early beta-cell response and 
peripheral insulin sensitivity. The finding that fasting glucose was not 
independently associated with postprandial glucose levels in women with NGM 
(Chapter 2) strengthens the concept of distinct pathophysiological mechanisms 
for elevated fasting glucose and postprandial glucose levels.  
Previous studies showed a progressive relationship between high glucose 
levels and cardiovascular risk. A meta-regression analysis with prospective data 
from 20 studies, showed that fasting and post-load glucose levels, even below 
the diabetic threshold, predict cardiovascular event risk (33). Furthermore, it was 
found that the contribution of 2-hour post-OGTT glucose levels to cardiovascular 
risk was stronger than the contribution of fasting glucose levels, which was 
shown in the Hoorn study as well as in the DECODE-study (34,35). This might 
cohere with the J-shaped relation that was found between fasting plasma 
glucose levels and (cardiovascular) mortality whereas the relation between 
elevated post-load glucose levels and (cardiovascular) mortality was graded 
and increasing (34). Post-load glucose levels, also in the normal range (<7.8 
mmol/l), were related with (cardiovascular disease) mortality, whereas no such 
association was found for fasting glucose levels in the normal range (<6.1 
mmol/l) (34). The association between 2-hour post-OGTT glucose levels and 
(cardiovascular disease) mortality indicates that other mechanisms than 
atherosclerosis may be involved in (cardiovascular disease) mortality, as we did 
not find an association between post-OGTT glucose and IMT in women with 
NGM (Chapter 3).  
The risk conferred by post-OGTT glucose levels has frequently been 
studied; much less is known about postprandial glucose levels. Two prospective 
studies reported an association between postprandial glucose levels and 
cardiovascular events among patients with (newly detected) diabetes (36,37). 
As described in Chapter 3 the lack of association between postprandial 
glucose levels and IMT in patients with diabetes might be explained by a higher 
within-subject variation in postprandial glucose as compared to women with 
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NGM or by the fact that patients with diabetes were extensively treated, which 
may have affected cross-sectional associations. Nevertheless, the strong 
association in individuals with NGM reported in the present thesis was somewhat 
surprising, because of the narrow range of the plasma glucose levels. Moreover, 
2-hour post-OGTT glucose levels were not associated with IMT in these women. 
The possibility that the association between postprandial glucose and IMT was 
based on chance is small, because the association was consistently found on 
two separate occasions (following the fat-rich as well as following the 
carbohydrate-rich meals). Measuring glucose levels after consumption of a 
meal might therefore provide important additional information. The underlying 
mechanism is however unknown.  
Evidence is growing that the formation of advanced glycation end-
products (AGEs) in the postprandial phase, plays a role in development of 
diabetes-related complications. The formation of AGEs is the potential 
explanation for the relation between postprandial glucose excursions and 
cardiovascular damage (38). It was previously found that postprandial 
hyperglycaemia in patients with type 1 diabetes was accompanied by an 
increment in reactive sugars (α-dicarbonyls) which are precursor molecules of 
AGEs (39). In line with this, in a substudy (n=53), we found an increase in AGE 
precursor molecules both in women with NGM and in women with type 2 
diabetes (submitted for publication). This increase was more pronounced after 
the carbohydrate-rich meal as compared to the fat-rich meal.  
Furthermore, the increase in glycation was correlated with the 
postprandial increase in glucose following the fat-rich meal, but not following 
the carbohydrate-rich meal. This intruiging finding is difficult to explain. Possibly, 
the amount of fat in the fat-rich meal induces oxidative stress, which in turn may 
promote the formation of glycation end-products (40). In addition, AGE-
precursors might be derived directly from the meal (41). 
 Hyper(pro)insulinaemia and cardiovascular risk 
The finding that the association between proinsulin and cardiovascular 
mortality was stronger than the association between insulin and cardiovascular 
mortality is in line with previous findings (42). Furthermore, the association 
between proinsulin levels and (cardiovascular) mortality was independent of 
insulin resistance and glucose tolerance status (Chapter 5). If elevated proinsulin 
levels reflected beta-cell dysfunction, associations between other estimates of 
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beta-cell function and mortality would have accompanied the association 
between proinsulin and mortality, which was not the case. Therefore, it more 
likely that proinsulin per se contributes to atherogenic or thrombotic risk. As 
previously demonstrated, the adverse effect of proinsulin may be mediated by 
enhancement of plasminogen activator inhibitor-1 (PAI-1) activity (43). It has 
also been demonstrated in vivo that proinsulin and insulin promote PAI-1 gene 
expression (44). A high PAI-1 activity promotes fibrosis and thrombosis and PAI-1 
concentrations increase with the development of diabetes or obesity (45). It has 
also been hypothesized that central obesity is the common factor causing 
elevations in proinsulin concentration, PAI-1 activity and increased risk for 
mortality. However, BMI and waist circumference only slightly attenuated the 
association between proinsulin and mortality risk, while other risk factors did not 
affect the association. The independency of the association between proinsulin 
and cardiovascular mortality was also demonstrated in another recent study 
(46). Therefore, at least in part, the association between proinsulin and mortality 
risk is independent of classical cardiovascular risk factors. 
In contrast, post-OGTT proinsulin concentrations were not predictive of 
mortality. This may be attributed to a higher biological variability in proinsulin 
concentrations after a glucose challenge.  
Meal-induced insulin secretion 
Several studies indicate that first-phase insulin secretion to a substantial 
degree is influenced by genetic factors. Approximately two thirds of the 
variance in first-phase insulin secretion is attributed to genetic factors (47). 
However, some metabolic and environmental factors can influence first-phase 
insulin secretion as well (48). We calculated the insulinogenic index as a 
representative of physiological meal-induced early insulin secretion. In Chapter 
4, we found that the insulinogenic index was affected by meal composition 
(acute effect) and by body composition (long-term effect).  
A carbohydrate-rich meal resulted in a higher absolute insulin response 
compared to a fat-rich meal, whereas the relative increment in insulin-to-
glucose in the first 30 minutes after meal ingestion was higher following the fat-
rich meal. The composition of the meals that were applied differed with regard 
to amount of carbohydrates (162 g in the carbohydrate-rich meal versus 56 g in 
the fat-rich meal), the amount of fat (4 g in the carbohydrate-rich meal versus 
50 g in the fat-rich meal) and, to a minor extent, the amount of protein (22 g in 
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the carbohydrate-rich meal versus 28 g in the fat-rich meal), so the specific 
effects of these macronutrients cannot be distinguished from this study. 
Probably, the lower carbohydrate-load together with the fat-induced 
retardation of gastric emptying contributed to the higher insulinogenic index 
following the fat-rich meal (Chapter 4). Furthermore, we demonstrated that a 
higher insulinogenic index is associated with lower glucose concentrations later 
following the meal. These lower glucose excursions are possibly due to 
suppression of hepatic glucose output by a rapid insulin response (49).  
Thus, if a fat-enriched, low-carbohydrate meal favourably affects early 
insulin secretion in patients with diabetes, substituting fat for carbohydrates 
without changing the energetic content might be useful in controlling 
postprandial glycaemia. The effects of substituting protein or fat for 
carbohydrates on postprandial glucose concentrations were previously 
demonstrated (50). Proteins were found to act as an insulin secretagogue in 
patients with diabetes (15) and fat instead of carbohydrates in a meal may 
reduce glucose excursions, probably at least partly due to the lower 
carbohydrate load. Therefore, Gannon et al. proposed that it is possible to 
improve blood glucose levels without weight loss in patients with type 2 
diabetes by modification of diet composition (50). Whether the improved 
glycaemic control following a fat-enriched meal results from an adequate early 
insulin response should be further studied by assessing the effects of separate 
nutrients on early insulin secretion. Although glycaemic control is of high 
importance in patients with diabetes, and we did not demonstrate an adverse 
association between postprandial triglyceride response and IMT, it is important 
to consider other potential metabolic effects of a fat-rich or protein-rich diet. 
Another important factor associated with a lower insulinogenic index in 
women with NGM was central obesity, measured by waist circumference. 
Central obesity is accompanied by a higher flux of fatty acids into portal 
circulation and these fatty acids might accumulate in muscle, liver and beta-
cell (51). According to the so-called 'lipotoxicity-hypothesis', the accumulation 
of triglycerides in the beta-cell leads to impaired beta-cell function. 
Alternatively, chronic low-grade inflammation by adipose tissue derived 
adipocytokines may be implicated in the association between waist 
circumference and impaired early insulin secretion (52). Besides the previously 
reported heritability of the insulin response (47), the present data showed that 
environmental (meal composition) and metabolic conditions (body 
composition) additionally affect meal-induced early insulin secretion.    
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Fasting or postprandial triglycerides 
The fasting triglyceride level has been shown to be an independent risk 
factor for coronary heart disease, especially in women (53). In addition, several 
other studies reported that postprandial levels of triglycerides were more 
strongly associated with atherosclerosis than fasting triglycerides (20,21,54-60). 
The results of the Hoorn prandial study contrast with these previous findings; we 
did not find an association between fasting or postprandial triglycerides and IMT 
(Chapter 3).  
Moreover, postmenopausal women with diabetes have a higher risk for 
cardiovascular disease as compared to men with diabetes (61) which can in 
part be attributed to changes in lipid metabolism. Indeed, postmenopausal 
women have higher levels of fasting triglycerides, low density lipoprotein (LDL)-
cholesterol and total cholesterol while HDL-cholesterol levels are lower 
compared to premenopausal women (62). This increase is partly caused by the 
decline in estrogen levels, which normally up-regulates transcription of the LDL-
receptor in the liver. In addition, postprandial triglycerides are increased in 
postmenopausal women as compared to premenopausal women (3).  
Despite the increased cardiovascular risk and the worsened lipid profile in 
postmenopausal women with diabetes, only one previous study determined the 
relation between postprandial triglycerides and cardiovascular disease 
stratified for gender. This study reported an association between postprandial 
triglycerides and carotid IMT in both men and women. However, an association 
with exercise-induced myocardial ischaemia was only present in men and not 
in women (54,60). This study applied a liquid-fat load instead of a mixed meal. 
Therefore, postprandial studies in postmenopausal women investigating 
changes in lipid metabolism in relation to cardiovascular disease are still 
urgently needed.  
One other study reported similar postprandial triglyceride levels in 
hypertriglyceridaemic persons with and without cardiovascular disease (63). It 
was previously demonstrated that postprandially, atherogenic triglyceride-rich 
lipoprotein remnants were associated with atherosclerosis, independent of 
postprandial triglycerides levels (64). The formation of these particles might lead 
to atherosclerosis rather than total levels of triglycerides. Other particle 
properties like LDL-particle size were not assessed in the Hoorn prandial study 
but might also affect development of atherosclerosis. Furthermore, recent 
attention for the functional properties of the HDL particle may contribute to our 
knowledge on the development of cardiovascular risk (65). 
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Alternatively, changes in lipid metabolism that occurred after the 
menopause in combination with the cross-sectional study design might explain 
the lack of association between triglycerides and IMT. Whether this was the 
case may probably be elucidated by longitudinal studies in postmenopausal 
women. 
Cholesteryl ester transfer protein in postmenopausal women 
The independent association between dietary and metabolic factors and 
CETP concentration was described in Chapters 6 and 7. Plasma CETP 
concentration can hypothetically be affected by changes in synthesis, cellular 
secretion or by decreased catabolic rate.  
The CETP gene has been the subject of many genetic analyses to identify 
polymorphisms associated with CETP concentration or HDL-cholesterol levels. In 
the promoter region of the CETP gene, the -629C/A polymorphism was found to 
be independent of other polymorphisms associated with HDL-cholesterol and 
CETP concentration (66). The association between the number of C alleles on 
the -629C/A polymorphism and elevated plasma CETP concentration was 
confirmed by our data as described in Chapter 6. Furthermore, the promoter 
region of the CETP gene contains a cholesterol-response element (67). Plasma 
cholesterol concentration was independently associated with plasma CETP 
concentration (Chapter 6), which can be explained by cholesterol-mediated 
stimulation of CETP synthesis. The postprandial data from Chapter 9 also 
demonstrate that CETP-synthesis may in part be enhanced by dietary 
cholesterol. Following the fat-rich meal, with a 10-fold higher cholesterol content 
than the carbohydrate-rich meal, CETP concentrations increased, whereas 
after the carbohydrate-rich meal, no statistically significant increase was found. 
In line with this, we found a positive correlation between postprandial changes 
in plasma cholesterol levels and postprandial increase in CETP concentration 
(Chapter 9).  
The female sex hormone estradiol also stimulates CETP gene expression 
and was found to be positively associated with plasma CETP concentrations 
(68). Indeed, CETP concentration is usually higher in women than in men, and 
CETP concentrations decrease, concomitant with a decrease in estradiol, after 
the menopause. Women who attended in the follow-up examination of the 
Hoorn Study were older than 60 years and therefore considered 
postmenopausal. As elevated CETP concentrations are considered to be 
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atherogenic, one may argue that postmenopausal women have favourably 
low CETP concentrations. However, despite the lower CETP concentrations as 
compared to premenopausal women, postmenopausal women still have 
higher CETP concentrations as compared to men (Chapter 6). Furthermore, the 
activity of CETP is increased after menopause probably due to an increase in 
triglyceride levels after the menopause (69). Therefore, data on CETP 
concentration or activity in postmenopausal women cannot be simply 
extrapolated to men or premenopausal women. 
From previous studies, some information is available about factors that 
potentially affect cellular secretion of CETP, which may underlie the inverse 
association between alcohol intake and CETP concentration that we found in 
the Hoorn Study (Chapter 6). From an in vitro study, it is known that glycation of 
CETP is needed for cellular secretion of the protein (70). A recent publication 
provided evidence that alcohol users have a lower glycation rate of CETP, 
possibly contributing to the lower plasma CETP concentration (71). We 
demonstrated for the first time an inverse relation between alcohol intake and 
CETP concentration in a large population-based study (Chapter 6). It has been 
suggested that the higher HDL-c concentrations often found in alcohol users are 
due to the lower CETP activity (72), but this requires further study. 
Finally, in Chapter 7, we described that a factor-analysis derived dietary 
pattern, the "Meat pattern", was associated with lower CETP concentration. 
Given the high correlation between cholesterol intake and this dietary pattern, 
we would have expected higher CETP concentrations following the "Meat 
pattern". On the other hand, the dietary pattern correlated with high amounts 
of saturated fat and mono-unsaturated fat intake. From experimental dietary 
studies, it is known that saturated fatty acids and mono-unsaturated fatty acids 
have opposite effects on CETP concentration (73). A diet rich in mono-
unsaturated fatty acids was shown to reduce CETP concentration, together with 
a decrease in cholesterol, whereas a diet rich in saturated fat increased levels 
of CETP and cholesterol (74). The mechanisms of these diet-induced changes in 
CETP are not clearly established. It is possible that a high intake in saturated fat 
increases the intracellular cholesterol content and therefore enhances CETP 
transcription. However, this does not explain the reduced CETP concentration 
when consuming a diet high in mono-unsaturated fatty acids. By definition, with 
the dietary pattern approach, it is not possible to distinguish the effects of 
separate macronutrients on CETP concentration. Furthermore, given the fact 
that a high conformation to the "Meat pattern" was associated with a higher 
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prevalence of diabetes, we do not consider the "Meat pattern" as a healthy 
dietary pattern.   
Gender differences with regard to the association between CETP 
concentration and cardiovascular disease were shown in Chapter 8. Elevated 
CETP concentration was associated with a higher prevalence of cardiovascular 
disease in women with diabetes, but not in men. The combination of elevated 
levels of CETP as compared to men (Chapter 6), an increase in cholesterol and 
triglycerides after the menopause and the insulin resistant state of diabetes is 
likely to be unfavourable with regard to cardiovascular risk in postmenopausal 
women. A higher concentration of cholesteryl esters in apolipoprotein-B 
containing particles is atherogenic in case of insufficient hepatic clearance 
(75). In addition, triglyceride-enriched HDL and LDL particles may enable 
hepatic lipase to the formation of small, dense HDL and LDL-particles (Chapter 
1). The postprandial increase in CETP concentration as described in Chapter 9 
together with the postprandial increase in apo-B containing particles may lead 
to an even more adverse lipid distribution in the postprandial phase, which 
might be especially true for postmenopausal women with diabetes. 
 
Implications for future research  
Oral glucose tolerance test or meal-test 
The gold standard test for assessing the glucose tolerance status is the 
OGTT. We showed that postprandial glucose levels were associated with IMT. It 
should be evaluated in prospective studies whether the measurement of post-
load glucose levels following a meal provides more information about future risk 
of macrovascular and microvascular complications than post-OGTT glucose 
levels. 
Meal composition and insulin secretion 
An adequate early insulin response is important for daytime glycaemic 
control. The hypothesis that modification of diet composition might improve 
blood glucose levels without weight loss in patients with type 2 diabetes (50), is 
supported by our data on isocaloric meals inducing differences in early insulin 
secretion and later glucose excursions. Whether the improved glycaemic 
control following a fat-enriched meal results from an adequate early insulin 
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response should be further studied by assessing the effects of meals with 
different amounts and types of fat on early insulin secretion.  
Furthermore, it is of importance to evaluate the effects of a fat-rich meal 
on other aspects of metabolism besides the effects on glycaemia, before 
considering substitution of dietary fat for carbohydrates. As we showed in 
Chapter 2, triglyceride excursions were much higher after the fat-rich meal as 
compared to the carbohydrate-rich meal, which should be investigated with 
regard to cardiovascular risk. The improvement of glycaemic control by 
changing nutrient composition of a meal as an additional tool besides weight 
reduction and pharmaceutical therapy would be an attractive treatment for 
patients with diabetes, when the effects on lipid metabolism and 
cardiovascular risk are well understood. 
Postprandial triglycerides and cardiovascular risk 
Our data showed that levels of postprandial triglycerides following two 
consecutive physiological meals were not associated with atherosclerosis in 
postmenopausal women. Prospective studies might aim to investigate the 
association between postprandial (triglyceride-rich) lipoprotein responses and 
cardiovascular disease incidence, stratified for gender. In addition, the 
differential mechanisms that are involved in digestion, absorption and 
clearance of a solid mixed meal versus a liquid fat-load should be unravelled.  
Cholesteryl Ester Transfer Protein inhibition 
Longitudinal studies assessing the effects of elevated CETP concentration 
are scarce. CETP inhibition does result in an improved lipid profile, but recently, 
a pharmaceutical trial of a CETP-inhibitor was stopped because of increased 
mortality rate in the treatment group. This might be related to the role of CETP in 
reverse cholesterol transport, which enhances cholesterol clearance in the 
presence of efficient hepatic clearance. Therefore, the individual metabolic 
setting may determine whether CETP contributes to cardiovascular disease risk 
(76). We suggest that the individual metabolic setting in postmenopausal 
women with diabetes provides a setting in which CETP is potentially 
atherogenic. These women have higher levels of cholesterol and triglycerides 
induced by the menopause, diabetes-related dyslipidaemia and high CETP 
concentrations as compared to men. We showed cross-sectionally, that in 
women with diabetes, higher levels of CETP coincided with an increased 
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prevalence of cardiovascular disease. Studies assessing the long-term effects of 
higher CETP concentration in this high-risk population for cardiovascular disease 
are not available. These are necessary before CETP inhibition can be 
considered for these women.    
The postprandial increase in CETP concentration following a fat-rich meal 
indicates that application of CETP inhibition might be relevant in the 
postprandial state. The combination of elevated levels of triglycerides together 
with higher CETP concentration following a meal will lead to a high CETP activity 
(77). The increased transfer of triglycerides to HDL and LDL-particles will result in 
the formation of atherogenic small dense particles. Thus, the postprandial state 
is susceptible for atherogenic lipid distribution induced by CETP.  
To conclude, 
The role of postprandial metabolism in cardiovascular disease was 
evaluated in the present thesis. Postprandial glucose metabolism is, more 
strongly than fasting and post-OGTT glucose levels, and than fasting and 
postprandial triglyceride levels, associated with atherosclerosis. We speculate 
that other lipoprotein particles than triglyceride-rich lipoproteins in the 
postprandial state may be involved in atherogenesis.  
The postprandial state may indeed promote atherosclerosis (78) because 
of elevation of glucose and changes in the concentration or composition of 
lipoproteins, the latter possibly mediated by CETP. The high cardiovascular 
disease risk due to diabetes in postmenopausal women might in part be 
explained by the unfavourable postprandial glucose and lipoprotein profile. 
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SUMMARY 
 
Introduction 
The global prevalence of type 2 diabetes is increasing rapidly and 
nowadays affects almost 250 million people. Cardiovascular disease is the most 
prevalent complication of type 2 diabetes, and primarily responsible for the 
increased morbidity and mortality rates in these patients. The present thesis 
focuses on the possible meal-induced metabolic mechanisms underlying the 
increased cardiovascular risk in type 2 diabetes. 
In Western society, we are in the postprandial state for a large part of the 
day. Metabolic risk factors for cardiovascular disease are usually measured in 
the fasting state, which only represents a small part of the actual metabolic 
state. Furthermore, the fasting state does not always predict the metabolic 
processes in the postprandial phase. Disturbances in postprandial metabolic 
control may substantially contribute to development of cardiovascular disease. 
The main aim of the studies presented in this thesis was to investigate 
associations of postprandial metabolism with cardiovascular disease risk. The 
contribution of fasting and post-load glucose, triglyceride and (pro)insulin levels 
and of fasting CETP concentration to cardiovascular disease risk is investigated. 
These questions were addressed in the Hoorn prandial study and in the Hoorn 
Study.  
 
Study design 
In postmenopausal women, diabetes confers a higher relative risk for 
cardiovascular disease than in men and fasting and postprandial triglyceride 
levels are increased. Therefore, most of the research questions were addressed 
in postmenopausal women with diabetes.  
The Hoorn prandial study was designed to elucidate the relative 
contribution of postprandial hyperglycaemia and postprandial 
hypertriglyceridaemia to cardiovascular disease risk. Postmenopausal 
normoglycaemic women and women with type 2 diabetes participated in a 
postprandial study in order to determine postprandial glucose, insulin, 
triglyceride and CETP concentrations (Chapter 2, 3, 4 and 9). 
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The Hoorn Study is a population-based cohort study consisting of 2484 
participants of which baseline measurements started in 1989. In 2000-2001, at 
the age of 60-85 years, participants with type 2 diabetes, impaired glucose 
metabolism and normal glucose metabolism were re-invited for follow-up 
examination. The Hoorn Study data were used for the analyses presented in 
Chapter 5, 6, 7, and 8. 
 
Main findings and discussion 
In Chapter 2, potential determinants of fasting and postprandial glucose 
and triglyceride excursions were assessed. Fasting and postprandial glucose 
levels were not associated with each other in women with normal glucose 
metabolism (NGM), but in patients with DM2 they did. The main associates of 
postprandial glucose in NGM women were age and fasting triglycerides. In 
contrast, fasting triglyceride levels were the strongest determinant of 
postprandial triglyceride levels in women with NGM and diabetes, which was in 
line with earlier studies.  
In Chapter 3, we investigated the relative contribution of these 
postprandial glucose and triglyceride excursions to carotid intima media 
thickness (cIMT), as a marker for atherosclerosis. Postprandial glucose levels 
were associated with cIMT in women with NGM. Of interest, no such association 
was found with either fasting or 2-hour glucose levels after an oral glucose 
tolerance test (OGTT). Measuring glucose levels following a meal is probably 
more representative for daytime glucose levels. These findings require 
prospective studies to confirm that post-load glucose levels following a meal is 
a stronger predictor of future risk of macrovascular and microvascular 
complications than post-OGTT glucose levels. Nevertheless, this study suggests 
that the postprandial glucose concentrations and/or the mechanisms 
responsible for postprandial glucose regulation, play a role in atherosclerosis.  
No an association between fasting or postprandial triglycerides and cIMT 
was found (Chapter 3). The composition of lipoproteins, which was not assessed 
in the postprandial state may be more strongly associated with atherosclerosis. 
Alternatively, given the changes in lipid metabolism that occur after the 
menopause, the postprandial triglyceride response in postmenopausal women 
might not be an appropriate reflection of triglyceride exposure in the past. 
Despite the increased cardiovascular risk due to diabetes in postmenopausal 
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women, until now, very few studies determined the relation between 
postprandial triglycerides and cardiovascular disease for men and women 
separately. Longitudinal studies, stratified for gender may probably elucidate 
whether postprandial triglycerides or lipoprotein composition are a risk factor for 
cardiovascular disease in postmenopausal women. 
An index for early insulin secretion was used in Chapter 4 to describe 
meal-induced early insulin secretion. In women with type 2 diabetes, early 
insulin secretion following the fat-rich meal was higher than following the 
carbohydrate-rich meal. In type 2 diabetes and in NGM, the early insulin 
secretion index was associated with lower postprandial (2 and 4 hour) glucose 
levels. The hypothesis that modification of diet composition might improve 
blood glucose levels without weight loss in patients with type 2 diabetes, is 
supported by these data. Managing hyperglycaemia by changing meal-
composition rather than using pharmaceutical drugs might be attractive. The 
longer term efficacy of this approach and the longer term effects on lipid 
metabolism should be considered before further recommendations can be 
made. 
The relationship of fasting and post-load levels of insulin and proinsulin 
with 11-year risk on cardiovascular disease mortality and all-cause mortality was 
studied in Chapter 5. A 13 pmol/l higher fasting proinsulin level independently 
predicted a 33% higher risk for cardiovascular mortality and a 21% higher risk for 
all-cause mortality. This association was independent of glucose tolerance 
status and insulin resistance. These findings suggest atherogenic properties for 
proinsulin as a molecule. Two-hour post-load insulin and proinsulin 
concentrations were not significantly associated with mortality. This might be 
due to higher biological variability in post-load as compared to fasting 
proinsulin concentrations.  
In Chapters 6 and 7, we assessed genetic, metabolic and dietary factors 
that were associated with fasting CETP concentration. CETP plays a key role in 
lipid metabolism and in reverse cholesterol transport by transferring triglycerides 
and cholesterol between lipoproteins. Variation in the -629C/A polymorphism of 
the CETP gene was an important determinant of CETP concentration. 
Independent of this polymorphism, women had higher CETP concentration as 
compared to men and total cholesterol levels were associated with higher CETP 
concentration, whereas alcohol intake was associated with lower CETP 
concentration (Chapter 6). The independent association between plasma total 
cholesterol and plasma CETP concentration (Chapter 6) can be explained by 
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cholesterol-mediated stimulation of CETP synthesis. The postprandial data from 
Chapter 9 also demonstrate that CETP-synthesis may in part be enhanced by 
dietary cholesterol. The female sex hormone estradiol is also known to stimulate 
CETP gene expression. Despite the resulting lower CETP concentrations in 
postmenopausal women as compared to premenopausal women, 
postmenopausal women still have higher CETP concentrations as compared to 
men (Chapter 6). From previous studies, some information is available about 
factors that potentially affect cellular secretion of CETP, which may underlie the 
inverse association between alcohol intake and CETP concentration (Chapter 
6).  
Furthermore, we found that a dietary pattern, which was rich in fat, was 
associated with lower CETP concentrations but with a higher prevalence of 
type 2 diabetes (Chapter 7). Given the high correlation between cholesterol 
intake and this dietary pattern, we would have expected this pattern to 
increase CETP concentration. On the other hand, the dietary pattern correlated 
with high amounts of saturated and mono-unsaturated fat intake, which are 
known to have opposite effects on CETP concentration. The mechanism of 
these diet-induced changes in CETP concentration is not clearly established.  
Whether CETP concentration was associated with prevalent 
cardiovascular disease or cIMT was assessed in Chapter 8. We found that the 
associations differed between men and women and between glucose 
tolerance status groups. In women with diabetes, a 1 mg/l higher CETP 
concentration was associated with a 3.3-fold increased prevalence of 
cardiovascular disease. The combination of elevated levels of CETP as 
compared to men, an increase in cholesterol and triglycerides after the 
menopause and the insulin resistant state are likely contributors to the elevated 
cardiovascular disease risk in postmenopausal women with type 2 diabetes. We 
would suggest that the individual metabolic setting in postmenopausal women 
with diabetes provides a setting in which CETP is potentially atherogenic. The 
postprandial increase in CETP concentration as described in Chapter 9 together 
with a postprandial increase in triglyceride-rich particles may lead to an even 
more adverse lipid distribution in the postprandial phase.  
 
To conclude, 
Disturbances in postprandial glucose and lipoprotein profile might both 
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contribute to cardiovascular risk. Regulation of postprandial glucose might be 
important even in healthy persons. We speculate that other lipoprotein particles 
than triglyceride-rich lipoproteins in the postprandial state may be involved in 
atherogenesis. The increased cardiovascular risk due to diabetes in 
postmenopausal women might in part be the result of an atherogenic lipid 
profile, of which the concentration and/or composition is mediated by CETP.  
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SAMENVATTING 
 
 
Metabole veranderingen na de maaltijd 
Wereldwijd komt type 2 diabetes steeds meer voor, tegenwoordig lijden 
bijna 250 miljoen mensen aan deze ziekte. Hart- en vaatziekten zijn als meest 
voorkomende complicatie bij type 2 diabetes verantwoordelijk voor de 
verhoogde ziekte- en sterftecijfers bij deze patiënten. In dit proefschrift staan de 
metabole omstandigheden na de maaltijd centraal. Deze omstandigheden 
spelen mogelijk een rol in het verhoogde risico op hart- en vaatziekten bij 
patiënten met type 2 diabetes.  
In de westerse wereld zijn we voor een groot deel van de dag in de 
postprandiale fase, dat is de periode na de maaltijd. Metabole risicofactoren 
voor hart- en vaatziekten worden meestal in nuchtere omstandigheden 
gemeten, maar dit geeft slechts een deel van de werkelijke metabole 
omstandigheden tijdens de dag weer. Verder voorspellen de nuchtere 
omstandigheden ook wat er in de postprandiale fase gebeurt. Verstoringen in 
het postprandiale metabolisme kunnen bijdragen aan het ontwikkelen van 
hart- en vaatziekten.  
Het doel van de studies in dit proefschrift is het onderzoeken van 
mogelijke associaties tussen het postprandiale metabolisme en hart- en 
vaatziekten. De bijdrage van nuchtere en postprandiale glucose, triglyceriden 
en (pro)insuline, en van nuchter cholesteryl ester transfer protein (CETP) aan 
risico het risico op hart- en vaatziekten is onderzocht in de Hoorn Studie en in de 
Hoorn prandial studie.  
 
Onderzoeksopzet 
Postmenopauzale vrouwen met diabetes lopen een hoger risico op hart- 
en vaatziekten dan mannen met diabetes. Daarom hebben we deze vrouwen 
onderzocht. De vrouwen kregen op de ene dag twee opeenvolgende vetrijke 
maaltijden en op een andere dag twee opeenvolgende koolhydraatrijke 
maaltijden om postprandiale glucose, insuline, triglyceriden en CETP te bepalen 
(Hoofdstuk 2, 3, 4 en 9).  
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De Hoorn Studie is een cohort studie van 2484 deelnemers, van wie de 
eerste metingen in 1989 gedaan zijn. In 2000-2001 is een deel van dit cohort 
weer uitgenodigd voor vervolgmetingen. De gegevens van de Hoorn Studie zijn 
gebruikt voor de onderzoeken die in Hoofdstuk 5, 6, 7, en 8 staan beschreven.  
 
Resultaten en discussie 
Mogelijke determinanten van nuchtere en postprandiale glucose en 
triglyceriden concentraties zijn beschreven in Hoofdstuk 2. Nuchtere en 
postprandiale glucosespiegels zijn in gezonde vrouwen niet aan elkaar 
gerelateerd, maar in vrouwen met diabetes wel. De belangrijkste factoren die 
geassocieerd zijn met postprandiale glucosespiegels in gezonde vrouwen zijn 
leeftijd en nuchtere triglyceriden waarden. De nuchtere triglyceride 
concentratie is de sterkste voorspeller van postprandiale triglyceride 
concentraties zowel in vrouwen met als zonder diabetes.  
In Hoofdstuk 3 bestudeerden we de relatieve bijdrage van postprandiale 
glucose en triglyceriden waarden aan intima media dikte (IMT) van de 
halsslagader, als maat voor aderverkalking. Postprandiale glucosewaarden 
waren geassocieerd met IMT in gezonde vrouwen terwijl IMT niet geassocieerd 
was met nuchtere glucose of met glucosewaarden 2 uur na een 
suikerwatertest. Mogelijk zijn postprandiale glucosewaarden een betere 
weerspiegeling van glucosedagspiegels dan glucosewaarden na een 
suikerwatertest. Er zijn lange termijn studies nodig om te bevestigen dat 
postprandiale glucosewaarden een sterkere voorspeller voor hart- en 
vaatziekten zijn dan glucosewaarden na een suikerwatertest. In ieder geval 
suggereren deze resultaten dat postprandiale glucosewaarden, en/of de 
onderliggende mechanismen hiervan, verantwoordelijk zijn voor het 
ontwikkelen van aderverkalking.  
We vonden geen relatie tussen postprandiale triglyceriden en IMT 
(Hoofdstuk 3). De samenstelling van de lipoproteïnen (deeltjes waarin de vetten 
in het bloed circuleren) is niet gemeten in de postprandiale fase en deze is 
mogelijk wel geassocieerd met aderverkalking. Een andere verklaring zou zijn 
dat de veranderingen in vetstofwisseling die optreden na de menopauze 
ervoor zorgen dat de triglyceriden waarden zoals we die gemeten hebben, niet 
de juiste afspiegeling zijn van de werkelijke blootstelling aan triglyceriden in de 
jaren ervoor. Hoe dan ook, ondanks het verhoogde risico op hart- en 
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vaatziekten veroorzaakt door diabetes in postmenopauzale vrouwen is er tot nu 
toe weinig onderzoek gedaan naar de relatie tussen postprandiale triglyceriden 
en hart- en vaatziekten bij vrouwen. Lange-termijn studies bij mannen en 
vrouwen zouden inzicht kunnen geven of postprandiale triglyceriden of juist de 
samenstelling van lipoproteïnen een risicofactor voor hart- en vaatziekten zijn. 
In Hoofdstuk 4 hebben we een index voor vroege insulinesecretie (30 
minuten) na twee verschillende maaltijden berekend. In vrouwen met diabetes 
was deze insulinesecretie hoger na de vetrijke maaltijd vergeleken met de 
koolhydraatrijke maaltijd. Een hogere insulinesecretie hing samen met lagere 
glucosespiegels na de maaltijd. Deze resultaten ondersteunen de hypothese 
dat het veranderen van de samenstelling van de maaltijd betere 
glucosespiegels kan geven. Dit zou een aantrekkelijk alternatief zijn voor het 
gebruik van bloedglucose verlagende medicijnen. De lange-termijn effecten 
en de effecten op de vetstofwisseling zouden echter ook nader bekeken 
moeten worden. 
De relatie van nuchtere en post-load insuline en proinsuline spiegels met 
sterfte is beschreven in Hoofdstuk 5. Hogere proinsuline, en niet insulinespiegels  
bleken samen te hangen met een hoger risico op sterfte en speciaal op sterfte 
aan hart- en vaatziekten. Proinsuline zou als molecuul schadelijk kunnen zijn 
voor de bloedvaten. Dat de post-load insuline en de proinsulinespiegels niet 
samenhingen met sterfte zou kunnen komen doordat de post-load proinsuline 
concentraties per dag sterker kunnen variëren dan de nuchtere waarden. 
In Hoofdstuk 6 en 7 hebben we genetische, metabole en 
voedingsfactoren die geassocieerd zijn met nuchtere CETP concentratie 
onderzocht. CETP is een eiwit dat zorgt voor uitwisseling van verschillende 
vetten tussen lipoproteïnen. Deze uitwisseling kan leiden tot het afvoeren van 
cholesterol uit het bloed (gunstig) maar ook tot kleinere lipoproteïnen 
(ongunstig). Variatie in het -629C/A polymorphisme dat een onderdeel is van 
het CETP gen hangt samen met CETP concentratie. Vrouwen hebben een 
hogere CETP concentratie dan mannen, cholesterol hangt samen met een 
hogere CETP concentratie en alcoholinname met een lagere CETP 
concentratie.  
Tenslotte vonden we dat het eten van vetrijk dieet met veel vlees 
geassocieerd is met lagere CETP concentraties en met een hogere prevalentie 
van diabetes. Hoe een dergelijk dieet de CETP concentratie verlaagt is 
onbekend en ook de interpretatie ervan is lastig. Gezien de associatie met 
diabetes beschouwen we een vetrijk dieet met veel vlees in ieder geval niet als 
 193
Samenvatting 
een gezond voedingspatroon.  
De associatie tussen CETP concentratie en het risico op hart- en 
vaatziekten is beschreven in Hoofdstuk 8. We vonden dat deze associatie 
verschilde tussen mannen en vrouwen en tussen mensen met en zonder 
diabetes. Alleen in vrouwen met diabetes was een hogere CETP concentratie 
geassocieerd met een hogere prevalentie van hart- en vaatziekten. De 
combinatie van hogere CETP concentraties bij vrouwen en de verhoging van 
cholesterol en triglyceriden (vetten) in het bloed na de menopauze, draagt 
mogelijk bij aan het verhoogde risico op hart- en vaatziekten in 
postmenopauzale vrouwen met diabetes. De toename in CETP en triglyceride-
rijke deeltjes na de maaltijd (Hoofdstuk 9) geeft waarschijnlijk een ongunstige 
verdeling van vetten over de lipoproteïnen, vooral in de periode na de 
maaltijd.  
 
Concluderend, 
Verstoringen in de glucose- en vetstofwisseling na de maaltijd dragen 
beide bij aan het risico op hart- en vaatziekten. Glucosewaarden na de 
maaltijd blijken zelfs in gezonde personen samen te hangen met het 
ontwikkelen van aderverkalking. In de vetstofwisseling zijn mogelijk andere 
lipoproteïnen dan triglyceride-rijke lipoproteïnen betrokken bij het ontstaan van 
hart- en vaatziekten. Het verhoogde risico op hart- en vaatziekten bij 
postmenopauzale vrouwen met diabetes zou voor een deel veroorzaakt 
kunnen worden door een ongunstig lipiden profiel, waarvan de samenstelling 
en de concentratie wordt beïnvloed door CETP.  
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Een reden om vooral geen AIO te worden na mijn studie was het 
schrikbeeld dat ik ervan had; vier jaar lang eenzaam bikkelen in een kamertje 
om een proefschrift te schrijven. Niets was minder waar! Ik heb heel veel 
verschillende, fijne, interessante en gezellige mensen mogen ontmoeten in deze 
periode. Van Limburgse zachte G’s tot West-Friese directheid en Amsterdamse 
eigenwijsheid, alles was vertegenwoordigd. Mijn dank gaat uit naar velen, van 
wie ik hier enkelen in het bijzonder wil noemen.   
 
Jacqueline, vandaag kan je voor het eerst als promotor optreden! Ik ben 
bij je begonnen toen je mijn co-promotor was en jij stond het dichtste bij in de 
begeleiding. Je bent een onderzoekster in hart en nieren en (bijna) altijd 
enthousiast, ik ging altijd vol ideeën aan de slag na onze besprekingen. Je 
betrokkenheid en brede interesse betreffen niet alleen het onderzoek maar ook 
de mensen met wie je werkt. Dit heeft ervoor gezorgd dat ik de samenwerking 
altijd als prettig ervaren heb. Dank voor het vertrouwen dat je liet blijken door 
me aan te nemen voor mijn huidige aanstelling. 
 
Giel, ondanks je verzuchting dat jij je nooit meer met stofjes (?) zou 
bemoeien heb je toch maar mooi de titel van mijn proefschrift verzonnen. Jij zal 
nooit vergeten dat je uiteindelijk voor de diabetespatiënt werkt. In Hoorn heb ik 
je af en toe heel blij gemaakt als ik je hulp nodig had bij het prikken en je weer 
even aan de praktijk kon snuiven.  
 
Rob, als promotor heb je steeds de lijn van het onderzoek uitgezet, en me 
toch heel vrij gelaten in de keuze van onderwerpen. Jij kan snel knopen 
doorhakken en dat is waardevol gebleken in de vergaderingen van grote 
samenstelling.  
 
Graag wil ik ook de leescommissie bedanken voor het kritisch doornemen 
van het huidige werk. Antonio Ceriello from Italy (and sometimes UK): many 
thanks for accepting the invitation and to share some of your expertise on 
postprandial glucose. Jaap Seidell: ik ben benieuwd naar je ongetwijfeld 
relevante en toepassingsgerichte vragen over voeding. Ivo Smulders, jij bent al 
langere tijd bij de Hoorn studie betrokken als vaat-expert, bedankt voor het 
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doornemen van mijn boekwerk. Piet Kostense, je hebt als statisticus de gave om 
een probleem met één schematisch plaatje op te lossen en er nog een 
hilarische draai aan te geven ook. Als ik bij jou vandaan kwam was ik ervan 
overtuigd dat dingen meestal niet zo moeilijk zijn als ze lijken. Jan Albert 
Kuivenhoven, je hebt al een heel traject van dit boekje meegemaakt en je 
bent voor mij altijd de CETP-expert gebleven. Ik vind het heel leuk dat je nu ook 
komt opponeren. Ik weet gelukkig al van je dat je lekker kritisch bent, dus ik 
bereid me voor! 
 
Roger, je was mijn partner in crime en vandaag ook mijn paranimf. Dat 
een Limburger en een Groninger best samen een onderzoek kunnen doen, dat 
hebben we wel laten zien. Tijdens de vele ritjes naar Hoorn, en het veelvuldig 
samen echo’s doen, pipetteren, lunchen en koffie drinken heb ik je steeds beter 
leren kennen en waarderen. Nu je het nog noordelijker dan Amsterdam gaat 
zoeken zal je het daar ook zeker gaan redden, ik wens je in ieder geval alle 
goeds toe.  
 
Michaela, je was één van de breinen achter het postprandiale 
onderzoek. Je stortte je steeds met veel energie op de manuscripten en je 
voorzag je opmerkingen van uitgebreide toelichting wat ik heel erg leerzaam 
vond!  
  
Peter ik heb heel wat over lipiden van je geleerd en je maakte me steeds 
attent op allerlei congressen op dat gebied. Ook heb je veel energie gestopt in 
de CETP metingen waarvan de resultaten in dit boekje staan. Tom, jij was met 
name bij het onderzoek van Roger betrokken, maar wat mijn manuscripten 
betreft: je was onovertroffen op het gebied van snel manuscripten nakijken, en 
je hebt een scherp oog voor interne consistentie, daarvoor dank. 
 
Karim, dank voor je enthousiaste inzet bij het postprandiale CETP-
manuscript. Het komt nu eindelijk tot een afronding.   
 
Jannet, Lida, Marianne en Tanja: jullie zorgden ervoor dat het onderzoek 
in Hoorn bleef draaien en dat de deelnemers zich welkom voelden. Een warm 
kleedje, een muziekje, een gezellig praatje, niets was teveel. Jullie hebben er 
soms lange dagen voor moeten maken. Bedankt, ook voor de gezelligheid. Af 
en toe zien we elkaar zeker nog in Hoorn. 
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In het DOC was er Jolanda; je kon onze theoretische onderzoeksplannen 
heel snel naar de praktijk vertalen en in planningen stoppen en dat maakte het 
werken in Hoorn heel aangenaam. 
 
De vaatmetingen hebben we geleerd van Maarten die met veel geduld 
om de techniek van de echo bijbracht. Dank daarvoor en niet in mindere mate 
voor de leuke gesprekken tijdens meerdere congressen. 
 
Op het lab waren er velen die aan onze monsters werkten, maar Astrid 
Kok heeft de planning daarvan in de gaten gehouden. Jeany Huyser was erg 
behulpzaam toen we een enorm aantal monsters voor insulinebepalingen 
inleverden en de stickers ontzettend in de weg zaten.  
 
Wiebe, kamergenoot vanaf de eerste dag. Na een jaar op een sombere 
kamer aan het eind van een gang werd het snel beter toen we op de vierde 
etage kwamen. Zeker in de fase dat we allebei gingen schrijven hebben we 
veel zinnig en minder zinnig zitten overleggen. Je manier van denken (hardop) 
verschilde nogal van die van mij, maar vaak raakten we daardoor in gesprek 
en dat hielp mij om mijn ideeën onder woorden te brengen.  
  
De directe AIO (en post-doc) collega’s Amber, Annemieke, Esther, Hata,  
Jeroen, Josina, Katja, Laura, Marieke, Sandra, Susan, Uriell en Wiebe dank voor 
alle gezelligheid. Heerlijk om zo veel collega’s te hebben met wie je alle voors 
en tegens van het AIO leven kan bespreken. Fijn dat ik de meeste van jullie nog 
blijf zien! Josina, mijn huidige kamergenoot, heel erg leuk om bij jou op de 
kamer te zitten. Je gezellige plantjes en smaakjesthee gaven me vanaf het 
begin een goed gevoel.  
 
Karina en Niels, ik ontkom er niet aan om jullie in één adem te noemen 
want jullie kwamen tegelijk en jullie gingen (ongeveer) tegelijk. Jullie waren 
enorm gemotiveerd voor je afstudeeronderzoek, ik vergeet niet meer dat jullie 
in één van je eerste weken al een soort minicollege gaven aan je begeleiders. 
Voor mij was het heel leuk om ineens een compleet CETP-team te hebben toen 
jullie kwamen. Het resultaat staat in dit boekje, dus de dank aan jullie is groot. 
  
Joyce: Haarlem en Hoorn, daar hebben we allebei wat mee! Ik voelde 
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me altijd heel erg welkom op mijn logeeradres in Hoorn bij jou en Elzo. Verder 
dan nu moeten we niet bij elkaar vandaan gaan wonen.  
 
Verder heb ik veel aan mijn oude vertrouwde vriendinnen uit Groningen 
te danken. We zien elkaar minder vaak als vroeger, maar we maakten (bijna) 
allemaal een grote stap vanuit Groningen naar elders in het land. Wat tof dat 
we elkaar al zo lang kennen, leve de telefoon. Petra, ik vind het heel erg leuk 
dat je vandaag paranimf bent. Ook geniet ik van vele andere GSV-ers die een 
stukje van mijn leven vorm(d)en en die ik overal weer tegen kom.  
 
En dan natuurlijk pap en mam, oma, HW, Nathalie, Tineke, Titus, Joas, 
Ezra, Sanne en Sara: wat fijn om vanzelfsprekend bij elkaar te horen en van 
elkaar te houden. Pap en mam, dank voor alle mogelijkheden om te studeren. 
Pa en ma de Kwaadsteniet, mijn andere ouders, bedankt voor de 
onvoorwaardelijke zorgzaamheid en trots.  
 
Arjan, je schreef mijn curriculum vitae voor dit boekje. Sinds 2 jaar én in de 
toekomst mogen we dat samen doen. “Al het water van de zee…” 
 
Soli Deo gloria - dank alleen aan God 
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CURRICULUM VITAE 
 
Op woensdag de veertiende december van 1977 kwam Marjan Alssema 
in het Groningse Leek ter wereld. Haar ouders gaven haar de namen Martje 
Jantiena mee, waarmee zij naar haar beide oma's is vernoemd. Na een 
zwerftocht langs verscheidene plaatsen in de noordelijke provincies kwam zij in 
het dorpje Schipborg bij Zuidlaren terecht. Laatstgenoemde plaatsen vormden 
het decor van haar jeugd; zij bezocht er de kleuter-, de lagere school en de 
kerk. Na de lagere school wachtte de middelbare school in Groningen. Zes jaar 
later, duizenden kilometers fietsen verder, behaalde zij in 1996 een VWO-
diploma dat duidelijk in het teken van de exacte vakken stond. 
 
Omdat de stad Groningen haar wist te bekoren, besloot Marjan zich aan 
de Rijksuniversiteit Groningen in te schrijven als - uiteindelijk toch wel - student in 
de biologie. Vanwege een geringe belangstelling voor de concrete flora en 
fauna en een groeiende affiniteit met de humane disciplines koos zij voor de 
medische biologie. Dat leidde tot literatuurstudies naar het effect van 
cholesterol op agressie en naar verschillen in reactie op stress tussen mannen 
en vrouwen, een onderzoek naar de effecten van de voeding tijdens de 
zwangerschap op de ontwikkeling van het kind (bij Friesland Nutrition) en een 
doctoraalscriptie over de invloed van licht op de biologische klok. Naast al 
deze activiteiten vond zij voldoende tijd om zich in het Groningse 
studentenleven te storten. Voor haar gebeurde alles op de Gereformeerde 
Studenten Vereniging (GSV), een vereniging van studenten van gereformeerd 
vrijgemaakten huize die studie en vriendschap hoog in het vaandel hebben 
staan. Op deze vereniging voelde zij zich zo thuis dat zij in 1999-2000 als assessor 
secundus in de senaat zitting had. 
 
Na de afronding van haar studie in 2001 verhuisde Marjan naar Haarlem, 
omdat zij in Amsterdam als clinical datamanager bij Chiron aan de slag kon. Bij 
Chiron begon ze haar medisch-biologische achtergrond te missen en ging haar 
belangstelling meer en meer naar wetenschappelijk onderzoek uit. Een 
belangstelling die haar op de Vrije Universiteit deed belanden: daar ging zij in 
2002 als AIO bij het EMGO-Instituut aan de slag. 
In deze periode rondde zij de masteropleiding epidemiologie af, trouwde 
zij met Arjan de Kwaadsteniet, verhuisde zij naar Rotterdam en slaagde zij er - 
 199
Curriculum vitae 
last but not least - onder leiding van prof.dr. R.J. Heine, prof.dr.ir. J.M. Dekker en 
prof.dr. G. Nijpels in dit proefschrift te voltooien. Deze blijk van bekwaamheid 
werd beloond, Marjan mocht blijven en zij werkt nu als post-doc in het diabetes-
onderzoek bij het EMGO. 
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